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1.	INTRODUCTION	
	
1.1	Cancer	
Cancer	is	one	of	the	leading	causes	of	death	worldwide	accounting	for	8.2	million	
deaths	 in	2012	(Globocan	2012,	 IARC).	 It	 is	a	multistep	process	 involving	genetic	as	
well	as	epigenetic	changes	that	result	in	the	activation	of	oncogenic	pathways	and/or	
the	inactivation	of	tumor	suppressive	mechanisms.	Two	seminal	reviews	by	Hanahan	
and	Weinberg	described	several	 fundamental	 traits	 that	are	necessary	 for	a	cancer	
cell	to	survive,	proliferate	and	disseminate,	known	as	the	hallmarks	of	cancer	[6,	7]	
(Fig.	1).	In	brief,	tumor	cells	are	able	to	sustain	proliferative	signaling,	are	insensitive	
to	growth-inhibitory	signals	and	evade	cell	death.	Furthermore,	they	show	a	limitless	
replicative	 potential,	 enhanced	 angiogenesis,	 invasion	 and	metastasis.	 In	 addition,	
tumors	are	characterized	by	genomic	instability	and	mutability	and	tumor-associated	
inflammation	 promotes	 tumorigenesis	 and	 progression.	 Moreover,	 tumor	 cells	
acquire	 a	deregulated	 cellular	 energy	metabolism	and	 the	 ability	 to	 actively	 evade	
the	immune	system.	
	
	
	
Figure	 1:	The	 hallmarks	 of	 cancer.	 The	 10	 fundamental	 traits	 acquired	 during	 tumor	 development	
that	enable	a	cancer	cell	to	survive,	proliferate	and	disseminate.	Modified	from	[7].	
	
1.2	The	tumor	suppressor	p53	
p53,	 also	 known	 as	 the	 guardian	 of	 the	 genome,	 is	 one	 of	 the	most	 important	
tumor	 suppressor	 proteins	 protecting	 against	 tumor	 development	 [8].	 It	 acts	 as	 a	
tetrameric	transcription	factor	controlling	the	expression	of	various	target	genes	 in	
response	 to	 diverse	 stimuli	 including	 DNA	 damage,	 oncogene	 activation	 or	 other	
types	of	cellular	stresses	and	induces	tumor	suppressive	processes,	such	as	cell	cycle	
arrest,	DNA	repair,	senescence	or	apoptosis	[9,	10].	The	frequency	of	p53	mutations	
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promoting inflammation
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in	 human	 cancer	 is	 very	 high	 ranging	 from	 50	 to	 70%	 in	 for	 example	 colorectal,	
ovarian	or	head	and	neck	cancer	[11-13].	Most	of	the	mutations	that	arise	in	the	p53	
gene	are	missense	mutations	with	80%	affecting	p53´s	DNA	binding	domain,	most	
often	at	the	six	hot-spot	amino	acid	residues	175,	245,	248,	249,	273,	282	[14].	p53	
mutations	 in	 one	 allele	 are	 usually	 followed	 by	 loss	 of	 heterozygosity	 i.e.	 the	
remaining	wild-type	allele	 is	 inactivated	by	deletion,	which	 results	 in	 the	complete	
loss	 of	 p53	 function	 [15].	 Interestingly,	mutant	 p53	 proteins	may	 lose	 their	 tumor	
suppressive	abilities	and	gain	new	tumor-promoting	functions,	thereby	undergoing	a	
„gain-of-function“	 (reviewed	 in	 [16]).	 In	 tumors	 retaining	 wild	 type	 p53,	 p53´s	
activity	is	often	decreased	by	deregulations	of	genes	directly	or	indirectly	controlling	
its	degradation,	such	as	MDM2	or	p14ARF	[17].		
p53	 levels	 are	 posttranslationally	 controlled	 by	 its	 main	 negative	 regulators,	
MDM2	and	MDM4.	MDM2	acts	as	an	E3	ligase	and	polyubiquitinates	p53,	leading	to	
its	proteasomal	degradation	[18-20].	MDM2	and	MDM4	bind	to	the	transactivation	
domain	 (TAD)	 of	 p53	 thereby	 inhibiting	 its	 transcriptional	 functions	 [21-23].	 p53	
directly	 induces	 the	 transcription	 of	 MDM2	 which	 results	 in	 a	 negative	
autoregulatory	 feedback	 loop	 that	 limits	 the	 activity	 of	 p53	 in	 response	 to	 its	
activating	stimuli	[24,	25].	MDM2-deficient	mice	display	embryonic	lethality	which	is	
rescued	 by	 p53	 knockout	 highlighting	 the	 tight	 control	 of	 p53	 by	 MDM2	 [26].	 In	
addition,	the	tumor-suppressor	ARF,	which	is	activated	by	hyperproliferative	signals,	
interrupts	 the	 p53-MDM2	 interaction	 by	 inhibiting	 MDM2´s	 E3	 ligase	 activity	 or	
sequestering	MDM2	to	nucleoli	[27-29].	
	In	unstressed,	normal	cells,	p53	is	kept	at	low	levels.	Acute	DNA	damage	leads	to	
the	activation	of	the	kinases	ATM	and	ATR,	which	in	turn	phosphorylate	the	kinases	
CHK1	 and/or	 CHK2	 [30].	 Once	 activated,	 these	 kinases	 phosphorylate	 p53	
predominantly	 at	 its	 amino	 terminus	 to	disrupt	 the	binding	of	MDM2	and	MDM4,	
resulting	 in	 increased	 p53	 levels	 [31,	 32].	 Phosphorylation	 of	 p53´s	 TAD	 not	 only	
results	 in	 the	disruption	of	MDM2/4	binding,	but	also	 initiates	 the	 interaction	with	
different	p53	binding	proteins	necessary	for	the	initiation	of	transcription	[33].	Upon	
DNA	damage,	 the	histone	acetyltransferases	CBP/p300,	pCAF,	GCN5	and	TIP60	are	
recruited	near	p53	binding	sites	via	 interaction	with	p53´s	TAD	which	results	 in	the	
acetylation	of	nearby	histones	and	chromatin	unwinding	[34-42].	Moreover,	CBP	and	
p300	 also	 acetylate	p53	 itself	 at	 its	 C-terminus	which	 leads	 to	 further	 stabilization	
and	activation	of	p53	[43,	44].	Though	acetylation	is	the	most	well-documented	p53-
dependent	 histone	 modification,	 histone	 methyltransferases	 such	 as	 PRMT1	 and	
CARM1	 cooperate	 with	 CBP/p300	 to	 facilitate	 transcription	 of	 GADD45	 [45].	
Additionally,	 the	 recruitment	 of	 chromatin	 remodeling	 factors	 such	 as	 SWI/SNF	
facilitates	 promoter	 opening	 [46].	 Moreover,	 p53	 facilitates	 the	 formation	 of	 the	
preinitiation	 complex	 (PIC)	 including	 RNA	 polymerase	 II	 and	 different	 basal	
transcription	factors	[47,	48]	and	assists	in	the	recruitment	of	TFIID,	TFIIA	as	well	as	
TFIIH	[49-55].	
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p53	 is	widely	known	as	a	 transcriptional	 inducer	 that	binds	 to	 specific	 response	
elements	 in	 a	 sequence-specific	manner.	 Upon	 activation,	 p53	 translocates	 to	 the	
nucleus	where	 it	 binds	 as	 a	 tetramer	 to	 the	 sequence	 RRRCWWGYYY	 (R	 =	 purine,					
W	=	A	or	T,	Y	=	pyrimidine),	arranged	as	two	palindromes	with	a	0	–	13	base	pair	(bp)	
long	spacer	[56,	57].	A	large	number	of	genes	that	are	transcriptionally	activated	by	
p53	have	been	described	up	to	date	[58,	59].		
In	 contrast	 to	 that,	 the	mechanism	 for	p53-mediated	gene	 repression	 remained	
largely	elusive.	Several	different	direct	and	indirect	mechanisms	have	been	proposed	
(reviewed	 in	 [60]).	 It	 has	 been	 shown	 that	 p53	 directly	 represses	 target	 genes	 by	
binding	to	a	p53	binding	site	that,	however,	differs	from	the	consensus	binding	site	
described	above.	In	some	cases	it	has	been	demonstrated	that	the	orientation	of	the	
p53	binding	site	 is	 important	for	the	effect	on	gene	expression	and	that	a	head-to-
tail	 formation	 (RRRCWYYYGW)	 instead	 of	 the	 common	 head-to-head	 formation	
(RRRCWWGYYY)	 switches	 the	 p53	 effect	 from	 activation	 to	 repression	 [61,	 62].	
Furthermore,	the	two	bases	located	in	the	core	of	the	p53	binding	site,	normally	AT,	
AA	or	TT,	are	changed	to	TC,	GA,	CA,	GC,	GG,	CC	or	CG	and	p53	response	elements	
associated	 with	 down-regulated	 genes	 show	 a	 weaker	 affinity	 compared	 to	 those	
associated	with	up-regulated	genes	[63].	In	addition,	differences	in	the	spacer	length	
have	 been	 observed	 within	 p53	 binding	 sites	 for	 repressed	 genes	 showing	 longer	
spacers	than	those	of	induced	ones	[64].	However,	a	recent	study	also	reported	that	
the	p53	response	element	associated	with	down-regulated	genes	hardly	differs	from	
the	 one	 linked	 to	 transcriptional	 up-regulation	 [65].	 p53	 may	 also	 compete	 with	
other	 transcription	 factors	 such	 as	 E2F1	 or	 BRN3A	 that	 show	 overlapping	 or	
neighboring	 binding	 sites	 [66,	 67].	 Another	 mechanism	 proposed	 for	 direct	
repression	by	p53	is	the	recruitment	of	chromatin-modifying	factors,	such	as	HDACs,	
as	described	for	the	p53-mediated	repression	of	c-Myc	[68].		
Apart	from	direct	repression,	several	indirect	mechanisms	for	gene	repression	by	
p53	 have	 been	 documented.	 p53	 is	 able	 to	 bind	 and	 thereby	 inactivate	 specific	
transactivation	factors,	such	as	SP1	or	the	glucocorticoid	receptor,	required	for	the	
transcriptional	 repression	of	Sgk	 [69]	and	hTERT	 [70],	 respectively.	 In	addition,	 the	
known	p53-target	p21	indirectly	represses	the	expression	of	different	genes	involved	
in	 the	 cell	 cycle	 [71-73].	 Increased	 levels	 of	 p21,	 an	 inhibitor	 of	 cyclin-dependent	
kinases,	result	in	hypophosphorylation	of	RB	which	in	turn	remains	complexed	with	
E2F.	 This	 results	 in	 decreased	 E2F-dependent	 gene	 expression.	 Furthermore,	 p53	
directly	 induces	 non-coding	 RNAs,	 including	microRNAs	 (miRNAs)	 or	 lncRNAs	 (long	
non-coding	 RNAs),	 or	 interacts	with	 the	miRNA-processing	machinery	 to	 indirectly	
down-regulate	mRNA-	and	protein-expression	(reviewed	in	[60]).		
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1.3	Non-coding	RNAs		
The	 Human	 Genome	 Project	 revealed	 20,000	 –	 25,000	 protein-coding	 genes	
which	 occupy	 only	 1%	 of	 the	 human	 genome	 [74].	 However,	 recent	 advances	 in	
sequencing	 analyses	 demonstrated	 that	 about	 70%	 of	 the	 human	 genome	 is	
transcribed	into	non-coding	RNAs	(ncRNAs)	[75,	76].	In	general,	two	main	groups	of	
ncRNAs	 are	 known	 –	 long	 ncRNAs	 defined	 as	 RNA	 molecules	 longer	 than	 200	
nucleotides	and	small	ncRNAs	including	tRNAs,	snRNAs,	snoRNAs	and	miRNAs.	
1.3.1	microRNAs	and	cancer	
miRNAs	are	a	class	of	endogenously	expressed,	20	–	25	nucleotides	long,	ncRNAs	
that	mediate	gene	repression	on	a	posttranslational	level	[77].	They	regulate	various	
processes,	such	as	cell	growth,	differentiation,	apoptosis	or	tumorigenesis	acting	as	
tumor	 suppressors	 or	 oncogenes	 [78].	 Aberrant	 miRNA	 expression	 patterns	 are	
characteristic	 for	different	kinds	of	human	cancers	 [79-82].	Furthermore,	a	general	
loss	of	miRNA	expression	has	been	observed	in	different	tumor	cells	indicating	that	
miRNAs	may	have	an	important	function	in	tumor	suppression	[82,	83].	In	addition,	
more	 than	60%	of	all	human	mRNAs	are	miRNA	targets	highlighting	 the	 regulatory	
importance	 of	 this	 group	 of	 small	 ncRNAs	 [84].	 miRNAs	 are	 located	 in	 introns	 or	
exons	 of	 non-coding	 and	 protein-coding	 genes	 [85].	 miRNA-encoding	 genes	 are	
transcribed	 by	 RNA	 polymerase	 II	 to	 form	primary	miRNA	 transcripts	 (pri-miRNAs)	
[78]	(Fig.	2).		
	
Figure	 2:	miRNA	 generation	 and	
function.	 miRNA	 genes	 are	
transcribed	in	the	nucleus	by	RNA	
polymerase	 II	 to	 form	 primary	
miRNA	transcripts	that	are	further	
processed	by	the	RNase	III	Drosha.	
The	 precursor	 miRNA	 is	
transported	out	of	 the	nucleus	by	
Exportin	 5.	 In	 the	 cytoplasm	 the	
RNase	 III	 Dicer	 generates	 a	 	 ̴22	
nucleotide	long	miRNA-antisense	-	
miRNA	 duplex	 that	 is	 unwound	
and	 one	 strand,	 the	 mature	
miRNA,	 is	 loaded	 into	 the	 RNA-
induced	 silencing	 complex	 (RISC).	
The	 miRNA	 guides	 the	 RISC	 to	
specific	 target	 mRNAs.	 miRNAs	
bind	 to	 specific	 seed-matching	
regions	 in	 the	 3´-UTR	 of	 mRNAs,	
thereby	 inducing	 either	 mRNA	
degradation	 or	 translational	
repression.	 Figure	 modified	 from	
[86].		
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Pri-miRNAs	 are	 further	 processed	 in	 the	 nucleus	 by	 the	 RNase	 III	 complex	 of	
Drosha	and	DGCR8	generating	~65	nucleotide	 long	precursor	miRNAs	(pre-miRNAs)	
with	a	stem-loop	structure,	which	are	transported	out	of	the	nucleus	by	Exportin	5.	
In	the	cytoplasm	the	pre-miRNAs	are	further	processed	by	the	RNase	III	Dicer,	which	
cleaves	off	the	double-stranded	part	of	the	hairpin.	Subsequently	the	miRNA-duplex	
is	unwound	and	one	of	 the	two	strands	–	the	mature	miRNA	-	 is	 incorporated	 into	
the	RNA-induced	silencing	complex	(RISC).	The	mature	miRNA	guides	this	complex	to	
(partially)	 complementary	 seed-matching	 sites	 in	 the	 3´-UTR	 of	 its	 target	 mRNAs	
resulting	 in	mRNA	destabilization	and/or	translational	 repression	depending	on	the	
grade	of	complementarity	of	the	seed	region	[87,	88].	
	
1.3.2	p53	and	the	miRNA-network	
The	tumor	suppressor	p53	regulates	miRNA-expression	and	-processing	but	is	also	
known	to	be	under	the	control	of	several	miRNAs	(reviewed	in	[4,	86]).		
As	a	transcription	factor,	p53	directly	controls	the	expression	of	several	miRNAs.	
In	2007,	the	miR-34	family	were	the	first	miRNA-encoding	genes	that	were	found	to	
be	 directly	 up-regulated	 by	 p53	 and	 to	mediate	 diverse	 tumor	 suppressive	 effects	
such	 as	 apoptosis,	 differentiation	 as	 well	 as	 inhibition	 of	 invasion,	 cell	 cycle,	
epithelial-mesenchymal	 transition	 (EMT)	 and	 metabolism	 by	 inhibiting	 the	
expression	of	key	regulators	of	these	processes	[89-96].	In	addition,	members	of	the	
miR-200	genes,	namely	miR-200c/141	and	miR-200a/200b/429	have	been	identified	
as	 direct	 p53	 targets.	 Their	 products	 down-regulate	 the	 EMT	 transcription	 factors	
(TFs)	ZEB1	and	ZEB2	and	consequently	inhibit	EMT	[97,	98].	Moreover,	miR-200c	has	
been	shown	to	inhibit	the	stemness	factors	KLF4	and	BMI1	[98].	The	miR-192	family,	
encoded	 by	 the	 two	 clusters	miR-194-1/215	 and	miR-192/194-2,	 is	 another	 direct	
p53	target	repressing	regulators	of	DNA	synthesis,	cell	cycle	and	metastasis	[99-103].	
Furthermore,	miR-107,	which	 inhibits	 tumor	 angiogenesis	 and	 cell	 cycle	 regulators	
[104,	 105],	 as	 well	 as	 miR-145,	 which	 targets	 the	 oncogenes	 c-MYC,	 KRAS	 and	
pluripotency	 regulators,	 were	 demonstrated	 to	 be	 directly	 regulated	 by	 p53	 [106-
108].	Recently,	also	the	miR-15a/16-1	cluster	was	shown	to	be	induced	by	p53	[109].	
These	miRNAs	 inhibit	 the	 cell	 cycle	 regulators	CDK6	 and	CCND1,	 induce	 apoptosis	
and	also	down-regulate	AP4,	 thereby	 inhibiting	EMT,	 invasion	and	metastasis	 [110-
113].	Further	up-regulated	miRNAs	by	p53	are	miR-29	[114],	-605	[115],	-149*	[116],	
-22	[117],	-23b	[118],	-1246	[119]	and	-1204	[120].	
p53	 also	 directly	 represses	 miRNAs	 with	 oncogenic	 functions.	 But	 only	 three	
examples	 of	 direct	 p53-mediated	 miRNA-repression	 are	 known	 up	 to	 now:	 the					
miR-17-92	cluster,	which	is	known	to	exert	different	pro-tumorigenic	functions	[121-
123]	 and	 the	miRNAs-224	and	 -502,	which	 inhibit	 autophagy	 and	 tumor	 growth	 in	
colon	cancer	cells	[124,	125].	
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Besides	functioning	as	a	transcription	factor,	p53	also	regulates	miRNA-levels	by	
influencing	miRNA-processing	 (Fig.	3).	The	processing	of	specific	primary	miRNAs	 is	
increased	by	p53	via	its	association	with	the	DEAD-box	RNA	helicase	p68	enhancing	
the	 interaction	 with	 the	 Drosha	 complex	 [126].	 Furthermore,	 a	 conditional	 Dicer	
knockout	 mouse	 model	 with	 decreased	 miRNA	 maturation	 shows	 reduced	 p53-
mediated	growth-arrest	and	premature	senescence	[127].	In	addition,	the	p53	family	
member	 p63	 induces	Dicer	which	 leads	 to	 reduced	metastasis	 [128].	 This	 effect	 is	
inhibited	by	mutant	p53.	Another	mechanism	by	which	p53	affects	miRNA-mediated	
processes	is	the	regulation	of	the	RNA-binding-motif	protein	RBM38	[129].	RBM38	is	
directly	induced	by	p53	and	selectively	inhibits	the	binding	of	miRNAs	to	its	targets,	
thereby	enhancing	certain	p53	functions.		
	
Figure	 3:	 p53	 in	 the	 control	 of	
miRNA	expression	and	processing.	
p53	 interacts	 with	 the	 miRNA-
network	via	different	mechanisms.	
As	 a	 transcription	 factor	 it	 directly	
induces	 or	 represses	 the	
expression	 of	 several	 miRNAs	 and	
influences	 miRNA	 processing	 by	
interacting	 with	 the	 RNA	 helicase	
p68	 which	 is	 part	 of	 the	 Drosha	
complex.	 Furthermore,	 p53	
induces	 the	 RNA-binding-motif	
protein	 RBM38	 leading	 to	 the	
inhibition	 of	 miRNA-mediated	
processes	 to	 enhance	 p53`s	
function.	 Mutant	 p53	 inhibits	 all	
those	 functions.	 Furthermore,	
mutant	 p53	 inhibits	 p63	 which	
then	 negatively	 affects	 Dicer	 and	
consequently	 miRNA-processing.	
Figure	from	[86].	
	
	
	
On	 the	 other	 hand,	 p53	 itself	 is	 targeted	 by	 several	miRNAs	 (see	 Fig.	 4).	 Since	
targeting	 of	 p53	 reduces	 its	 tumor-suppressive	 functions,	 those	 miRNAs	 are	
predominantly	 oncomirs	 that	 are	 often	 overexpressed	 in	 human	 tumors.	 The	 first	
miRNA	found	to	repress	p53	and	to	negatively	regulate	p53-induced	apoptosis	was	
miR-125b	 [130].	 miR-125b	 is	 a	 prognostic	 marker	 in	 colorectal	 cancer	 which	 is	
associated	with	poor	prognosis	and	increased	tumor	size	[131].	Also	miR-504	targets	
p53	 [132].	 This	 miRNA	 was	 shown	 to	 inhibit	 apoptosis	 and	 to	 lead	 to	 increased	
tumorigenicity	 of	 colon	 cancer	 cells.	miR-25	 and	miR-30d	 represent	p53-regulating	
miRNAs	 that	 show	 enhanced	 expression	 in	 different	 types	 of	 tumors	 [133-135].	
Additionally,	miR-33	and	miR-380-5p	were	shown	to	target	the	3´-UTR	of	p53	[136,	
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137].	Moreover,	p53	is	down-regulated	by	miR-1285	[138].	Further	miRNAs	directly	
inhibiting	p53	are	miR-150	[139],	-214	[140]	and	-375	[141].			
Several	 tumor	 suppressive	 miRNAs	 regulate	 p53	 indirectly	 via	 p53-modifying	
enzymes	(see	Fig.	4).	MDM2,	 the	main	negative	regulator	of	p53,	 is	a	target	of	 the	
miRNAs	 miR-145,	 miR-192/194/215,	 miR-29b	 and	 miR-605	 [103,	 115,	 142].	
Consequently,	 induction	 of	 those	 miRNAs	 leads	 to	 repression	 of	 MDM2	 and	
induction	of	p53.	In	the	case	of	the	p53-induced	miR-192/194/215	and	miR-605	this	
results	in	a	positive	feedback	loop.	In	addition,	miR-122	indirectly	suppresses	MDM2	
levels	 by	 targeting	 CCNG1	 [143,	 144].	 Furthermore,	 it	 is	 known	 that	 the	 miR-34a	
target	 SIRT1	 negatively	 regulates	 p53	 expression	 and	 that	 miR-29	 down-regulates	
the	PI3K/AKT	pathway	which	indirectly	leads	to	increased	p53-levels	[145-147].	
	
	
Figure	4:	miRNAs	that	directly	or	indirectly	regulate	p53.	Several	tumor	suppressive	miRNAs	regulate	
p53	indirectly	via	p53-modifying	enzymes	which	results	in	enhanced	p53	activation.	Some	oncogenic	
miRNAs	directly	target	p53´s	3´-UTR	to	suppress	p53	activity.	Figure	modified	from	[4].	
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1.3.3	Long	non-coding	RNAs		
lncRNAs	 are	 defined	 as	 RNA	 transcripts	 larger	 than	 200	 nucleotides	 with	 no	
protein-coding	 functions.	The	NONCODE	database	currently	 lists	more	 than	30,000	
human	 lncRNA	transcripts	 [148].	They	are	known	to	be	transcribed	from	their	own	
promoters	and	are	often	under	the	control	of	key	transcription	factors,	such	as	p53,	
NFĸB,	 Sox2,	Oct4	 or	Nanog	 [149].	Different	 types	 of	 lncRNAs	have	been	described	
including	 long	 intergenic	 ncRNAs	 (lincRNAs),	 transcribed	 pseudogenes,	 antisense	
RNAs	or	enhancer	RNAs	[150].	lncRNAs	were	described	to	play	a	role	in	cancer	with	
either	tumor-suppressive	or	oncogenic	functions	and	to	regulate	gene	expression	by	
diverse	 mechanisms	 [150].	 Many	 lncRNAs	 bind	 histone-modifying	 or	 chromatin-
remodeling	proteins,	such	as	the	polycomb	repressive	complexes	PRC1	and	PRC2,	to	
mediate	 the	 repression	 of	 gene	 transcription	 [151].	 In	 addition,	 lncRNAs	 act	 as	
enhancer	 RNAs	 (eRNAs),	 that	 are	 transcribed	 from	 enhancer	 regions	 and	 regulate	
their	 activity	 [152].	 Furthermore,	 they	 influence	 tumor	 suppressor	 activity	 by	
epigenetic	 silencing	 or	 activating	 the	 expression	 of	 tumor	 suppressor	 target	 genes	
[153,	 154].	 Moreover,	 lncRNAs	 affect	 posttranscriptional	 mRNA	 processing	 as	
described	 for	 MALAT1	 and	 NEAT1	 [155,	 156]	 and	 act	 as	 competitive	 endogenous	
RNAs	(ceRNA)	that	function	as	miRNA	sponges	[157].	
	
1.3.4	p53	and	the	lncRNA-network	
In	2009,	Guttman	et	al.	described	a	number	of	 lncRNAs,	which	are	significantly	
up-regulated	in	a	p53-dependent	manner	in	mouse	embryonic	fibroblasts	after	DNA	
damage	 [149].	 The	 p53-inducible,	 tumor-suppressive	 lincRNA-p21	 is	 located	 about	
15	kbp	upstream	of	the	gene	encoding	p21	and	facilitates	p53-mediated	repression	
as	well	as	posttranscriptional	regulation	of	p53	[153,	158,	159].	In	addition,	PANDA,	
which	 is	 transcribed	 from	 the	 CDKN1A	 promoter,	 is	 directly	 induced	 by	 p53	 and	
suppresses	 the	 expression	 of	 pro-apoptotic	 genes,	 thereby	 controlling	 apoptosis	
[160].	Furthermore,	the	lncRNA	loc285194	was	found	to	be	regulated	by	p53	[161].	It	
is	 located	 in	 a	 region	 with	 frequent	 focal	 copy	 number	 alterations	 and	 loss	 of	
heterozygosity	 in	 different	 kinds	 of	 cancer	 and	 its	 deletion	 promotes	 proliferation	
and	 is	 associated	with	 poor	 survival	 in	 osteosarcoma	 patients	 [162].	 In	 particular,	
loc285194	acts	as	a	ceRNA	to	repress	miR-211´s	oncogenic	functions	[157,	161].	RoR	
represents	another	lincRNA,	which	is	transcriptionally	induced	by	p53	[163].	Similar	
to	 MDM2,	 RoR	 suppresses	 p53´s	 translation	 which	 results	 in	 an	 autoregulatory	
feedback	loop.	Moreover,	the	maternally	imprinted	gene	H19	is	negatively	regulated	
by	p53	 [164].	H19	 seems	 to	have	opposing	 roles	 in	 cancer.	 It	was	described	as	 an	
oncogene	 in	 hepatocellular	 carcinoma	 and	 bladder	 cancer	 but	 displays	 tumor-
suppressive	functions	in	a	colorectal	cancer	mouse	model	[165,	166].		
In	addition	to	lincRNA-p21	and	RoR,	there	are	several	lncRNAs	that	are	involved	
in	 the	 (in-)direct	 transcriptional	 regulation	 of	 the	 tumor	 suppressor	 p53.	MALAT1,	
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which	 is	 overexpressed	 in	 several	 types	 of	 cancers,	 controls	 cell	 cycle	 progression	
and	 its	depletion	 results	 in	a	G1	arrest	 and	 the	activation	of	p53	 [167].	Moreover,	
MALAT1	 influences	 alternative	 mRNA	 splicing	 by	 modulating	 the	 activity	 of	 SR	
splicing	 factors	 [156].	 In	contrast,	 the	 imprinted	 lncRNA	MEG3	negatively	 regulates	
MDM2	expression	which	 leads	 to	an	accumulation	of	p53	 [168].	p53	has	a	natural	
antisense	 transcript,	Wrap53,	 that	 is	 located	 on	 the	 opposite	 strand	 immediately	
upstream	of	p53	and	partly	overlaps	with	p53	in	an	antisense	fashion	[169].	Wrap53	
positively	regulates	p53	on	the	posttranscriptional	level.	Moreover,	several	enhancer	
RNAs	 (eRNAs)	 are	 transcribed	 from	 p53-bound	 enhancer	 regions	 and	 thereby	
contribute	to	the	long-distance	regulation	of	DUSP4,	PAPPA	and	IER5	by	p53	[170].	
	
1.4	Epithelial-mesenchymal	transition	in	cancer	progression	
The	epithelial-mesenchymal	 transition	 (EMT)	 represents	a	 reversible	 switch	 that	
allows	 immotile,	 polarized,	 epithelial	 cells	 to	 acquire	 mesenchymal	 traits	
characterized	by	the	loss	of	polarity,	the	reduction	of	intercellular	adhesions	and	an	
increase	in	motility	(Fig.	5).		
	
	
Figure	5:	Model	of	EMT.	Epithelial	cells	are	characterized	by	cell	polarity,	cell	adhesion,	a	stationary	
phenotye	 and	 high	 expression	 of	 the	 adherens	 junction	 protein	 E-cadherin.	 During	 EMT,	 epithelial	
cells	switch	to	a	mesenchymal	phenotype	characterized	by	the	loss	of	cell	polarity	and	adhesion,	the	
ability	 to	 invade	and	migrate	and	 the	expression	of	 the	EMT-promoting	 transcription	 factors	SNAIL,	
ZEB	and	TWIST.	
	
Initially,	 the	 transition	 between	 an	 epithelial	 and	mesenchymal	 phenotype	was	
identified	 as	 an	 embryonal	 program	 involved	 in	 developmental	 processes,	 such	 as	
gastrulation,	neural	crest	formation	and	heart	morphogenesis	[171].	Moreover,	EMT	
is	associated	with	tissue	regeneration	and	fibrosis	[172,	173].	Furthermore,	it	is	also	
widely	 accepted	 by	 now	 that	 EMT	 plays	 an	 important	 role	 in	 tumorigenesis.	 It	
enables	cancer	cells	to	acquire	invasive	and	stem-cell	like	traits,	which	allow	cells	to	
disseminate	from	the	primary	tumor	to	form	metastases	in	distant	organs	[174].	
EMT	 is	 induced	 via	 several	 different	 stimuli,	 including	 hypoxia,	 deregulated						
TGF-β-,	Wnt-,	Notch-	and/or	receptor	tyrosine	kinase	signaling,	which	activates	the	
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expression	of	canonical	EMT-activating	 transcription	 factors,	 such	as	SNAIL,	ZEB1/2	
and	TWIST,	as	well	as	the	Krüppel-like	factor	KLF8	or	the	bHLH	factor	E47	[175,	176].	
EMT-TFs	 are	 known	 to	 repress	 the	 adherens-junction	 protein	 E-cadherin/CDH1	 via	
binding	 to	 so-called	 E(enhancer)-boxes	 in	 its	 promoter.	 Repression	 of	 CDH1	 is	
considered	 as	 a	 hallmark	 during	 EMT	 [177].	 Furthermore,	 mesenchymal-specific	
markers	 such	 as	 the	 intermediate	 filament	 Vimentin	 and	 the	 extracellular	 matrix	
glycoprotein	Fibronectin	are	up-regulated.			
More	recently	also	miRNAs	have	been	implicated	in	the	control	of	EMT.	The	miR-
200	family	for	example	was	shown	to	target	the	EMT	transcription	factors	ZEB1	and	
ZEB2	[97]	and	miR-34a	to	down-regulate	SNAIL	[1,	178].		
Interestingly,	 the	 EMT-inducing	 transcription	 factors	 have	 not	 only	 been	
implicated	in	promoting	invasion	and	migration	but	also	in	inducing	stemness	[179-
181].	This	allows	cancer	cells	to	acquire	stem	cell	traits	such	as	the	capacity	for	self-
renewal	which	is	necessary	for	metastasis	formation	[182].		
It	has	been	shown	that	disseminated	cancer	cells	regain	their	epithelial	phenotype	
by	reversing	EMT	 in	a	process	called	mesenchymal-epithelial	 transition	(MET).	MET	
allows	cells	to	form	tumors	at	the	metastatic	site	[174].		
	
1.5	The	role	of	vitamin	D3	in	cancer	
Vitamin	D3	is	synthesized	in	skin	exposed	to	sunlight	or	is	derived	from	the	diet.	
Two	hydroxylation	steps	mediated	by	the	hydroxylases	CYP27A1	and	CYP27B1	in	the	
liver	 and	 in	 the	 kidney,	 respectively,	 convert	 vitamin	 D3	 to	 the	 active	 metabolite	
calcitriol	 (1,25-dihydroxy-vitamin	 D3)	 [183].	 The	 catabolic	 hydroxylase	 CYP24A1	
mediates	 the	 degradation	 of	 calcitriol	 and	 the	 intermediate	 metabolite	 25-
hydroxyvitamin	 D3	 (25(OH)D3)	 [183].	 Interestingly,	 CYP27B1	 is	 also	 expressed	 at	
extrarenal	 sites	 including	 brain,	 colon,	 pancreas	 or	 skin,	 which	 allows	 local	
conversion	 of	 the	 intermediate	 metabolite	 25-hydroxyvitamin	 D3	 (25(OH)D3)	 to	
calcitriol	[184].		
Calcitriol	 regulates	 intestinal	 calcium-	 and	 phosphate-absorption	 and	 controls	
bone	mineralization	[185].	Moreover,	 it	 increases	differentiation	and	apoptosis	and	
has	 been	 shown	 to	 inhibit	 proliferation,	 inflammation,	 angiogenesis	 and	
invasion/metastasis	 [186].	 There	 is	 increasing	 evidence	 that	 vitamin	 D3	 acts	 as	 an	
anticancer	 agent	 [187].	 Alterations	 in	 the	 synthesis	 and	 catabolism	 of	 vitamin	 D3	
metabolites	 often	 occur	 during	 cancer	 progression.	 Elevated	 expression	 levels	 of	
CYP27B1	 were	 detected	 in	 breast	 and	 prostate	 cancer,	 and	 during	 early	 stages	 of	
colorectal	cancer	[188-192].	However,	CYP24A1	is	up-regulated	in	a	variety	of	cancer	
types	and	 limits	the	anti-tumorigenic	effect	of	vitamin	D3	by	catabolising	25(OH)D3	
and	 calcitriol	 [193-195].	 Several	 small-molecule	 inhibitors	 for	 CYP24A1	 act	 as	
anticancer	agents	and	enhance	the	antiproliferative	effect	of	calcitriol	[196-198].	
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The	 genomic	 response	 to	 calcitriol	 results	 from	 its	 binding	 to	 the	 vitamin	 D	
receptor	(VDR),	which	regulates	gene	expression	via	sequence-specific	binding	sites.	
Several	direct	VDR	target	genes,	 such	as	CDKN1A	or	CDH1,	have	been	 identified	 in	
colorectal	cancer	cells	(reviewed	in	[199]).	Among	these,	CST5,	which	codes	for	the	
cysteine	 protease	 inhibitor	 cystatin	 D,	 has	 been	 described	 as	 a	 tumor	 suppressive	
factor	 in	 colorectal	 cancer	 [200].	 In	 addition,	 calcitriol	 indirectly	 affects	 the	
expression	of	a	 large	number	of	genes	by	antagonizing	Wnt/β-catenin	signaling	via	
different	 mechanisms	 [201].	 Calcitriol	 promotes	 VDR/β-catenin	 interaction	 which	
results	 in	 reduced	 binding	 of	 β-catenin	 to	 TCF4	 [202].	 Additionally,	 it	 induces													
E-cadherin	 which	 leads	 to	 the	 inhibition	 of	 Wnt	 signaling	 by	 nuclear	 export	 of											
β-catenin	and	its	relocalization	to	the	plasma	membrane	[202].	Moreover,	calcitriol-
induced	 DKK-1,	 an	 extracellular	 inhibitor	 of	 Wnt	 signaling,	 binds	 to	 the	 Wnt														
co-receptor	LRP6	thereby	preventing	Wnt-Frizzled-LRP6	complex	formation	[203].		
Several	 epidemiological	 studies	 have	 revealed	 a	 negative	 correlation	 between	
sunlight	 exposure	 and	 the	 incidence	 for	 colon	 and	 prostate	 cancer	 suggesting	 a	
potential	 role	 of	 vitamin	 D3	 in	 reducing	 cancer	 risk	 [204].	 Furthermore,	 high	
circulating	 25(OH)D3	 levels	 are	 associated	 with	 a	 30	 –	 40%	 lower	 risk	 to	 develop	
colorectal	cancer	and	an	increased	overall	survival	in	colorectal	cancer	patients	[205,	
206].	 Moreover,	 prostate	 cancer	 patients	 with	 low	 prediagnostic	 25(OH)D3-levels	
have	a	60%	higher	risk	to	die	from	cancer	[207].	However,	no	or	only	a	weak	positive	
correlation	 between	 circulating	 25(OH)D3-levels	 and	 lower	 cancer	 risk	 for	 breast	
[208]	or	prostate	cancer	[209]	has	been	shown.	
Several	 in	 vitro	 and	 in	 vivo	 studies	 have	 confirmed	 the	 role	 of	 calcitriol	 as	 an	
anticancer	 agent.	 It	 has	 been	 shown	 that	 calcitriol	 inhibits	 proliferation,	
inflammation	 and	 angiogenesis	 and	 leads	 to	 the	 induction	 of	 apoptosis,	
differentiation	 and	 reduced	 invasion	 and	 migration	 in	 several	 different	 types	 of	
cancer	cells	[187].	Furthermore,	a	tumor-inhibiting	effect	of	dietary	calcitriol	uptake	
was	detected	in	several	different	animal	models	[199].	Meta-analyses	of	randomized	
clinical	 studies	 show	a	 significant	 impact	of	 vitamin	D3	on	 the	 reduction	of	 cancer	
mortality	 [210-214].	 Several	 large-scale	 and	 long-term	 randomized	 clinical	 trials	
studying	the	effect	of	vitamin	D3	are	expected	to	be	completed	within	the	next	five	
years	[215].		
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2.	AIMS	OF	THE	STUDY	
	
	
The	present	work	had	the	following	aims:	
	
	
1) Characterization	 of	 the	 regulatory	 network	 between	 p53,	 miR-34a	 and	 its	
target	 SNAIL	 during	 mesenchymal-epithelial	 transition	 of	 colorectal	 cancer	
cell	lines.	
	
2) Genome-wide	 identification	 and	 characterization	 of	 p53-regulated	 proteins,	
mRNAs,	miRNAs	and	lncRNAs	in	colorectal	cancer	cells.			
	
3) Characterization	 of	 the	 newly	 identified	 p53	 target	 gene	 CST5	 and	
determination	of	its	role	in	p53-mediated	mesenchymal-epithelial	transition.	
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3.	MATERIALS	
	
3.1	Chemicals	and	reagents	
Chemical	 Supplier	
Ammonium	peroxodisulfate	(APS)	 Carl	Roth	GmbH,	Karlsruhe,	Germany	
Ampicillin	 Sigma-Aldrich,	St.Louis,	MD,	USA	
BD	Matrigel™	Basement	Membrane	Matrix	 BD	Bioscience,	Heidelberg,	Germany	
Calcitriol	 Sigma-Aldrich,	St.Louis,	MD,	USA	
Complete	mini	protease	inhibitor	cocktail	 Roche	Diagnostics	GmbH,	Mannheim,	Germany	
Dimethyl-sulfoxide	(DMSO)	 Carl	Roth	GmbH,	Karlsruhe,	Germany	
dNTPs	(deoxynucleotides	triphosphate)	 Thermo	Fisher	Scientific,	Inc.,	Waltham,	MA,	USA	
Doxycycline	hyclate	 Sigma-Aldrich,	St.Louis,	MD,	USA	
DAPI	(2-(4-Amidinophenyl)-6-indolecarbamidine-
dihydrochloride)	 Carl	Roth	GmbH,	Karlsruhe,	Germany	
ECL/HRP	substrate	 Immobilon,	Merck	Millipore,	Billerica,	MA,	USA	
Ethidium	bromide	 Carl	Roth	GmbH,	Karlsruhe,	Germany	
Etoposide	 Sigma-Aldrich,	St.Louis,	MD,	USA	
Fast	SYBR®	Green	Master	Mix	 Applied	Biosystems,	Foster	City,	CA,	USA	
Fast	SYBR	Green	Master	Mix	Universal	RT	 Exiqon	A/S,	Vedbaek,	Denmark	
FCS	(Fetal	calf	serum)	 Gibco®,	Life	Technologies	GmbH,	Darmstadt,	Germany	
FuGENE®6	Transfection	Reagent	 Promega,	Madison,	WI,	USA	
Hi-Di™	Formamide	 Applied	Biosystems,	Foster	City,	CA,	USA	
HiPerFect	Transfection	Reagent	 Qiagen	GmbH,	Hilden,	Germany	
Immobilon-P	Transfer	Membrane	 Immobilon,	Merck	Millipore,	Billerica,	MA,	USA	
LB-Agar	(Lennox)	 Carl	Roth	GmbH,	Karlsruhe,	Germany	
LB-Medium	(Luria/Miller)	 Carl	Roth	GmbH,	Karlsruhe,	Germany	
Mitomycin	C		 Sigma-Aldrich,	St.Louis,	MD,	USA	
Nonidet®P40	substitute	 Sigma-Aldrich,	St.Louis,	MD,	USA	
Nutlin-3a	 Sigma-Aldrich,	St.Louis,	MD,	USA	
Opti-MEM®	Reduced	Serum	Medium	 Life	Technologies	GmbH,	Darmstadt,	Germany	
Paraformaldehyde	 Merck	KgaA,	Darmstadt,	Germany	
ProLong	Gold	antifade		 Invitrogen	GmbH,	Karlsruhe,	Germany	
Propidium	iodide	 Sigma-Aldrich,	St.Louis,	MD,	USA	
Puromycin	dihydrochloride	 Sigma-Aldrich,	St.Louis,	MD,	USA	
Rotiphorese	gel	30	(37,5:1)	 Carl	Roth	GmbH,	Karlsruhe,	Germany	
Sea	plaque®	agarose	 Lonza	Ltd,	Basel,	Switzerland	
Skim	milk	powder	 Fluka,	Sigma-Aldrich,	St.Louis,	MD,	USA	
Sodium	dodecyl	sulfate	(SDS)	 Carl	Roth	GmbH,	Karlsruhe,	Germany	
Temed	(tetramethylethylendiamin,1,2-bis	
(dimethylamino)	–ethan)	 Carl	Roth	GmbH,	Karlsruhe,	Germany	
TritonX	100	 Carl	Roth	GmbH,	Karlsruhe,	Germany	
Tween	20	 Sigma-Aldrich,	St.Louis,	MD,	USA	
Water	(molecular	biological	grade)	 Gibco®,	Life	Technologies	GmbH,	Darmstadt,	Germany	
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3.2	Enzymes	
Enzyme	 Supplier	
DNase	I	(RNase-free)	 Sigma-Aldrich,	St.Louis,	MD,	USA	
FIREPol®	DNA	Polymerase	 Solis	BioDyne,	Tartu,	Estonia	
Platinum®	Taq	DNA	polymerase	 Invitrogen	GmbH,	Karlsruhe,	Germany	
Proteinase	K	 Sigma-Aldrich,	St.Louis,	MD,	USA	
Restriction	endonucleases	 New	England	Biolabs	GmbH,	Frankfurt,	Germany	
RNase	A	 Sigma-Aldrich,	St.Louis,	MD,	USA	
T4	DNA	ligase	 Thermo	Fisher	Scientific,	Inc.,	Waltham,	MA,	USA	
Trypsin	(10x,	phenol-red	free)	 Invitrogen	GmbH,	Karlsruhe,	Germany	
	
3.3	Kits	
Kit	 Supplier	
BCA	Protein	Assay	Kit		 Pierce,	Thermo	Fisher	Scientific,	Inc.,	Waltham,	MA,	USA	
BigDye®	Terminator	v3.1	Cycle		
Sequencing	Kit		 Life	Technologies	GmbH,	Darmstadt,	Germany	
DyeEx®	2.0	Spin	Kit	 QIAGEN	GmbH,	Hilden,	Germany	
High	Pure	RNA	Isolation	Kit	 Roche	Diagnostics	GmbH,	Mannheim,	Germany	
High	Pure	miRNA	Isolation	Kit	 Roche	Diagnostics	GmbH,	Mannheim,	Germany	
miRCURY	LNATM	Universal	RT	microRNA	PCR	–	
Universal	cDNA	Synthesis	Kit	II	 Exiqon	A/S,	Vedbaek,	Denmark	
Pure	Yield™	Plasmid	Midiprep	System	 Promega	GmbH,	Mannheim,	Germany	
TaqMan®	MicroRNA	Reverse		
Transcription	Kit	
Applied	Biosystems,	Life	Technologies	GmbH,	
Darmstadt,Germany	
TaqMan®	PreAmp	Master	Mix		 Applied	Biosystems,	Life	Technologies	GmbH,	Darmstadt,Germany	
TaqMan®	Universal	Master	Mix	 Applid	Biosystems,	Life	Technologies	GmbH,	Darmstadt,	Germany	
QIAprep	Spin	Miniprep	Kit	 QIAGEN	GmbH,	Hilden,	Germany	
QIAquick	Gel	Extraction	Kit	 QIAGEN	GmbH,	Hilden,	Germany	
QuikChange	II	Site-Directed	Mutagenesis	Kit	 Stratagene,	Agilent	Technologies	GmbH	&	Co.KG,	Waldbronn,	Germany	
Verso	cDNA	Kit	 Thermo	Fisher	Scientific,	Inc.,	Waltham,	MA,	USA	
	
3.4	Antibodies	
3.4.1	Primary	antibodies	
Epitope	 Clone	 Ordering	no.	 Company	 Use	 Dilution	 Source	
β-actin	 		 #	A2066	 Sigma	 WB	 1:1000	 rabbit	
CST5	 N-19	 #	sc-46890	 Santa	Cruz	 WB;	IF	 1:200;	1:50	 goat	
E-cadherin		 4A2C7	 #	334000	 Invitrogen	 WB;	IF	 1:1000;	1:50	 mouse	
mouse	IgG	 	 	 Santa	Cruz	 ChIP	 	 mouse	
p21	 CP-74	 	 Neomarkers	 WB	 1:1000	 mouse	
p53	 DO-1	 #	sc-126	 Santa	Cruz	 WB;	ChIP	 1:1000	 mouse	
rabbit	IgG	 	 #	R-5506	 Sigma	 ChIP	 	 rabbit	
SNAIL	 		 #	3879S	 Cell	Signaling	 WB	 1:200	 rabbit	
SNAIL	 	 #	AF3639	 R&D	Systems	 WB	 1:500	 goat	
SLUG	 H-140	 #	sc-15391x	 Santa	Cruz	 WB	 1:2000	 rabbit	
VSV	 		 #	V4888	 Sigma	 WB;	ChIP	 1:7500	 rabbit	
WB	=	Western	blot,	IF	=	immunofluorescence,	ChIP	=	chromatin	immunoprecipitation		
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3.4.2	Secondary	antibodies	
Name	 Source	 Application	 Supplier	
anti-goat	HRP	 donkey	 WB	 Jackson	Immuno	Reseach,	Ltd.,	Newmarket,	Suffolk,	UK	
anti-goat	Cy3	 donkey	 IF	 Jackson	Immuno	Reseach,	Ltd.,	Newmarket,	Suffolk,	UK	
anti-mouse	HRP	 goat	 WB	 Promega	GmbH,	Mannheim,	Germany	
anti-mouse-
Alexa	Fluor-555	 goat	 IF	 Invitrogen	GmbH,	Karlsruhe,	Germany	
anti-rabbit	HRP	 goat	 WB	 Sigma-Aldrich,	St.Louis,	MD,	USA	
WB	=	Western	blot,	IF	=	immunofluorescence	
	
3.5	Vectors	and	oligonucleotides	
3.5.1	Vectors	
Name	 Insert	 Reference	
pBV-Luc	 	 [216]	
pBV-Luc	miR-486	p53	BS	 miR-486	p53	BS	 this	work	
pcDNA	 	 	
pcDNA-p53-VSV	 p53	 	
pGL3-control-MCS	 	 [217,	218]	
pGL3-KLF12	3´-UTR,	miR-34a	BS	 KLF12	3´-UTR,	miR-34a	BS	 this	work	
pGL3-KLF12	3´-UTR,	miR-34a	BS	mut	 KLF12	3´-UTR,	miR-34a	BS	mutated	 this	work	
pGL3-KLF12	3´-UTR,	miR-205	BS	 KLF12	3´-UTR,	miR-205	BS	 this	work	
pGL3-KLF12	3´-UTR,	miR-205	BS	mut	 KLF12	3´-UTR,	miR-205	BS	mutated	 this	work	
pGL3-HMGB1	3´-UTR,	miR-205	BS	 HMGB1	3´-UTR,	miR-205	BS	 this	work	
pGL3-HMGB1	3´-UTR,	miR-205	BS	mut	 HMGB1	3´-UTR,		miR-205	BS	mutated	 this	work	
pGL3-CIT	3´-UTR,	miR-486	BS	 CIT	3´-UTR,		miR-486	BS	 this	work	
pGL3-CIT	3´-UTR,	miR-486	BS	mut	 CIT	3´-UTR,		miR-486	BS	mutated	 this	work	
pRL	 Renilla	 [219]	
pRTR	 	 [220]	
pRTR-p53-VSV	 p53	 [1]	
pRTR-SNAIL-VSV	 SNAIL	 [1]	
BS:	binding	site;	UTR:	untranslated	region;	mut:	mutated	
	
3.5.2	Oligonucleotides	
 
3.5.2.1	Oligonucleotides	used	for	qPCR	
Name	 Sequence	(5´à 	3´)	
β-actin	Fwd	 TGACATTAAGGAGAAGCTGTGCTAC	
β-actin	Rev	 GAGTTGAAGGTAGTTTCGTGGATG	
β-catenin	Fwd	 AGCTGACCAGCTCTCTCTTCA	
β-catenin	Rev	 CCAATATCAAGTCCAAGATCAGC	
CIT	Fwd	 TGGAAGGTGATGACCGTCTA		
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Name	 Sequence	(5´à 	3´)	
CIT	Rev	 ACGTCCACAAGACACAGTGC		
CST5	Fwd	 CCTCTGCAGGTGATGGCTG	[200]	
CST5	Rev	 GGACTTGGTGCATGTGGTTC	[200]	
CDH1	Fwd	 CCCGGGACAACGTTTATTAC	
CDH1	Rev	 GCTGGCTCAAGTCAAAGTCC	
HMGB1	Fwd	 ATATGGCAAAAGCGGACAAG		
HMGB1	Rev	 GCAACATCACCAATGGACCAG		
LINC01021	Fwd	 TGTTTTCCTTTTTGCCCAAT	
LINC01021	Rev	 CGCCTGGTAAAACAACCAGT	
MDFI	Fwd	 AAATCCACCACCTCCCAGA	
MDFI	Rev	 CAGGAACTCGCAGAACAGG	
pri-miR-200b	Fwd	 CGCAGCAGTGGAACCTGT	
pri-miR-200b	Rev	 GTGAGGAGGTGCTGGGATG	
pri-miR-200c	Fwd	 CTTAAAGCCCCTTCGTCTCC	
pri-miR-200c	Rev	 AGGGGTGAAGGTCAGAGGTT	
pri-miR-205	Fwd	 CCACCTTTCCTCAGGAGTCA		
pri-miR-205	Rev	 CCAAGATGGGTACTTGAGAGATG		
pri-miR-34a	Fwd	 CGTCACCTCTTAGGCTTGGA	
pri-miR-34a	Rev	 CATTGGTGTCGTTGTGCTCT	
pri-miR-34b/c	Fwd	 GAGCTGCCTGTGCATCATC	
pri-miR-34b/c	Rev	 GGATGAAATCAGCATTTTCCA	
pri-miR-486	Fwd	 CTCCTTGGAGTAGCCTCTCG		
pri-miR-486	Rev	 CCAGCTCTCCTCCTGTGTG		
p21	Fwd	 GGCGGCAGACCAGCATGACAGATT	
p21	Rev	 GCAGGGGGCGGCCAGGGTAT	
SLUG	Fwd	 TGGTTGCTTCAAGGACACAT	
SLUG	Rev	 GTTGCAGTGAGGGCAAGAA	
SNAIL	Fwd	 GCACATCCGAAGCCACAC	
SNAIL	Rev	 GGAGAAGGTCCGAGCACA	
ST14	Fwd	 CTTCCCTCATCTCTCCCAACT	
ST14	Rev	 GCGTGGGGTCTGAGTACCT	
Vimentin	Fwd	 TACAGGAAGCTGCTGGAAGG	
Vimentin	Rev	 ACCAGAGGGAGTGAATCCAG	
Fwd:	forward;	Rev:	reverse	
	
3.5.2.2	Oligonucleotides	used	for	qChIP	
Name	 Sequence	(5´à 	3´)	
p53	BS	CST5	Fwd	 TAAGAGACCGGAAAGGTTGAGA	
p53	BS	CST5	Rev	 AGGGCCTTTGCACTGACTATT	
SNAIL	BS	CST5	Fwd	 GGGGACACCCAAGTAGGATAA	
SNAIL	BS	CST5	Fwd	 GGAGCTGGATCTCCCAGAG	
SNAIL	BS	CDH1	Fwd	 TAGAGGGTCACCGCGTCTAT	
SNAIL	BS	CDH1	Rev	 TCACAGGTGCTTTGCAGTTC	
ELF1α	Fwd	 CACACGGCTCACATTGCAT	
ELF1α	Rev	 CACGAACAGCAAAGCGACC	
p53	BS	MDFI	Fwd	 CAAGCCCTGTGGTTTTTCC	
p53	BS	MDFI	Rev	 CCATGTGGGAAGCACAGA	
p53	BS	miR-205	Fwd	 AGGATCTAGCATCAGCAAAACAT		
p53	BS	miR-205	Rev	 CCATTGCAGTTTGAATTCCTT		
p53	BS	miR-486	Fwd	 GAACAGTCCACAGGCACAGA		
p53	BS	miR-486	Rev	 AACAGAATTTTCCATTGCCG		
p53	BS	LINC01021	Fwd	 CATGAGGAATTCATGCCTTG	
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Name	 Sequence	(5´à 	3´)	
p53	BS	LINC01021	Rev	 TCCCAGGTCACCACAAGAG	
p53	BS	ST14	Fwd	 GAATGACCTGGAGCACTTGAAT	
p53	BS	ST14	Rev	 CCCTGGAGGTGCTGATGT	
BS:	binding	site;	Fwd:	forward;	Rev:	reverse	
	
3.5.2.3	Oligonucleotides	used	for	cloning	and	mutagenesis	
Name	 Sequence	(5´à 	3´)	
CIT	3´-UTR		
miR-486	BS	Fwd	 TTTGGTACCGGTAACTTGCCCAGACATGC		
CIT	3´-UTR		
miR-486	BS	Rev	 TTTGAATTCGGCATCAATGAGGCTGGTAG		
CIT	3´-UTR		
miR-486	BS	mut	Fwd	 CTAGGTCTCCAAAACTACCCCCTTTTTCTTCATTACCTTTT	
CIT	3´-UTR		
miR-486	BS	mut	Rev	 AAAAGGTAATGAAGAAAAAGGGGGTAGTTTTGGAGACCTAG	
HMGB1	3´-UTR		
miR-205	BS	Fwd	 TTTGAATTCATGAATTATTACAGTGTTTATCCT	
HMGB1	3´-UTR		
miR-205	BS	Rev	 TTTACTAGTGCTGGCCCAATTAATTAAAAATA	
HMGB1	3´-UTR		
miR-205	BS	mut	Fwd	 CATTTTGAAAGTCTGTCCTTCACCCACTAATAGAAAAGTATG	
HMGB1	3´-UTR		
miR-205	BS	mut	Rev	 CATACTTTTCTATTAGTGGGTGAAGGACAGACTTTCAAAATG	
KLF12	3´-UTR		
miR-34a	BS	Fwd	 TTTGAATTCCCTTAATATTCATAGTTCATAATCCA	
KLF12	3´-UTR		
miR-34a	BS	Fwd	 TTTACTAGTGAAACTGTGAAAATATAGCAATTT	
KLF12	3´-UTR		
miR-34a	BS	mut	Fwd	 TTCTACTCATCCCCACAGTCGGTTCCACTTAACCTGTACAG	
KLF12	3´-UTR		
miR-34a	BS	mut	Rev	 CTGTACAGGTTAAGTGGAACCGACTGTGGGGATGAGTAGA	
KLF12	3´-UTR		
miR-205	BS	Fwd	 TTTGAATTCATTTCTCCAGTTTATCTAAAGACC	
KLF12	3´-UTR		
miR-205	BS	Rev	 TTTACTAGTTTTTGTTCCATACAAAATGCTTTATTTA	
KLF12	3´-UTR		
miR-205	BS	mut	Fwd	 GTATAATTATCTGACCCAAGGCCCGAAGGTTAAATAAAGCATTTG	
KLF12	3´-UTR		
miR-205	BS	mut	Rev	 CAAATGCTTTATTTAACCTTCGGGCCTTGGGTCAGATAATTATAC	
miR-486	p53	BS	Fwd	 TTTGGTACCGGTAACTTGCCCAGACATGC		
miR-486	p53	BS	Rev	 TTTGAATTCGGCATCAATGAGGCTGGTAG		
LINC01021_A	Fwd	 TTTACTAGTCTGGGAATCAATGTGTGAGGT	
LINC01021_A	Rev	 TTTGAGCTCTTAAGCCCCTCATTCGTTATATTTT	
Oligonucleotides	used	for	the	generation	of	a	small	RNA	library	(miR-Seq)	
adenylated	3’	adapter	 Phospho-TGGAATTCTCGGGTGCCAAGG-(C7amino)	
5’	RNA	adapter	 GUUCAGAGUUCUACAGUCCGACGAUC	
specific	oligonucleotide	for	
reverse	transcription	 GCCTTGGCACCCGAGAATTCCA	
5’	PCR	oligonucleotide	 AATGATACGGCGACCACCGAGATCTACACGTTCAGAGTTCTACAGTCCGA	
3’	PCR	oligonucleotide	 CAAGCAGAAGACGGCATACGAGAT-6nt	Barcode-GTGACTGGAGTTCCTTGGCACCCGAGAATTCCA	
BS:	binding	site;	UTR:	untranslated	region;	Fwd:	forward;	Rev:	reverse,	mut:	mutated	
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3.5.3	miRNA	mimics	and	antagomiRs	
The	following	pre-microRNA	mimics	and	antagomiRs	were	purchased	from	Ambion:	
− pre-miR-control	
− pre-miR-34a	
− pre-miR-205	
− pre-miR-486-5p	
− anti-miR-control	
− anti-miR-34a	
	
3.6 Buffers	and	solutions	
− 2x	Laemmli	buffer:	
125	mM	TrisHCl	(pH	6.8),	4%	SDS,	20%	glycerol,	0.05%	bromophenol	blue	(in	
H2O),	10%	β-mercaptoethanol	(added	right	before	use)	
− 10x	„Vogelstein“	PCR	buffer:	
166	 mM	 NH4SO4,	 670	 mM	 Tris	 (pH	 8.8),	 67	 mM	 MgCl2,	 100	 mM	 β-
mercaptoethanol	
− Propidium	iodide	staining	solution:	
800	µl	propidium	iodide	(1.5	mg/ml),	1000	µl	RNase	A	(10	mg/ml),	add	20	ml	
PBS	0.1%	TritonX	100			
− RIPA	buffer:	
1%	NP40,	0.5%	sodium	deoxycholate,	0.1%	SDS,	250	mM	NaCl,	50	mM	TrisHCl	
(pH	8.0)		
− SDS	buffer:	
50	mM	Tris	(pH	8.1),	100	mM	NaCl,	0.5	%	SDS,	5	mM	EDTA		
− 10x	Tris-glycine-SDS	running	buffer:	
720	g	Glycin,	150	g	Tris	base,	50	g	SDS,	pH	8.3-8.7,	add	5	l	ddH2O	
− Triton	dilution	buffer:	
100	mM	Tris-HCl	(pH	8.6),	100	mM	NaCl,	5	mM	EDTA	(pH	8.2),	0.2%	NaN3,	5%	
TritonX-100	
− Towbin	buffer:	
200	mM	glycine,	20%	methanol,	25	mM	Tris	base	(pH	8.6)	
− 10x	TBS-T:	
500 	ml	1M	Tris	(pH	8.0),	438.3	g	NaCl,	50	ml	Tween20,	add	5l	ddH2O	
− Urea	lysis	buffer:	
30	mM	Tris	Base,	7	M	Urea,	2	M	Thio-Urea,	pH	8.5	
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3.7	Laboratory	equipment	
Device	 Supplier	
5417C	table-top	centrifuge		 Eppendorf	AG,	Hamburg,	Germany	
ABI	3130	genetic	analyzer	capillary	sequencer	 Applied	Biosystems,	Foster	City,	USA	
Axiovert	25	microscope		 Carl	Zeiss	GmbH,	Oberkochen,	Germany	
BD	AccuriTM	C6	Flow	Cytometer	Instrument	 Accuri,	Erembodegem,	Belgium	
Biofuge	fresco	 Heraeus;	Thermo	Fisher	Scientific,	Inc.,	Waltham,	MA,	USA	
Biofuge	pico	table	top	centrifuge	 Heraeus;	Thermo	Fisher	Scientific,	Inc.,	Waltham,	MA,	USA	
Boyden	chamber	transwell	membranes	
(pore	size	8.0	µm)		 Corning	Inc.,	Corning,	NY,	USA	
CF40	Imager		 Kodak,	Rochester,	New	York,	USA	
Falcons,	dishes	and	cell	culture	materials	 Schubert	&	Weiss	OMNILAB	GmbH	&	Co.	KG	
Fisherbrand	FT-20E/365	transilluminator	 Fisher	Scientific	GmbH,	Schwerte,	Germany	
Forma	scientific	CO2	water	jacketed	incubator	
Thermo	Fisher	Scientific,	Inc.,	Waltham,	MA,	
USA	
GeneAmp®	PCR	System	9700		 Applied	Biosystems,	Foster	City,	USA	
Herasafe	KS	class	II	safety	cabinet	 Thermo	Fisher	Scientific,	Inc.,	Waltham,	MA,	USA	
HTU	SONI130		 G.	Heinemann	Ultraschall-	und	Labortechnik,	Schwäbisch	Gmünd	
Megafuge	1.0R	 Heraeus;	Thermo	Fisher	Scientific,	Inc.,	Waltham,	MA,	USA	
Mini-PROTEAN®-electrophoresis	system	 Bio-Rad,	München,	Germany	
MultiImage	Light	Cabinet		 Alpha	Innotech,	Johannesburg,	South	Africa	
ND	1000	NanoDrop	Spectrophotometer	 NanoDrop	products,	Wilmington,	DE,	USA	
Neubauer	counting	chamber		 Carl	Roth	GmbH	&	Co,	Karlsruhe,	Germany	
Orion	II	luminometer	 Berthold	Technologies	GmbH	&	Co.	KG,	Bad	Wildbad,	Germany	
PerfectBlue™	SEDEC	'Semi-Dry'	blotting		
system		
Peqlab	Biotechnologie	GmbH,	Erlangen,	
Germany	
Varioscan	Flash	Multimode	Reader	 Thermo	Scientific,	Inc.,	Waltham,	MA,	USA	
Waterbath	 Memmert	GmbH,	Schwabach,	Germany	
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4.	METHODS	
	
4.1	Bacterial	cell	culture	
4.1.1	Propagation	and	seeding	
The	 bacterial	 E.coli	 strain	 XL1-blue	 was	 used	 for	 cloning	 procedures	 and	 the	
replication	 of	 plasmids	 that	 harbored	 a	 resistance	 against	 ampicillin.	 The	 bacteria	
were	 propagated	 in	 LB-medium	 (agitation,	 225	 rpm)	 or	 on	 LB-agar	 plates	 at	 37°C	
overnight.	To	select	for	those	cells	with	an	antibiotic	resistance,	100	µg/ml	ampicillin	
was	added	to	the	LB-medium.	
4.1.2	Transformation	
To	 transform	plasmid	DNA,	 competent	E.coli	 XL1-blue	 strains	 that	were	 kept	 at						
-80°C	were	carefully	thawed	on	ice	and	the	plasmid	DNA	was	added.	Afterwards,	the	
cells	 were	 kept	 on	 ice	 for	 30	 minutes	 followed	 by	 a	 heat	 shock	 at	 42°C	 for	 90	
seconds.	Subsequently,	the	bacteria	were	placed	on	ice	for	2	minutes	and	incubated	
in	 1	 ml	 LB-medium	 without	 antibiotics	 at	 37°C	 for	 1	 hour.	 Finally,	 the	 cells	 were	
centrifuged	 at	 2000	 rpm	 for	 5	 minutes,	 the	 supernatant	 was	 discarded	 and	 the	
bacteria	were	 resuspended	and	plated	on	a	 LB	 agar	plate	 containing	 ampicillin	 for	
overnight	incubation.	
4.1.3	Purification	of	plasmid	DNA	from	E.coli	
Small	amounts	of	plasmid	DNA	were	generated	inoculating	a	single	bacterial	clone	
in	 5	 ml	 of	 LB-medium	 that	 was	 supplemented	 with	 ampicillin.	 After	 overnight	
incubation	 at	 37°C,	 225	 rpm	 the	 plasmid	 DNA	 was	 isolated	 according	 to	 the	
manufacturer´s	protocol	using	the	QIAprep	Spin	Miniprep	Kit	(Qiagen).	To	prepare	a	
bigger	 volume	 with	 a	 higher	 plasmid	 concentration,	 150	 ml	 of	 LB-medium	 (with	
ampicillin)	 were	 incubated	 overnight	 at	 37°C,	 225	 rpm	 and	 the	 plasmid	 DNA	 was	
isolated	the	next	day	following	the	instructions	of	the	Pure	Yield™	Plasmid	Midiprep	
System	(Promega).		
	
4.2	Cell	culture	of	human	cell	lines	
4.2.1	Propagation	of	human	cell	lines	
The	colorectal	cancer	cell	lines	HCT116	and	RKO	and	their	derivatives	were	kept	in	
McCoy´s	 medium	 (Invitrogen)	 supplemented	 with	 10%	 fetal	 calf	 serum	 (FCS,	
Invitrogen)	and	1%	Penicillin/Streptavidin	(Invitrogen).	The	cell	lines	SW480,	H1299,	
HEK293T	were	cultured	 in	DMEM	(Dulbecco´s	modified	Eagles	medium,	 Invitrogen)	
   METHODS  
21 
 
that	 was	 supplemented	with	 10%	 FCS	 and	 1%	 Penicillin/Streptavidin.	 All	 cell	 lines	
were	 passaged	 twice	 a	 week	 or	 at	 a	 confluency	 of	 ~80%	 and	 kept	 in	 a	 humified	
incubator,	at	37°C	and	5%	CO2.	
4.2.2	Transfection	of	oligonucleotides	and	vector	constructs	
For	 the	 transfection	 of	 oligonucleotides	 and	 vector	 constructs,	 cells	 were	
trypsinized,	 counted	 and	 seeded	 into	 6-well	 or	 12-well	 plates.	 Transfection	 was	
carried	out	immediately	after	seeding	so	that	the	cells	were	not	yet	attached	to	the	
surface	of	the	cell	culture	plates.	For	oligonucleotide	transfection,	100	µl	Opti-MEM	
(Invitrogen)	 was	 mixed	 with	 10	 µl	 of	 the	 respective	 oligonucleotide	 [10	 µM]	
(Ambion/Applied	 Biosystems)	 for	 a	 final	 concentration	 of	 100	 nM	 and	 with	 10	 µl	
HiPerFect	(Qiagen).	For	the	transfection	of	vector	constructs,	150	µl	Opti-MEM	was	
supplemented	 with	 4	 µg	 of	 plasmid	 DNA	 and	 5	 µl	 FuGENE6	 (Promega).	 The	
transfection	 reagent	mix	 was	 incubated	 for	 20	minutes	 at	 room	 temperature	 and	
added	drop-wise	to	the	cells.		
4.2.3	Conditional	expression	in	cell	pools	
The	episomal	vector	pRTR	[220]	was	used	to	generate	cell	pools	with	a	conditional	
expression	vector.	After	transfection	with	FuGENE6	(Promega),	those	cells	containing	
the	 pRTR	 vector	were	 selected	 using	 2	 µg/ml	 Puromycin	 (Sigma;	 stock	 solution:	 2	
mg/ml	 in	H20)	for	10	days.	To	determine	the	percentage	of	cells	that	were	positive	
for	eGFP-expression,	100	ng/ml	doxycycline	(DOX)	(Sigma;	stock	solution	100	µg/ml	
in	H20)	was	added	to	the	medium	and	eGFP-positive	cells	were	determined	by	FACS	
analysis	after	48	hours	(see	4.5.1).	
4.2.4	Cryo-preservation	of	mammalian	cell	lines	
For	cryo-preservation	of	mammalian	cells,	~80%	confluent	cells	were	trypsinized,	
pelleted	 by	 centrifugation	 (1200	 rpm,	 5	 minutes)	 and	 resuspended	 in	 a	 prepared	
mixture	of	50%	FCS,	10%	of	the	respective	growth	medium	and	10%	DMSO	(Roth).				
1	ml	aliquots	of	the	resuspended	cells	were	slowly	cooled	down	to	-80°C	in	cryo	vials	
using	 a	 freezing	 device	 and	 stored	 in	 liquid	 nitrogen.	 For	 cell	 recovery,	 cells	 were	
thawed	quickly	at	37°C	in	a	water	bath,	resuspended	in	the	respective	medium	and	
centrifuged	 for	 5	 minutes	 at	 1200	 rpm.	 Afterwards,	 the	 pelleted	 cells	 were	
resupended	and	seeded	in	a	cell	culture	flask	for	cultivation.		
	
4.3	Chromatin	immunoprecipitation	(ChIP)	assay	
SW480/pRTR-p53-VSV	and	SW480/pRTR	were	cultured	as	described	above.	Cells	
were	treated	with	DOX	for	16	hours	before	cross-linking	to	induce	ectopic	expression	
of	 p53.	 Cross-linking	was	 performed	 using	 1%	 formaldehyde	 (Merck)	 and	 stopped	
after	five	minutes	by	adding	0.125	M	glycine.	Cells	were	harvested	with	SDS	buffer	
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(50	 mM	 Tris	 pH	 8.1,	 0.5%	 SDS,	 100	 mM	 NaCl,	 5	 mM	 EDTA)	 and	 pelleted	 and	
resuspended	in	IP	buffer	(2/3	SDS	buffer	and	1/3	Triton	dilution	buffer	(100	mM	Tris-
HCl	 pH	 8.6,	 100	 mM	 NaCl,	 5	 mM	 EDTA,	 pH	 8.0,	 0.2%	 NaN3,	 5%	 Triton	 X-100).	
Chromatin	was	 sheered	by	 sonication	 to	generate	DNA	 fragments	with	an	average	
size	 of	 500	 bp.	 Preclearing	 and	 incubation	 with	 polyclonal	 VSV	 antibody	 (V4888,	
Sigma)	 or	 IgG	 control	 (M-7023,	 Sigma)	 for	 16	 hours	 was	 performed	 as	 previously	
described	[94].	Washing	and	reversal	of	cross-linking	was	performed	as	described	in	
[221].	 Immunoprecipitated	DNA	was	analyzed	by	qRT-PCR	and	the	enrichment	was	
expressed	as	percentage	of	 the	 input	 for	each	condition	 [221].	qChIP	primers	used	
are	listed	in	3.5.2.2.	
	
4.4	Episomal	vectors	for	ectopic	protein-expression		
The	pRTR	vector	 is	an	 improved	version	of	the	pRTS	vector	and	 its	generation	 is	
described	in	[220].	The	pRTR-p53-VSV	vector	was	generated	by	excising	the	p53-VSV	
sequence	 from	 a	 pcDNA-p53-VSV	 vector	 and	 subsequent	 ligation	 into	 a	 pUC19	
shuttle	 vector	 harboring	 SfiI	 restriction	 sites.	 After	 that,	 the	 C-terminally	 cDNA	
sequence	of	p53	was	excised	and	ligated	into	the	pRTR	vector	via	its	SfiI	restriction	
sites.	
	
4.5	Flow	cytometry	
4.5.1	Determination	of	the	transfection	efficiency	(eGFP)	
The	pRTR	vector	has	a	DOX-inducible	bidirectional	promoter	expressing	the	gene	
of	 interest	 in	 one	 and	 eGFP	 in	 the	 other	 direction.	 To	 verify	 the	 transfection	
efficiency	of	cell	 lines	transfected	with	the	pRTR	vector,	the	cells	were	treated	with	
and	without	DOX	for	48	hours	and	the	percentage	of	cells	showing	eGFP	expression	
was	 measured	 using	 a	 BD	 AccuriTM	 C6	 Flow	 Cytometer	 instrument	 (Accuri).	 The	
associated	 CFlow®	 software	 was	 used	 to	 determine	 the	 proportion	 of	 fluorescent	
cells.		
4.5.2	Cell	cycle	analysis	by	propidium	iodide	staining	
The	 supernatant	 of	 sub-confluent	 cells,	 that	were	 cultured	 under	 the	 indicated	
conditions,	was	transferred	into	a	falcon	tube,	cells	were	washed	once	with	HBSS-/-	
and	 trypsinized.	 When	 the	 cells	 were	 fully	 detached	 from	 the	 surface	 of	 the	 cell	
culture	flask,	trypsin	was	inactivated	using	the	transferred	supernatant	and	the	cell	
suspension	was	 pelleted	 by	 centrifugation	 (1200	 rpm,	 5	minutes).	 Afterwards,	 the	
cells	were	washed	 once	 in	 HBSS+/+,	 pelleted	 and	 resuspended	 in	 ice-cold	 ethanol	
(70%)	that	was	added	dropwise	to	the	cells.	Next,	the	cells	were	stored	overnight	at		
-20°C,	 washed	 with	 PBS	 the	 next	 day,	 centrifuged	 and	 resuspended	 in	 propidium	
iodide	 (PI)	 staining	 solution	 (filtered	 using	 a	 0.22	 µm	 filter,	 Millipore).	 After	
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incubation	 at	 37°C	 for	 30	 minutes,	 the	 cell	 cycle	 distribution	 of	 the	 cells	 was	
measured	 using	 a	 BD	 AccuriTM	 C6	 Flow	 Cytometer	 Instrument	 (Accuri)	 and	 the	
corresponding	Cflow®	software.	
	
4.6	Immunofluorescence	and	confocal-laser	scanning	microscopy	
Cells	were	 seeded	on	 glass	 cover-slides	 and	 treated	 as	 indicated.	 Subsequently,	
the	 cells	 were	 washed	 three	 times	 using	 PBS,	 fixed	 with	 4%	 paraformaldehyde	
(solved	in	PBS)	for	10	minutes,	permeabilized	with	0.2%	TritonX	100	for	20	minutes	
and	blocked	for	30	minutes	using	filtered	100%	FCS.	After	 incubation	with	the	pre-
blocked	 first	 antibody	 in	 a	 solution	 of	 50%	 FCS	 (in	 PBS)	 and	 0.05%	 PBS-T	 for	 one	
hour,	 the	 glass	 slides	 were	 washed	 three	 times	 with	 0.05%	 PBS-T.	 The	 secondary	
antibody	(diluted	in	0.05%	PBS-T	and	50%	FCS	in	PBS)	was	applied	for	30	minutes	and	
the	 cells	 were	 washed	 again	 three	 times	 with	 0.05%	 PBS-T.	 To	 stain	 nucleic	
chromatin,	 DAPI	 (Roth)	 was	 added	 to	 the	 last	 washing	 step.	 In	 the	 end,	 the	 glass	
slides	 were	 placed	 on	 an	 object	 plate	 and	 covered	 with	 ProLong®	 Gold	 antifade	
(Invitrogen).	 The	 laser	 scanning	microscopy	 LSM	 700,	 Zeiss,	 was	 used	 to	 take	 the	
respective	pictures.	A	Plan	Apochromat	20x/0.8	M27	objective,	ZEN	2009	software	
(Zeiss)	 and	 the	 following	 settings	 were	 used:	 image	 size	 2048x2048	 and	 16	 bit,	
pixel/dwell	 of	 25.2	 µs,	 pixel	 size	 0.31	 µm,	 laser	 power	 2%	 and	master	 gain	 600	 -	
1000.	
	
4.7	Isolation	of	RNA	and	reverse	transcription	
To	 isolate	 total	RNA,	 the	High	Pure	RNA	 Isolation	Kit	 (Roche)	was	used	and	 the	
isolation	was	performed	according	to	the	manufacturer´s	protocol.	RNA	was	eluted	
in	50	µl	elution	buffer.	The	amount	and	quality	of	the	RNA	was	determined	using	a	
Nanodrop	spectrophotometer	and	1	µg	of	RNA	was	used	 for	 reverse	 transcription.	
For	 cDNA	 generation,	 the	 Verso	 cDNA	 Synthesis	 Kit	 (Thermo	 Fisher	 Scientific)	was	
applied	 according	 to	 the	 manufacturer´s	 instructions	 using	 anchored	 oligo(dT)	
primers.	 To	 isolate	 miRNAs	 the	 High	 Pure	 miRNA	 Isolation	 Kit	 (Roche)	 was	 used	
according	to	the	manufacturer´s	protocol.	For	cDNA	generation	the	Universal	cDNA	
Synthesis	Kit	from	the	miRCURY	LNA	Universal	RT	microRNA	PCR	Kit	(Exiqon)	and	the	
TaqMan	MicroRNA	Reverse	Transcription	Kit	(Applied	Biosystems)	were	used.		
	
4.8	Luciferase	assay	
3x104	 cells/well	 of	 the	 colorectal	 cancer	 cell	 line	H1299	were	 seeded	 into	a	12-
well	plate.	After	24	hours,	the	cells	were	transfected	with	100	ng	of	an	empty	firefly	
luciferase	 reporter	 plasmid	 (pGL3)	 or	 the	 pGL3	 vector	 containing	 the	 respective	
miRNA	 binding	 sequence,	 20	 ng	 of	 Renilla	 reporter	 plasmid	 as	 a	 normalization	
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control	and	 the	 respective	pre-miRNA	 [25	nM]	or	 its	negative	control	 [25	nM].	For	
antagomiR-transfection	a	concentration	of	50	nM	was	used.	After	incubation	for	48	
hours,	 the	Dual	Luciferase	Reporter	assay	kit	 (Promega)	was	used	according	 to	 the	
manufacturer´s	protocol.	The	Orion	II	luminometer	(Berthold)	was	used	to	measure	
the	 luminescence	 intensities	 in	 a	 96-well	 format	 and	 the	 SIMPLICITY	 software	
package	(DLR)	was	applied	for	data-analyses.	
	
4.9	Migration	and	invasion	analysis	in	Boyden-chambers	
SW480	cells	stably	 transfected	with	 the	pRTR-p53-VSV	vector	were	treated	with	
DOX	 for	96	hours.	Uninduced	cells	 served	as	a	negative	control.	During	 the	 last	24	
hours,	 the	cells	were	 serum	deprived	 (0.1%	FCS).	 For	migration	analysis	5x104	cells	
were	 counted	 and	 seeded	 in	 the	 upper	 compartment	 of	 a	 Boyden	 chamber	 (pore	
size	8.0	µm;	Corning)	in	serum	free	medium.	The	lower	chamber	contained	medium	
with	10%	FCS	as	a	chemo-attractant.	For	 invasion	analysis,	7x104	cells	were	seeded	
on	a	Matrigel	(BD	Bioscience;	3.3	ng/ml	in	serum-free	medium)	coated	membrane.	
For	 migration	 and	 invasion,	 the	 cells	 were	 cultured	 for	 48	 hours	 in	 a	 Boyden	
chamber	 and	 subsequently	 fixed	 in	 ice-cold	 methanol	 for	 10	 minutes.	 Cells	 that	
remained	 in	 the	upper	compartement	of	 the	chamber	were	 removed	and	 those	at	
the	lower	side	of	the	membrane	were	stained	with	DAPI	[1	µg/ml].	The	pictures	were	
taken	with	an	AxioCam	MRm	camera	using	an	Axiovert	Observer	Z.1	microscope.	In	
addition,	 the	 Axiovision	 software	 (Zeiss)	 was	 used.	 For	 each	 condition	 pictures	 of	
three	 different	 fields	 were	 taken	 and	 the	 cell	 number	 was	 determined	 by	 using	
fluorescence	 microscopy.	 The	 relative	 migration	 was	 expressed	 as	 the	 number	 of	
treated	to	control	cells	with	the	control	cells	set	as	one.	
For	CST5-mediated	effects,	SW480/pRTR-p53-VSV	cells	were	seeded	in	triplicates	
into	6-well	plates	and	transfected	with	siRNA	against	CST5	or	the	respective	control	
for	 48	 hours.	 For	 the	 last	 24	 hours	 previous	 to	 the	 analysis,	 cells	 were	 serum	
deprived	(0.1%).	To	analyze	migration,	3x105	cells	were	seeded	in	the	upper	chamber	
of	 a	Boyden	 chamber	 (8.0	µm	pore	 size;	 Corning)	 in	 serum	 free	medium.	After	 42	
hours,	p53	expression	was	induced	by	adding	DOX	to	the	indicated	samples.		
	
4.10	PCR	methods	
4.10.1	Colony	PCR	
For	 the	 identification	 of	 bacterial	 clones	 harboring	 a	 vector	 insert	 in	 the	 right	
orientation,	single	colonies	from	the	LB	agar	plate	were	picked	and	transferred	into	a	
20	µl	 reaction	mix	 (dNTPs,	10	x	PCR	buffer,	FIREPol®	DNA	polymerase	and	primers	
specific	 for	 the	 vector	 or	 insert).	 The	 PCR	 reaction	 had	 the	 following	 cycling	
conditions:	5	minutes	at	95°C,	25	cycles	 (95°C	 for	20	seconds,	58°C	 for	30	seconds	
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and	72°C	for	X	minute/s	(1	minute	per	1	kbp	length	of	the	expected	PCR	product)).	
Finally	 the	 product	 size	 was	 checked	 on	 an	 agarose	 gel	 whose	 percentage	 was	
adapted	to	the	length	of	the	expected	PCR	product.	
4.10.2	Cloning	of	3´-UTR	sequences	
Shortened	versions	of	 the	3´-UTRs	of	 the	human	KLF12,	HMGB1	and	CIT	mRNAs	
were	 amplified	 by	 PCR	 from	 cDNA	 of	 SW480	 cells.	 The	 resulting	 PCR	 product	was	
ligated	into	the	pGL3	vector	[218]	and	verified	by	sequencing.	All	primers	that	were	
used	for	cloning	are	listed	in	chapter	3.5.2.3.	
4.10.3	qPCR	using	SYBR	Green	
A	 LightCycler	 480	 (Roche)	 was	 used	 for	 quantitative	 real-time	 PCR	 (qPCR).	
Experiments	 were	 conducted	 using	 the	 Fast	 SYBR	 Green	 Master	 Mix	 (Applied	
Biosystems)	and	the	expression	level	of	β-actin	was	used	for	normalization.	All	qPCR	
primers	are	 listed	 in	3.5.2.1.	Only	 those	primers	 that	showed	a	single	peak	 in	 their	
melting	curves	were	used.		
4.10.4	qPCR	using	TaqMan/Exiqon	Probes	
For	 detection	 of	 mature	 miR-34a,	 RNA	 was	 reverse	 transcribed	 using	 the	
miRCURY	LNA	Universal	RT	microRNA	PCR-Kit	(Exiqon)	and	qRT-PCR	was	performed	
with	the	SYBR	Green	master	mix	provided	using	Exiqon	LNA	primer	(Exiqon	204486).	
U6	 primer	 were	 used	 for	 normalization	 (Exiqon	 203903).	 For	 detection	 of	mature	
miR-486-5p	(Applied	Biosystems,	Catalog	#	4427975,	001278)	and	miR-205	(Applied	
Biosystems,	 Catalog	 #	 4427975,	 000509),	 cDNA	 was	 generated	 using	 the	 TaqMan	
MicroRNA	Reverse	 Transcription	 Kit	 (Applied	Biosystems),	 qRT-PCR	was	 performed	
using	 the	 TaqMan	 Universal	 Master	 Mix	 (Applied	 Biosystems)	 and	 values	 were	
normalized	 to	 RNU48	 (Applied	 Biosystems,	 Catalog	 #	 4373383,	 001006).	 For	 miR-
486-5p	detection	RNA	had	to	be	preamplified	using	the	TaqMan	PreAmp	Master	Mix	
(Applied	Biosystems).		
	
4.11	Protein	isolation,	SDS-PAGE	and	Western	blot	
For	 protein	 isolation,	 cells	 were	washed	 two	 times	with	 cold	 PBS	 and	 lysed	 in	
RIPA	 buffer.	 Lysates	 were	 sonicated	 using	 the	 HTU	 SONI130	 (G.	 Heinemann	
Ultraschall-	 und	 Labortechnik)	 for	 three	 pulses	 (~3	 seconds	 per	 pulse)	 with	 an	
intensity	of	85%.	Next,	the	lysates	were	centrifuged	(16,060	g,	4°C,	15	minutes)	and	
the	 supernatant	 was	 transferred	 into	 a	 new	 tube.	 For	 the	 determination	 of	 the	
protein-concentration	the	BCA	Protein	Assay	Kit	(Pierce,	Thermo	Scientific)	was	used	
according	to	the	manufacturer´s	protocol	and	the	concentration	was	measured	using	
the	 Varioskan	 Flash	 Multimode	 Reader	 and	 the	 SkanIt	 RE	 for	 Varioskan	 2.4.3	
software	 (Thermo	Scientific).	Afterwards,	up	 to	100	µg	of	 the	protein	 lysates	were	
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supplemented	with	 2x	 Laemmli	 buffer	 and	denatured	 at	 95°C	 for	 5	minutes.	After	
denaturation,	the	protein	 lysates	were	loaded	on	a	10%	or	12%	SDS	acrylamide	gel	
together	with	a	pre-stained	protein	ladder	(Fermentas).	A	voltage	of	90	–	120	V	was	
applied	 for	 electrophoresis	 in	 a	 Mini-PROTEAN®-electrophoresis	 system	 (Bio-Rad)	
with	 Tris-glycine-SDS	 running	 buffer.	 Next,	 the	 proteins	 were	 transferred	 on	 an	
Immobilion	 PVDF	 membrane	 (Millipore)	 using	 Towbin	 buffer,	 the	 PerfectBlue™	
SEDEC	 blotting	 system	 (Peqlab)	 and	 a	 EPS	 600	 power	 supply	 (Pharmacia	 Biotech)	
running	constantly	at	125	mA	per	gel	with	a	maximum	voltage	of	10	V.	The	blotting	
time	varied	according	to	the	size	of	the	proteins	to	be	detected	(25	–	65	minutes).	To	
prevent	unspecific	binding	of	antibodies,	 the	membrane	was	blocked	 for	1	hour	 in	
5%	 skim	 milk/TBS-Tween20	 (TBS-T).	 Thereafter,	 the	 membrane	 was	 incubated	
overnight	 at	 4°C	 with	 a	 primary	 antibody	 dilution	 in	 TBS-T.	 The	 next	 day,	 the	
membrane	 was	 incubated	 with	 the	 secondary	 horseradish-peroxidase	 (HRP)-
conjugated	antibody	for	1	hour	at	room	temperature.	After	washing	(2x15	minutes	
in	TBS-T)	the	ECL/HRP	substrate	was	added	to	the	membrane	and	ECL-signals	were	
detected	using	a	CF440	Imager	(Kodak).	All	antibodies	used	are	listed	in	3.4.	
	
4.12	pSILAC	
Sample	Preparation	
pSILAC	 was	 performed	 as	 described	 previously	 [217].	 In	 brief,	 5x105	
SW480/pRTR-p53-VSV	cells	were	seeded	on	10	cm	dishes	and	grown	in	light	DMEM	
supplemented	with	 light	 L-arginine	 (84	mg/l)	 and	 L-lysine	 (40	mg/l),	 10%	 dialyzed	
FBS,	100	units/ml	penicillin	and	0.1	mg/ml	streptomycin.	After	p53	induction	for	16	
hours	with	100	ng/ml	DOX,	cells	were	shifted	to	heavy	SILAC	medium	(84	mg/l	13C6	
15N4-L-arginine	and	40	mg/l	13C6	15N2-L-lysine).	The	noninduced	control	samples	were	
shifted	 to	medium-heavy	media	 (84	mg/l	 13C6-L-arginine,	 40	mg/l	 2H4-L-lysine).	 To	
minimize	arginine-to-proline	conversion	the	light,	medium-heavy	and	heavy	medium	
was	supplemented	with	100	mg/l	of	unlabeled	proline.	All	reagents	(DMEM,	dialyzed	
FBS	and	amino	acids)	were	purchased	from	Cambridge	Isotope	Laboratories.	After	24	
hours	 cells	 were	 harvested	 with	 urea	 buffer	 (30	 mM	 Tris	 base,	 7	 M	 urea,	 2	 M	
thiourea,	 pH	 8.5).	 In	 total,	 six	 independent	 pSILAC	 analyses	 were	 performed,	
including	two	with	a	 label-swap,	and	subjected	to	further	proteomic	analysis	which	
was	performed	by	Friedel	Drepper,	Silke	Oeljeklaus	and	Bettina	Warscheid.	
	
Gel	Electrophoresis	and	Tryptic	Digestion	of	Proteins	
Following	 cell	 lysis,	proteins	 (30	µg	per	 replicate)	were	 separated	by	SDS-PAGE	
using	 4	–	12%	 NuPage	 Bis-Tris	 gradient	 gels	 (Life	 Technologies)	 and	 visualized	 by	
colloidal	 Coomassie	 Brilliant	 Blue.	Gel	 lanes	were	 cut	 into	 20	 slices.	 Proteins	were	
subjected	 to	 in-gel	 digestion	using	 trypsin	 and	prepared	 for	 LC-MS/MS	analyses	 as	
described	[222].	
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Mass	Spectrometric	Analyses	
LC/MS	analyses	were	performed	using	an	UltiMate	3000	RSLCnano	HPLC	system	
(Thermo	 Scientific,	 Dreieich,	 Germany)	 and	 an	 Orbitrap	 Elite	 mass	 spectrometer	
(Thermo	 Scientific,	 Bremen,	 Germany).	 Peptide	 mixtures	 were	 washed	 and	 pre-
concentrated	for	5	min	on	a	5	mm	×	0.3	mm	PepMapTM	C18	µ-precolumn	(Thermo	
Scientific)	followed	by	separation	on	a	50	cm	×	75	µm	C18	reversed-phase	nano	LC	
column	 (Acclaim	 PepMapTM	 RSLC	 column;	 2	 µm	 particle	 size;	 100	 Å	 pore	 size;	
Thermo	Scientific)	at	a	 temperature	of	40°C	using	a	45	min	 linear	gradient	 ranging	
from	4	 to	36%	 (v/v)	acetonitrile	 [ACN;	 in	0.1%	 (v/v)	 formic	acid]	 followed	by	36	 to	
82%	(v/v)	ACN	in	5	min	and	5	min	at	82%	ACN	at	a	flow	rate	of	250	nl/min.	The	mass	
spectrometer	was	 operated	 using	 a	Nanospray	 Flex	 ion	 source	with	 stainless	 steel	
emitters	 (Thermo	 Scientific)	 and	 externally	 calibrated	 using	 standard	 compounds.	
Full	 MS	 scans	 (m/z	 370	–	1,700)	 were	 acquired	 in	 the	 orbitrap	 at	 a	 resolution	 of	
60.000	 (at	 m/z	 400)	 with	 an	 automatic	 gain	 control	 (AGC)	 of	 1×106	 ions	 and	 a	
maximum	 fill	 time	 of	 200	 ms.	 Up	 to	 25	 of	 the	 most	 intense	 multiple	 charged	
precursor	 ions	 above	 a	 signal	 threshold	 of	 2.500	 were	 fragmented	 by	 collision-
induced	dissociation	in	the	linear	ion	trap	at	a	normalized	collision	energy	of	35%,	an	
activation	 q	 of	 0.25,	 an	 activation	 time	 of	 10	 ms,	 an	 AGC	 of	 5×103	 ions,	 and	 a	
maximum	fill	time	of	150	ms.	The	dynamic	exclusion	time	for	previously	fragmented	
precursor	ions	was	45	s.		
	
Mass	Spectrometric	Data	Analysis	
Mass	 spectrometric	 raw	 data	 were	 processed	 with	 Andromeda/Max-Quant	
(version	 1.3.0.5)	 [223,	 224].	 Peaklists	 of	 MS/MS	 spectra	 were	 generated	 by	
MaxQuant	using	default	settings	and	searched	against	the	organism-specific	UniProt	
human	 protein	 database	 including	 protein	 isoforms	 (version	 2013_05;	 88,817	
entries)	 [225]	 and	 the	 set	 of	 common	 contaminants	 provided	 by	 MaxQuant.	 The	
species	 was	 restricted	 to	 human	 since	 all	 experiments	 were	 performed	 with	 the	
human	 cell	 line	 SW480.	Database	 searches	were	performed	with	 tryptic	 specificity	
allowing	 two	missed	cleavages,	mass	 tolerances	of	20	ppm	for	 the	 first,	6	ppm	for	
the	 main	 search	 of	 precursor	 ions	 and	 0.5	 Da	 for	 fragment	 ions;	 oxidation	 of	
methionine	 and	 acetylation	 of	 protein	 N-termini	 as	 variable	 modification;	
carbamidomethylation	of	cysteine	as	fixed	modification.	A	false	discovery	rate	of	1%	
calculated	 as	 described	 previously	 [223]	was	 applied	 for	 filtering	 both	 the	 peptide	
identifications	and	the	list	of	proteins.	For	protein	identification,	at	least	one	unique	
peptide	 with	 a	 minimum	 length	 of	 seven	 amino	 acids	 was	 required.	 Proteins	
identified	by	the	same	set	of	peptides	were	combined	to	a	single	protein	group	by	
MaxQuant.	 SILAC-based	 relative	 protein	 quantification	 was	 based	 on	 unique	
peptides,	 Arg6	 and	 Lys4	 as	 medium-heavy	 (M)	 and	 Arg10	 and	 Lys8	 as	 heavy	 (H)	
labels.	 The	 variability	 of	 individual	 protein	 abundance	 ratios	 was	 calculated	 by	
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MaxQuant	 and	 is	 the	 standard	 deviation	 of	 the	 natural	 logarithms	 of	 all	 peptide	
ratios	 used	 to	 determine	 the	 protein	 ratio	 multiplied	 by	 100	 [223].	 Only	 proteins	
quantified	 in	 at	 least	 two	 biological	 replicates	 were	 included	 in	 the	 statistical	
analysis.	Protein	abundance	ratios	 reported	as	 induced/non-induced	 (H/M	or	M/H)	
and	normalized	to	 the	median	of	 the	respective	replicate	by	MaxQuant	 to	account	
for	systematic	deviations	such	as	mixing	errors	were	log2-transformed	and	the	mean	
log2	 ratios	 and	 p-values	 were	 calculated	 across	 all	 replicates	 with	 valid	 values	 for	
individual	 protein	 groups.	 Reproducibility	 of	 the	 results	 was	 further	 assessed	 by	
correlating	 log2	ratios	and	computing	p-values	for	pairs	of	replicates.	 In	nine	out	of	
15	 pairwise	 comparisons,	 a	 set	 of	 proteins	 appeared	 to	 be	 down-regulated	 in	 one	
replicate	but	unregulated	 in	 the	other.	 In	order	 to	account	 for	 this	effect,	proteins	
exhibiting	log2	fold	changes	≤	-0.3	or	≥	0.3	with	a	p-value	≤	0.05	across	all	replicates	
but	 showing	 p-values	 >	 0.3	 in	 more	 than	 half	 of	 the	 pairwise	 comparisons	 of	
replicates	 indicative	 of	 a	 heterogeneous	 regulation	were	 separately	marked	 in	 the	
list	 of	 candidates	 (class	 II	 hits	 that	 are	 marked	 with	 an	 asterisk	 (*)	 in	 Figure	 35,					
Table	2).		
The	 mass	 spectrometry	 proteomics	 data	 have	 been	 deposited	 to	 the	
ProteomeXchange	 Consortium	 (http://proteomecentral.proteomexchange.org)	 via	
the	PRIDE	partner	repository	[226]	with	the	dataset	identifier	PXD001976.	
	
4.13	Real-time	impedance	measurement	
Cellular	 impedance	 was	 measured	 using	 a	 xCelligence	 real-time	 cell	 analyzer	
(RTCA)	 (Roche)	according	 to	 the	manufacturer´s	protocol.	5000	cells	per	well	were	
seeded	 into	an	E-plate	16	and	were	allowed	to	equilibrate	 for	30	minutes	at	 room	
temperature.	Subsequently	the	E-plate	16	was	placed	into	the	xCelligence	device	and	
the	impedance	of	the	cells	was	measured	every	60	minutes	for	a	period	of	96	hours.	
After	24	hours	DOX	was	added	to	 the	respective	wells.	The	electrical	 impedance	 is	
represented	as	a	dimension/unit-less	parameter	termed	cell-index,	which	represents	
the	relative	change	in	electrical	impedance	that	occurs	in	the	presence	and	absence	
of	 cells	 in	 the	 wells.	 This	 change	 is	 calculated	 based	 on	 the	 following	 formula:												
CI	 =	 (Zi−Z0)/15,	where	Zi	 determines	 the	 impedance	 at	 an	 individual	 experimental	
time	point	and	Z0	 is	 the	 impedance	measured	at	 the	beginning	of	 the	experiment.	
The	 impedance	 is	measured	 at	 three	different	 frequencies	 (10,	 25	or	 50	 kHz)	 (ref:	
Roche	 Diagnostics	 GmbH.	 Introduction	 of	 the	 RTCA	 DP	 Instrument.	 RTCA	 DP	
Instrument	 Operator‘s	 Manual,	 A.	 Acea	 Biosciences,	 Inc.;	 2008.).	 To	 validate	 the	
results	 of	 the	 impedance	 measurement,	 the	 cells	 were	 simultaneously	 seeded	 in	
triplicates	 into	 a	 96-well	 plate	 and	 the	 number	 of	 living	 cells	 was	 counted	 using	
trypan	blue	after	96	hours.	
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4.14	RNA	interference	
			For	 RNA	 interference	 siRNAs	 (Ambion	 silencer	 siRNA	 negative	 control:	 #1	
ID#4611;	siCST5	AM16708	ID#10755)	were	transfected	at	a	final	concentration	of	10	
nM	for	the	indicated	time	points	using	HiPerfect	transfection	reagent	(Qiagen).		
	
4.15	Sequencing	
4.15.1	DNA-sequencing	
To	 verify	 a	 specific	 DNA	 sequence,	 Sanger	 sequencing	 was	 performed.	 The	
BigDye®	 Terminator	 v3.1	 Cycle	 Sequencing	 Kit	 (Life	 Technologies)	 was	 used	
according	 to	 the	 manufacturer´s	 instructions.	 The	 reaction	 mix	 contained	 1	 µg	 of	
DNA,	 5	 pmol	 of	 primer,	 the	BigDye	 Terminator	 and	 the	 5x	 Sequencing	buffer.	 The	
following	 conditions	 for	 PCR-amplification	 were	 applied:	 15x	 (10	 seconds	 at	 96°C,	
90	seconds	at	60°C).	Afterwards,	 the	PCR	product	was	purified	using	the	DyeEx	2.0	
Spin	Kit	 (Qiagen)	 in	a	5417C	centrifuge	 (Eppendorf).	4	µl	of	purified	DNA	was	 then	
mixed	 with	 16	 µl	 of	 Hi-Di	 Formamide	 (Applied	 Biosystems)	 and	 sequenced	 in	 an	
ABI3130	 genetic	 analyzer	 capillary	 sequencer	 (Applied	 Biosystems).	 Finally,	 data	
were	analyzed	applying	the	3130	Data	Collection	Software	v3.0	and	the	sequencing	
analysis	software	5.2	(Applied	Biosystems).	
4.15.2	RNA-sequencing	
3x105	 SW480/pRTR-p53-VSV	 as	 well	 as	 SW480/pRTR	 were	 seeded	 on	 10	 cm	
plates	 and	 total	 RNA	 was	 isolated	 after	 48	 hours	 DOX	 treatment.	 Total	 RNA	 was	
isolated	using	the	High	Pure	RNA	Isolation	Kit	(Roche)	and	its	quality	was	determined	
with	 a	 Bioanalyzer	 (Agilent	 Technologies).	 Library	 preparation	 was	 done	 using	 an	
RNA-Seq	Sample	Prep	Kit	(Illumina)	according	to	the	manufacturer´s	instructions	and	
sequenced	 on	 a	 HiSeq	 2000	 (Illumina).	 The	 analysis	 of	 the	 RNA-Seq	 data	 was	
performed	by	 Thomas	Bonfert.	 101-nt	 sequence	 reads	 from	SW480/pRTR-p53-VSV	
and	SW480/pRTR	 cells	were	aligned	 separately	 in	 a	 three-step	mapping	procedure	
described	 recently	 [227]	 using	 the	 short	 read	 alignment	 program	 Bowtie	 (version	
0.12.7)	 [228].	 In	 step	1,	 reads	were	aligned	 to	pre-rRNA	sequences	 (18S,	5.8S,	28S	
and	 spacer	 regions).	 In	 step	 2,	 the	 remaining	 unmapped	 reads	 were	 aligned	 to	
Ensembl	 transcripts	 (ENSEMBL	version	60),	with	 the	exclusion	of	pseudogenes	and	
haplotypes.	Finally,	 in	 step	3,	 reads	 that	could	not	be	aligned	 to	known	transcripts	
were	aligned	to	the	human	reference	genome	(hg19).	Reads	that	could	be	mapped	
equally	well	to	more	than	one	location	were	discarded.	Bowtie	was	configured	for	all	
three	steps	 in	 the	 following	way:	The	 first	60	nucleotides	were	chosen	as	 the	seed	
region.	Three	mismatches	were	allowed	in	the	seed	and	10	mismatches	in	the	overall	
alignment.	 Expression	 levels	 of	 Ensembl	 genes	 were	 determined	 using	 the	 rpkm	
(number	 of	 reads	 per	 kilobase	 of	 gene	 per	million	mapped	 reads)	measure	 [229].	
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Only	reads	mapped	to	an	exon	or	exon-exon	junction	were	included	in	the	number	
of	 reads	 mapped	 to	 a	 gene.	 Log2	 fold	 changes	 between	 the	 two	 samples	
(SW480/pRTR-p53-VSV	 and	 SW480/pRTR	 cells)	 were	 calculated	 from	 gene	 rpkm	
values	 and	 used	 to	 define	 induced	 (log2	 fold	 change	 ≥	 1)	 and	 repressed	 (log2	 fold	
change	≤	-1)	genes.	The	RNA-Seq	data	can	be	accessed	in	the	GEO	database	using	the	
accession	number	GSE67109.	
4.15.3	miRNA-sequencing	
The	 miRNA-sequencing	 was	 performed	 by	 Anne	 Dueck,	 Norbert	 Eichner	 and	
Gunter	Meister.	 Total	 RNA	 from	SW480/pRTR-p53-VSV	 and	 SW480/pRTR	 cells	was	
isolated	 using	 the	 Trizol	 reagent	 (Life	 Technologies)	 following	 the	 manufacturer´s	
protocol.	10	µg	of	the	total	RNA	was	run	on	a	12%	Urea-PAGE	(National	Diagnostics)	
to	 purify	 the	 small	 RNA	 fractions	 of	 each	 sample.	 Gel	 pieces	 were	 isolated	
corresponding	to	a	size	of	about	15	-	30	nt	and	the	contained	RNA	was	collected	by	
crushing	the	gel,	elution	over	night	in	elution	buffer	(300	mM	NaCl,	2	mM	EDTA)	and	
precipitation	with	2.5V	100%	ethanol.	The	small	RNA	fraction	was	solved	in	12	µl	of	
RNAse-free	water,	10	µl	were	used	for	the	generation	of	a	small	RNA	library.	Cloning	
was	 performed	 as	 described	 before	 [230].	 In	 short,	 an	 adenylated	 adapter	 was	
ligated	to	the	3’	end	of	the	RNA	by	a	truncated	T4	RNA	Ligase	2	[231],	followed	by	
the	 ligation	of	 the	5’	adapter	by	T4	RNA	Ligase	1	 (NEB).	After	reverse-transcription	
with	a	specific	primer,	the	cDNA	was	amplified	by	PCR.	The	correct	PCR	product	was	
gel-purified,	eluted	in	elution	buffer,	precipitated	and	solved	in	water.	The	quality	of	
the	 libraries	was	 assessed	 by	 qPCR	 and	 Bioanalyzer	measurements.	 Libraries	were	
sequenced	on	a	HiScan	by	the	KFB	(Kompetenzzentrum	für	fluoreszente	Bioanalytik,	
Regensburg,	Germany).		
The	 analysis	 of	 the	miR-Seq	 data	was	 performed	 by	 Florian	 Erhard.	 Fastq	 files	
were	 processed	 with	 an	 in-house	 pipeline	 consisting	 of	 adapter	 trimming,	 read	
alignment,	read	counting	and	normalization.	Adapters	were	trimmed	by	computing	a	
suffix-prefix	 alignment	 of	 each	 read	 against	 the	 Illumina	 3´	 adapter	 sequence.	
Trimmed	 reads	 were	 then	 aligned	 to	 the	 reference	 genome	 (hg19)	 using	 bowtie	
0.12.7	 [228]	 allowing	 for	 up	 to	 2	mismatches.	All	 best	matches	were	 retained	 and	
multi-mapping	 reads	 were	 equally	 divided	 among	 all	 mapping	 sites.	 To	 compute	
miRNA	 read	 counts	 all	 reads	 mapping	 to	 annotated	 mature	 miRNA	 positions	
(according	to	mirbase	v16	[232])	were	considered.	At	their	3´	end,	a	tolerance	of	+/-	
3	bp	was	allowed,	but	no	tolerance	at	their	5´	end.	Normalization	was	performed	by	
fitting	a	 robust	 linear	model	 to	 the	quantile-quantile	plot	of	 log	miRNA	counts	and	
taking	 the	offset	as	normalization	 factor.	The	miR-Seq	data	can	be	accessed	 in	 the	
GEO	database	using	the	accession	number	GSE67181.	
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4.15.4	ChIP-sequencing	
ChIP	assays	were	performed	as	described	in	4.15.	The	immunoprecipitated	DNA-
fragments	were	quantified	using	a	Bioanalyzer	(Agilent	Technologies).	Libraries	were	
generated	using	a	ChIP-Seq	Sample	Prep	Kit	(Illumina	Part	#	11257047)	according	to	
the	 manufacturer´s	 instructions	 and	 sequenced	 on	 a	 HiSeq	 2000	 (Illumina).	 The	
analysis	of	 the	ChIP-Seq	data	was	performed	by	Thomas	Bonfert.	 101-nt	 sequence	
reads	 were	 aligned	 separately	 for	 the	 two	 samples	 (SW480/pRTR-p53-VSV	 and	
SW480/pRTR	 cells)	 with	 the	 same	 three-step	 mapping	 procedure	 as	 for	 RNA-Seq	
analysis.	 Peaks	 were	 identified	 using	 MACS	 (version	 1.4.2)	 [233]	 with	 default	
parameters.	 The	output	of	MACS	 contains	 the	 genomic	 start	 and	 stop	 coordinates	
for	every	called	peak,	as	well	as	 the	coordinate	of	 the	peak	maximum	(denoted	as	
peak	 summit).	 For	 every	 called	 peak,	 the	 Ensembl	 gene	 with	 minimum	 distance	
between	 peak	 summit	 and	 respective	 transcription	 start	 site	was	 determined.	 The	
ChIP-Seq	 data	 can	 be	 accessed	 in	 the	 GEO	 database	 using	 the	 accession	 number	
GSE67108.	
	
Analysis	of	Sequence	Motifs	
Genomic	sequences	+/-	250	bp	around	the	called	peak	summits	were	extracted	
for	every	peak	with	an	associated	gene	within	20	kbp	from	the	peak	summit.	If	the	
peak	 start	 or	 end	 was	 less	 than	 250	 bp	 away	 from	 the	 summit,	 the	 extracted	
sequence	started	or	ended	with	the	peak	start	or	end,	respectively.	MEME	(version	
4.7.0)	 [234]	 was	 applied	 on	 the	 generated	 sequences	 in	 order	 to	 discover	 p53	
binding	 site	 motifs.	 The	 default	 parameter	 settings	 were	 used.	 The	 maximum	
number	 of	 motifs	 to	 find	 was	 set	 to	 3.	 This	 step	 was	 repeated	 separately	 for	
sequences	 of	 peaks	 associated	 with	 induced	 and	 repressed	 genes,	 respectively.	
SpaMo	 (version	 4.7.0)	 [235]	 was	 used	 to	 search	 for	 enriched	 transcription	 factor	
binding	motifs	located	in	direct	proximity	to	the	best	predicted	motif	by	MEME.	The	
input	of	SpaMo	were	peak	sequences,	the	output	of	the	MEME	run	and	the	JASPAR	
core	database	[236]	as	source	for	secondary	motifs.	All	other	parameters	were	set	to	
default.	
	
4.16	Site	directed	mutagenesis	
For	 site	 directed	 mutagenesis	 of	 miRNA	 binding	 sites	 in	 the	 3´-UTR	 of	 their	
respective	 target	 genes,	 the	 3´-UTR	 fragments	were	 ligated	 into	 the	 pGEM	 T	 Easy	
vector	(Promega).	Afterwards,	the	QuikChange	II	Site-Directed	Mutagenesis	Kit	was	
used	 according	 to	 the	 manufacturer´s	 instructions.	 All	 primers	 used	 for	 the	
mutagenesis	PCR	are	listed	in	3.5.2.3.	To	verify	successful	mutagenesis,	the	mutated	
plasmids	were	sequenced.	
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4.17	Statistical	analysis	
A	 Student´s	 t-test	 (unpaired,	 two-tailed)	 was	 used	 to	 determine	 significant	
differences	between	two	groups	of	samples.	A	Kolmogorov-Smirnov	test	was	applied	
to	 calculate	 the	 significance	 of	 cumulative	 distribution	 analyses.	 For	 correlation	
analyses	 a	 two-tailed	 Pearson´s	 correlation	 was	 applied.	 p-values	 <	 0.05	 were	
considered	as	significant	(*:	p	<	0.05;	**:	p	<	0.01;	***:	p	<	0.001).		
				
4.18	Web-based	expression	analyses	and	algorithms	
The	 Oncomine	 database	 [237]	 was	 used	 to	 analyze	 the	 differential	 mRNA	
expression	of	HMGB1,	KLF12	and	CIT	in	human	cancer	versus	normal	tissue	datasets.	
The	threshold	for	the	p-value	and	fold	change	was	set	to	0.05	and	1.5,	respectively.		
The	PROGgene	database	[238]	was	used	to	analyze	the	clinical	significance	of	the	
target	 gene	 set	 HMGB1,	 KLF12	 and	 CIT.	 To	 analyze	 overall	 and	 metastasis	 free	
survival,	 the	 colorectal	 cancer	 datasets	 GSE15736	 and	 GSE11121	 were	 used,	
respectively.		
miRNA	 target	 prediction	of	 up-regulated	miRNAs	was	performed	 combining	 the	
results	from	the	public	databases	TargetScan	(http://www.targetscan.org)	and	Pictar	
(http://pictar.mdc-berlin.de)	[239,	240].	Only	conserved	target	sites	were	considered	
for	further	analysis.		
A	 KEGG	 pathway	 enrichment	 analysis	 of	 differentially	 up-	 and	 down-regulated	
mRNAs	and	proteins	was	perfomed	using	 the	DAVID	bioinformatics	database	 [241,	
242].	
To	visualize	p53-binding	signals	the	ChIP-Seq	results	were	uploaded	in	wig-format	
to	the	UCSC	genome	browser	[243].	
Data	 from	 the	 TCGA	 (The	 Cancer	 Genome	 Atlas)	 database	 [244]	were	 used	 for	
differential	 mRNA	 expression	 analyses	 in	 different	 tumor	 stages	 in	 the	 colorectal	
cancer	dataset	(n	=	424).	Only	those	differences	that	showed	a	p-value	≤	0.05	were	
taken	into	account.	
	
4.19	Wound	healing	assay	
SW480/pRTR-p53-VSV	cells	were	seeded	into	12-well	plates	and	the	scratch	was	
applied	when	cells	were	grown	to	a	confluent	cell	layer	using	a	pipet	tip.	Two	hours	
before	 applying	 the	 scratch,	 the	 cells	 were	 treated	 with	Mitomycin	 C	 [10	 ng/ml].	
After	scratching,	the	cells	were	washed	three	times	with	HBSS+/+	and	medium	with	
or	without	DOX	was	added.	In	addition,	images	of	the	initial	wound	area	were	taken	
with	 an	Axiovert	Observer	 Z.1	microscope	 connected	 to	 an	AxioCam	MRm	camera	
using	 the	 Axiovision	 software	 (Zeiss).	 Afterwards,	 cells	 were	 allowed	 to	 close	 the	
wound	 for	 a	 time	 period	 of	 48	 hours	 and	 images	 were	 captured	 with	 the	 above	
mentioned	device.		
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To	 investigate	 the	 impact	 of	 CST5	 on	 p53-mediated	 inhibition	 of	 migration,	
SW480/pRTR-p53-VSV	 cells	 were	 seeded	 into	 culture	 inserts	 (IBIDI,	 80241)	 and	
transfected	with	siRNA	against	CST5	or	the	respective	control	for	48	hours.	After	42	
hours,	 p53	 expression	 was	 induced	 by	 adding	 DOX	 to	 the	 indicated	 samples	 and	
Mitomycin	C	was	 added	 for	 2	 hours	 before	 applying	 the	 scratch	by	 taking	out	 the	
culture	 insert.	 Cells	 were	 washed	 three	 times	 with	 HBSS	 +/+,	 medium	 with	 or	
without	DOX	was	added	and	the	pictures	showing	the	initial	wound	area	were	taken.	
After	 48	 hours	 final	 pictures	 were	 taken.	 The	 experiment	 was	 performed	 in	
triplicates	and	three	pictures	of	different	wound	areas	were	captured	for	each	well.	
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5.	RESULTS	
	
5.1	miR-34	and	SNAIL	form	a	double-negative	feedback	loop	to	regulate	epithelial-
mesenchymal	transitions	
	
The	following	results	are	published	in:		
	
Siemens	H*,	Jackstadt	R*,	Hünten	S*,	Kaller	M*,	Menssen	A*,	Götz	U	and	Hermeking	
H	 (2011).	 miR-34	 and	 SNAIL	 form	 a	 double-negative	 feedback	 loop	 to	 regulate	
epithelial-mesenchymal	transitions.	Cell	Cycle	10	(24),	4256-71.	[1]	
*	Equally	contributing	authors.		
	
							All	figures	shown	in	this	section	are	exclusively	based	on	my	experimental	work.	
Figures	 from	 contributing	 authors	 have	 deliberately	 not	 been	 included	 in	 the	
following	section	as	they	are	only	adjacent	to	the	scope	of	this	thesis.	However,	to	
provide	a	comprehensive	picture	of	the	published	findings	the	text	refers	to	results	
from	 contributing	 authors	 of	 the	 publication	 above.	 The	 respective	 name	 of	 the	
contributing	author	is	clearly	stated	in	the	text.	 
 
5.1.1	p53-dependent	regulation	of	SNAIL	is	mediated	by	miR-34a		
p53	has	been	described	to	suppress	tumorigenesis	by	the	inhibition	of	epithelial-
mesenchymal	 transition	 [98,	 245].	 To	 study	 p53-dependent	 regulations	 and	
processes	 related	 to	 mesenchymal-epithelial	 transitions,	 we	 used	 the	 colorectal	
cancer	 cell	 line	 HCT116	 p53+/+	 and	 its	 isogenic	 clone	 harboring	 a	 homozygous	
deletion	of	p53	[246]	and	treated	those	cells	with	Nutlin-3a,	an	inhibitor	of	the	E3-
ligase	 MDM2	 [247],	 to	 activate	 p53	 expression.	 Expectedly,	 Nutlin-3a	 treatment	
resulted	in	p53	activation	on	protein	level	in	the	HCT116	p53+/+	but	not	in	HCT116	
p53-/-	cells	(Fig.	6).		
	
	
Figure	6:	p53-dependent	regulation	of	SNAIL-	and	E-cadherin	protein	levels	in	the	colorectal	cancer	
cell	line	HCT116.	HCT116	p53+/+	and	HCT116	p53-/-	were	treated	with	the	MDM2-inhibitor	Nutlin-3a	
for	 the	 indicated	 timepoints.	 Western	 blot	 analysis	 of	 the	 indicated	 proteins.	 ß-actin	 served	 as	 a	
loading	control.		
0    12      24     48     72      0   12       24   48      72
HCT116 p53+/+ HCT116 p53-/-
hours + Nutlin-3a
- p53
- SNAIL
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- β-actin
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Furthermore,	we	detected	a	robust	induction	of	the	adherens	junction	protein	E-
cadherin	upon	p53	expression	 in	 the	HCT116	p53+/+	 cells	whereas	no	change	was	
observed	in	the	HCT116	cell	line	carrying	the	p53	deletion	(Fig.	6).	This	induction	was	
confirmed	 by	 an	 immunofluorescence	 analysis	 showing	 the	 p53-dependent	
localization	of	E-cadherin	to	the	outer	cell	membrane	(Fig.	7).	
	
	
Figure	 7:	 p53-dependent	 regulation	 of	 E-cadherin	 expression	 and	 localization	 in	 the	 colorectal	
cancer	 cell	 line	HCT116.	HCT116	p53+/+	and	HCT116	p53-/-	were	 treated	with	 the	MDM2-inhibitor	
Nutlin-3a	for	72	hours	and	subsequently	subjected	to	an	immunofluorescence	analysis	of	E-cadherin	
protein-expression	and	localization.	DAPI	was	used	to	stain	nuclear	DNA.	200x	magnification.	
	
Moreover,	Nutlin-3a	treatment	resulted	 in	 increased	E-cadherin	mRNA	 levels	as	
well	 as	 decreased	 expression	 of	 the	 mesenchymal	 marker	 Vimentin	 in	 HCT116	
p53+/+	cells	(Fig.	8).		
	
Figure	8:	p53-dependent	regulation	of	EMT-related	factors	as	well	as	primary	miRNA-transcripts	in	
the	 colorectal	 cancer	 cell	 line	 HCT116.	 HCT116	 p53+/+	 and	 HCT116	 p53-/-	 were	 treated	with	 the	
MDM2-inhibitor	Nutlin-3a	for	the	 indicated	timepoints	and	the	 indicated	mRNAs	were	measured	by	
qPCR	 analysis.	 ß-actin	 served	 as	 a	 normalization	 control.	 Fold	 changes	 represent	 mean	 values	 of	
triplicate	 analyses	 of	 Nutlin-3a	 versus	 DMSO	 treated	 cells	 and	 error	 bars	 represent	 standard	
deviations.	
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Since	the	mesenchymal	marker	SNAIL	is	known	to	repress	E-cadherin	expression,	
we	 investigated	 the	effect	of	p53	on	SNAIL	protein-	and	mRNA-level.	 Interestingly,	
SNAIL	was	repressed	in	a	p53-dependent	manner	on	both,	protein-	and	mRNA-level	
(Fig.	6,	8).	 It	was	striking	that	SNAIL	protein	levels	were	lower	in	untreated	HCT116	
p53+/+	cells	when	compared	to	HCT116	p53-/-	cells.		
As	p53	is	known	to	induce	MET-like	processes	through	the	regulation	of	miRNAs	
[98,	245],	we	checked	for	the	expression	of	the	primary	transcripts	of	miR-34a,	miR-
34b/c	and	the	miR-200	family	members,	miR-200b-429	and	miR-200c-141	(Fig.	8).	All	
primary	miRNA	transcripts	were	induced	in	a	p53-dependent	manner	in	the	HCT116	
p53+/+	cell	line	but	not	in	HCT116	p53-/-	cells	after	Nutlin-3a	treatment.	
To	 further	 interrogate	 the	 p53-dependency	 of	 those	 EMT-related	 factors,	 I	
established	 the	 DOX-inducible	 colorectal	 cancer	 cell	 line	 SW480/pRTR-p53-VSV,	
which	 is	described	 in	detail	on	page	42.	Upon	activation	of	p53	by	 treatment	with	
DOX,	SNAIL	was	down-regulated	on	protein-	and	mRNA-level	(Fig.	9).	
	
	
	
Figure	 9:	 p53-induced	 regulation	 of	 EMT-related	 factors	 in	 the	 colorectal	 cancer	 cell	 line	
SW480/pRTR-p53-VSV.	 SW480/pRTR-p53-VSV	 cells	 were	 treated	 with	 DOX	 for	 the	 indicated	
timepoints.	(A)	Western	blot	analysis	of	the	indicated	proteins.	ß-actin	served	as	a	loading	control.	(B)	
The	indicated	mRNAs	were	measured	by	qPCR	analysis.	ß-actin	served	as	a	normalization	control.	Fold	
changes	represent	mean	values	of	triplicate	analyses	of	DOX-treated	versus	untreated	cells	and	error	
bars	represent	standard	deviations.	
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As	seen	before	 in	the	HCT116	cells,	 the	SNAIL	target	CDH1	 showed	a	prominent	
up-regulation	upon	ectopic	p53	expression	(Fig.	9B).	Furthermore,	the	mesenchymal	
marker	SLUG	was	down-regulated	on	protein	level	in	the	SW480/pRTR-p53-VSV	cells	
after	 DOX	 treatment	 (Fig.	 9A),	 which	 could	 possibly	 be	 explained	 by	 the	 MDM2-
mediated	 degradation	 of	 SLUG	upon	 p53	 induction	 [248].	 In	 addition,	 the	 primary	
miRNA	 transcripts	 of	 the	miR-34	 and	miR-200	 families	were	 induced	 upon	 ectopic	
p53	 expression	 (Fig.	 9B).	 pri-miR-34a	 showed	 the	 most	 pronounced	 induction	
whereas	 pri-miR-34b/c,	 -miR-200b/429	 and	 -miR-200c/141	 were	 moderately	
induced.	
To	 check	whether	 the	down-regulation	of	 SNAIL	 is	 causally	 linked	 to	 the	 robust	
induction	 of	 miR-34a	 upon	 p53	 expression,	 we	 treated	 the	 SW480/pRTR-p53-VSV	
cells	 with	 an	 antagomir-miR-34a	 and	 simultaneously	 induced	 p53	 expression									
(Fig.	10).	As	shown	before,	treatment	with	DOX	led	to	the	induction	of	p53	protein	
levels	 and	 a	 repression	 of	 the	 mesenchymal	 marker	 SNAIL.	 The	 same	 effect	 was	
demonstrated	 when	 the	 cells	 were	 simultaneously	 treated	 with	 an	 antagomir	
control-oligonucleotide.	 However,	 when	 the	 cells	 were	 treated	with	 an	 antagomir	
against	 miR-34a	 the	 repression	 of	 SNAIL	 was	 less	 pronounced	 compared	 to	 the	
control	transfection.	This	indicates	that	SNAIL	repression	after	induction	of	p53	is	-	at	
least	in	part	-	mediated	by	miR-34a.		
	
	
	
	
	
	
	
	
	
	
	
	
Figure	10:	p53-dependent	down-regulation	of	SNAIL	is	mediated	by	miR-34a	in	the	colorectal	cancer	
cell	 line	SW480.	Western	blot	analysis	of	the	indicated	proteins,	ß-actin	served	as	a	loading	control.	
SW480/pRTR-p53-VSV	 cells	 were	 transfected	 with	 the	 indicated	 oligonucleotides	 for	 48	 hours	 and	
treated	 with	 or	 without	 DOX	 for	 24	 hours	 before	 harvesting.	 Antagomir-miR-34a	 represents	 an	
oligonucleotide	specifically	targeting	miR-34a	and	antagomir-control	is	the	respective	control.		
	
Next,	we	 addressed	 the	 question	whether	 SNAIL	 is	 a	 direct	miR-34a	 target.	My	
colleague	Dr.	Markus	Kaller	inspected	the	3´-UTR	of	SNAIL	for	putative	miR-34a	seed-
matching	sequences	using	two	different	alghorithms,	TargetScan	and	miRanda	[239,	
249],	 and	 identified	 a	 highly	 conserved	 miR-34a	 seed	 sequence	 in	 this	 region.	 A							
3´-UTR-reporter	of	SNAIL	displayed	a	significant	repression	after	cotransfection	of	a	
pre-miR-34a	oligonucleotide.	Mutation	of	the	seed-matching	sequence	in	the	3´-UTR		
abolished	the	miRNA-mediated	repression.	These	results	indicate	that	p53	represses	
SNAIL	indirectly	via	direct	induction	of	miR-34a.	
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5.1.2	miR-34a	regulates	markers	of	mesenchymal-epithelial	transition	
To	investigate	whether	miR-34a	alone	induces	MET-like	changes,	my	colleague	Dr.	
Helge	 Siemens	 transfected	 the	 colorectal	 cancer	 cell	 line	 SW480	with	 a	 pRTR-miR-
34a	vector	and	checked	for	expression	changes	of	MET-related	factors	after	ectopic	
miR-34a	 expression.	 Indeed,	 western	 blot	 analysis	 revealed	 a	 robust	 down-
regulation	 of	 the	mesenchymal	markers	 SNAIL,	 ZEB1,	 Vimentin	 and	 an	 increase	 of	
the	 epithelial	 marker	 E-cadherin	 after	 induction	 of	 miR-34a.	 Furthermore,	 HDAC1	
and	ß-catenin	were	both	repressed	on	protein	level.	In	addition,	the	localization	of	ß-
catenin	 changed	 from	 nuclear	 to	 cytoplasmic	 after	 miR-34a	 expression.	 qPCR	
analyses	confirmed	the	up-regulation	of	CDH1	and	the	down-regulation	of	Vimentin,	
SNAIL,	ZEB1	and	SLUG.		
Furthermore,	 the	 stemness	markers	CD133,	OLFM4,	BMI1	 as	well	 as	 the	known	
miR-34a	 targets	 CD44	 [250]	 and	 c-MYC	 [251,	 252]	 were	 down-regulated	 upon	
ectopic	 miR-34a	 expression	 indicating	 a	 potential	 loss	 of	 stemness.	 The	 down-
regulation	of	stem	cell-like	properties	has	already	been	described	for	miR-200c	[245,	
253].	Furthermore,	an	investigation	of	the	3´-UTR	of	the	EMT-inducing	factors	SLUG,	
ZEB1	 and	 ZEB2	 for	 miR-34a-	 as	 well	 as	 miR-200-seed-matches	 revealed	 miR-200	
binding	sites	in	the	3´-UTRs	of	SLUG,	ZEB1	and	ZEB2	as	shown	previously	[97,	98].	A	
miR-34a	 seed-match	was	 only	 present	 in	 the	 3´-UTR	of	ZEB2.	 However,	ZEB1-	 and	
ZEB2	3´-UTR	constructs	were	only	repressed	upon	pre-miR-200	transfection	whereas	
the	 transfection	 of	 a	 pre-miR-34a	 oligonucleotide	 did	 not	 have	 any	 effect.	 This	
indicates	that	miR-34a	induces	MET-like	changes	in	the	studied	colorectal	cancer	cell	
line	 SW480	 by	 directly	 down-regulating	 SNAIL.	 However,	 the	 results	 of	 Dr.	 Helge	
Siemens	 show	 that	 other	mesenchymal	markers	 such	 as	SLUG,	ZEB1	 and	ZEB2	 are	
not	 direct	miR-34a	 targets.	 Their	 repression	might	 rather	 be	mediated	 by	 the	 up-
regulation	of	the	miR-200	family,	which	is	in	part	the	result	of	down-regulated	SNAIL	
levels.		
	
5.1.3	miR-34a	dependent	regulation	of	MET-like	changes	
Next,	 we	 investigated,	 whether	 p53	 inhibits	 EMT-associated	 functions,	 such	 as	
migration	and	 invasion,	via	the	 induction	of	miR-34a.	A	scratch-assay	revealed	that	
wound	closure	was	significantly	decreased	after	DOX	treatment	in	the	SW480/pRTR-
p53-VSV	cells	when	compared	 to	 the	untreated	control	 (Fig.	11A,	B).	 Furthermore,	
SW480/pRTR-p53-VSV	cells	showed	a	significant	reduction	in	relative	migration	after	
ectopic	p53	expression	(Fig.	11C).			
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To	address	the	question	how	miR-34a	contributes	to	cellular	functions	mediated	
by	 p53,	 we	 transfected	 the	 SW480/pRTR-p53-VSV	 cells	 with	 an	 antagomir	 against	
miR-34a	 and	 treated	 the	 cells	 with	 or	 without	 DOX	 before	 subjecting	 them	 to	 a	
scratch	 and	 invasion	 assay	 (Fig.	 12).	 Treatment	 with	 the	 antagomir-miR-34a	 after	
ectopic	 p53	 expression	 reversed	 both,	 the	 inhibition	 of	 wound	 closure	 and	 the	
inhibition	of	invasion	(Fig.	12A	and	B,	respectively).	Furthermore,	antagomir-miR-34a	
treatment	 led	 to	 an	 increase	 in	 migration	 and	 invasion	 when	 compared	 to	 the	
control	transfection.	The	data	indicate	that	p53-induced	miR-34a	mediates	MET-like	
changes	including	decreased	wound	closure,	migration	and	invasion.	
	
	
Figure	 12:	 p53	 mediates	 the	
inhibition	 of	 wound-closure	
and	 invasion	 via	 miR-34a	 in	
SW480	 cells.	 SW480/pRTR-
p53-VSV	 cells	 were	 trans-
fected	 with	 the	 indicated	
oligonucleotides	 for	 48	 hours	
and	 treated	 with	 or	 without	
DOX	 for	 24	 hours.	 (A)	 Scratch	
assay:	 48	 hours	 after	 the	
scratch	 the	 wound	 width	 of	
five	scratches	in	two	wells	was	
measured	 and	 represented	 as	
the	 average	 of	 the	 closed	wound	 area	 [%]	 +/-	 SE	 (n=2).	 (B)	 Invasion	 assay:	 Cells	were	 seeded	 in	 a	
Boyden-chamber	 and	 allowed	 to	 invade	 through	 the	 membrane	 for	 48	 hours.	 Represented	 is	 the	
mean	relative	invasion	+/-	SD	(n=3).	
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Figure	11:	p53	inhibits	wound	closure	and	migration	 in	SW480	cells.	(A)	SW480/pRTR-p53-VSV	cells	
were	 treated	with	or	without	DOX	 for	48	hours	before	a	 scratch	was	generated	and	 representative	
pictures	were	taken	directly	after	the	scratch	(0	hours)	and	after	48	hours;	100x	magnification.	(B)	The	
wound	 width	 of	 five	 scratches	 in	 two	 wells	 was	measured	 and	 represented	 as	 the	 average	 of	 the	
closed	 wound	 area	 [%]	 +/-	 SE	 (n=2).	 (C)	 SW480/pRTR-p53-VSV	 (un-)treated	 with	DOX	 for	 48	 hours	
were	seeded	in	Boyden-chambers	and	were	allowed	to	migrate	for	48	hours.	Represented	is	the	mean	
relative	migration	+/-	SD	(n=3). 
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These	 results	 were	 confirmed	 by	 my	 colleague	 Dr.	 Helge	 Siemens	 who	
investigated	SW480/pRTR-miR-34a	cells	 for	their	wound	healing	capacity	as	well	as	
their	invasion	and	migration	ability	after	ectopic	miR-34a	expression.	Overexpression	
of	 miR-34a	 inhibited	 wound	 closure	 as	 well	 as	 invasion	 and	 migration.	 Taken	
together,	miR-34a	is	essential	to	mediate	the	inhibition	of	migration	and	invasion	in	
colorectal	cancer	cells.	
	
5.1.4	Relevance	of	SNAIL	as	a	miR-34a	target	
Next,	 we	 determined	 the	 relevance	 of	 SNAIL	 repression	 on	 miR-34a-mediated	
MET-like	changes.	Dr.	Helge	Siemens	generated	all	the	following	data.	He	established	
a	colorectal	cancer	cell	line	harboring	an	inducible	pRTR-SNAIL-VSV	vector.	The	SNAIL	
cDNA	cloned	into	the	pRTR	vector	was	lacking	its	3´-UTR	sequence	and	therefore	the	
miR-34a	 binding	 site	 in	 order	 to	 check	 whether	 ectopic	 expression	 of	 a	miR-34-
insensitive	SNAIL	cDNA	reverses	the	MET-like	changes	mediated	by	miR-34a.		
Ectopic	expression	of	SNAIL	in	SW480/pRTR-SNAIL-VSV	cells	partly	prevented	the	
inhibition	of	migration	in	a	wound-healing	and	Boyden	chamber	assay.	Furthermore,	
HCT116	p53-/-	cells,	that	displayed	higher	levels	of	SNAIL	than	HCT116	p53+/+	cells,	
showed	 increased	migration	 compared	 to	 the	 HCT116	p53+/+	 cell	 line.	Moreover,	
siRNA	mediated	knockdown	of	SNAIL	 in	HCT116	p53-/-	cells	resulted	in	a	significant	
decrease	in	their	migratory	capacity.	Taken	together,	SNAIL	is	relevant	for	increased	
migration	observed	after	loss	of	p53	and	presumably	also	miR-34.	
	
5.1.5	Direct	repression	of	miR-34	by	SNAIL	
Based	 on	 the	 negative	 feedback	 loop	 between	 the	miR-200	 family	 genes	 and	
ZEB1/2	 [254,	 255],	we	 hypothesized	 that	miR-34a	might	 also	 be	 a	 direct	 target	 of	
SNAIL.	 To	 test	 this	 hypothesis,	 Dr.	 Helge	 Siemens	 ectopically	 expressed	 SNAIL	 in	
DLD1/pRTR-SNAIL-VSV	 cells,	 which	 resulted	 in	 several	 EMT-like	 effects:	 down-
regulation	 of	 the	 adherens-junction	 protein	 E-cadherin,	 enhanced	 wound	 closure,	
migration	 and	 invasion	 and	 the	 appearance	 of	 F-actin	 stress	 fibers.	 In	 addition,	
mRNA	 levels	 of	 the	 mesenchymal	 markers	 Vimentin	 and	 ZEB1	 were	 up-regulated	
whereas	 CDH1	 showed	 a	 prominent	 down-regulation.	 Interestingly,	 the	 primary	
transcripts	 of	 miR-34a	 and	 miR-200c	 were	 strongly	 repressed	 upon	 ectopic	
expression	 of	 SNAIL.	 Knocking-down	 SNAIL	 in	 the	 mesenchymal	 cell	 line	 SW480	
resulted	in	increased	expression	of	the	primary-miR-34a	and	–miR-34b/c	transcripts	
which	confirms	that	SNAIL	directly	or	indirectly	mediates	their	repression.		
To	determine	whether	SNAIL	is	a	direct	repressor	of	the	miR-34	family	genes,	Dr.	
Markus	Kaller	examined	the	respective	promoters	for	potential	SNAIL	binding	sites.		
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Promoter-proximal	 E-boxes	were	 identified	 for	 both,	miR-34a	 and	miR-34b/c.	 Also	
the	promoter	of	 the	miR-200c	 gene	harbored	 three	conserved	SNAIL	binding	 sites.	
Indeed,	 a	 ChIP-assay	 in	 the	 DLD1/pRTR-SNAIL-VSV	 cells	 revealed	 binding	 of	 SNAIL	
upstream	of	 the	miR-34a,	 -34b/c	and	 -200c	promoters	which	confirmed	that	SNAIL	
functions	as	a	direct	repressor	of	 the	miR-34	 family	and	miR-200c.	Taken	together,	
miR-34	and	SNAIL	form	a	double-negative	feedback	loop	that	controls	the	transition	
between	the	epithelial	and	mesenchymal	state.	  
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5.2	p53-regulated	networks	of	protein,	mRNA,	miRNA	and	lncRNA	expression	
revealed	by	integrated	pSILAC	and	NGS	analyses	
The	following	results	are	published	in:		
	
Hünten	S,	Kaller	M*,	Drepper	F*,	Oeljeklaus	S,	Bonfert	T,	Erhard	F,	Dueck	A,	Eichner	
N,	 Friedel	 CC,	 Meister	 G,	 Zimmer	 R,	 Warscheid	 B	 and	 Hermeking	 H	 (2015).														
p53-Regulated	Networks	of	Protein,	mRNA,	miRNA	and	lncRNA	Expression	Revealed	
by	 Integrated	 Pulsed	 Stable	 Isotope	 Labeling	 With	 Amino	 Acids	 in	 Cell	 Culture	
(pSILAC)	and	Next	Generation	Sequencing	(NGS)	Analyses.	Mol	Cell	Proteomics,	2015	
Jul	16.	pii:	mcp.M115.050237.	[2]	*equally	contributing	authors	
	
						All	figures	shown	in	this	section	are	either	based	exclusively	on	my	experimental	
data	or	built	on	my	preparatory	work	and	experimental	planning	under	supervision	
of	 Prof.	 Hermeking.	 Together	 with	 Prof.	 Hermeking	 I	 planned	 and	 developed	 the	
concept	 of	 this	 study	 including	 its	 main	 objectives	 and	 wrote	 major	 parts	 of	 the	
manuscript.	I	established	the	cell	 line	used	for	the	study,	evaluated	its	functionality	
and	 prepared	 the	 cells	 for	 miRNA-,	 RNA-	 and	 ChIP-sequencing.	 Furthermore,	 I	
performed	 isotopic	 labeling	 of	 the	 cells	 for	 subsequent	 proteomic	 analysis.	 I	
comparatively	 analyzed	NGS	and	pSILAC	datasets	 after	 their	 raw	data	 analysis	 and	
evaluated	the	results	for	further	analysis	of	interesting	candidate	genes.	I	performed	
all	 cell	 culture	 related	 experiments,	 KEGG	 pathway	 and	 target	 prediction	 analyses	
and	analyzed	clinical	relevance	of	the	candidate	genes.	
To	provide	a	comprehensive	picture	of	the	published	findings	the	text	and	figures	
also	refer	to	contributions	of	the	co-authors	that	supported	bioinformatics	as	well	as	
mass	 spectrometric	 analyses.	 In	 case	 of	 contributions	 of	 the	 co-authors	 these	 are	
clearly	indicated	in	the	text	and	the	corresponding	figure	legends.	Sequencing	of	the	
RNA-	 and	 ChIP-samples	 was	 performed	 by	 GATC,	 Konstanz.	 miRNA-sequencing	 of	
total	 RNA	 samples	 was	 done	 in	 collaboration	 with	 A.	 Dueck,	 N.	 Eichner	 and	 G.	
Meister.	Mass	spectrometric	analysis	was	performed	by	F.	Drepper,	S.	Oeljeklaus	and	
B.	 Warscheid.	 Bioinformatics	 analysis	 of	 the	 miRNA-sequencing	 raw	 data	 was	
performed	 by	 F.	 Erhard	 and	 R.	 Zimmer.	 T.	 Bonfert,	 C.	 Friedel	 and	 R.	 Zimmer	
conducted	 raw	 data	 analyses	 of	 RNA-	 and	 ChIP-sequencing	 data.	 A	 list	 with	
corresponding	expression	fold	changes	was	provided	by	the	respective	contributing	
authors	after	raw	data	analyses	of	(mi-)RNA-Seq	and	pSILAC	results.	After	raw	data	
analysis	of	the	ChIP-Seq	data,	T.	Bonfert,	C.	Friedel	and	R.	Zimmer	provided	the	DNA-
binding	 motifs	 of	 p53	 and	 neighboring	 transcription	 factors,	 the	 localization	 and	
distribution	 of	 called	 ChIP-Seq	 peaks	 as	 well	 as	 a	 list	 showing	 all	 occupied	 p53	
binding	 sites	 that	 were	 identified	 (including	 their	 sequence	 and	 localization).	 M.	
Kaller	 supported	 bioinformatics	 analyses	 of	 mRNA,	miRNA	 and	 lncRNA	 expression	
results,	 cumulative	 distribution	 analyses	 and	 comparative	 analyses	 of	 p53	 pSILAC	
data	with	miR-34a	pSILAC	results.	 
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5.2.1	NGS	and	pSILAC	analyses	after	p53	activation	
We	 studied	 the	 effect	 of	 p53	 activation	 on	 the	 expression	 of	 proteins,	mRNAs	
and	 ncRNAs	 as	 well	 as	 genome-wide	 DNA-binding	 by	 p53.	 For	 this	 purpose,	 a	
recently	 described,	 episomal	 pRTR	 vector	 system	 that	 allows	 DOX-inducible	
expression	of	the	introduced	cDNA	was	employed	(see	5.1)	[1,	220].	SW480	CRC	cells	
were	 transfected	 with	 pRTR-p53-VSV	 vectors	 and	 after	 selection	 for	 two	 weeks,	
stable	cell	pools	were	obtained.	As	a	control,	an	SW480	cell	pool	harboring	a	pRTR	
vector	 only	 expressing	 GFP	 was	 generated.	 95.7%	 and	 85.2%	 of	 the	 cells	 in	 the	
SW480/pRTR-p53-VSV	and	SW480/pRTR	pools,	 respectively,	were	positive	 for	GFP-
expression	 48	 hours	 after	 addition	 of	 DOX	 (Fig.	 13A).	 SW480/pRTR-p53-VSV	 cells	
showed	a	prominent	induction	of	p53	expression	after	addition	of	DOX	and	the	p53	
target	p21	was	up-regulated	(Fig.	13B).	
	
	
Figure	 13:	 Characterization	 of	 SW480	 cells	 ectopically	 expressing	 p53.	 (A)	 Flow	 cytometric	
determination	of	the	percentage	of	GFP	expressing	cells	in	SW480	cell	pools	stably	transfected	with	a	
pRTR-p53-VSV	 or	 a	 control	 pRTR	 vector	 48	 hours	 after	 addition	 of	 DOX.	 (B)	 The	 indicated	 proteins	
were	detected	by	Western	blot	analysis.	β-actin	served	as	a	loading	control.	
	
Moreover,	 p53	 activation	 resulted	 in	 the	 adoption	 of	 a	 flat	 and	 enlarged	 cell	
shape	indicating	a	p53-induced	cell	cycle	arrest	(Fig.	14A).	In	addition,	we	detected	a	
20%	increase	in	the	G1-phase	and	a	minor	increase	in	the	sub-G1-phase	after	addition	
of	DOX	(Fig.	14B).		
	
	
Figure	14:	Microscopic	and	FACS	analyses	of	SW480/pRTR-p53-VSV	cells.	(A)	Representative	phase-
contrast	pictures	(200x	magnification)	of	SW480/pRTR-p53-VSV	cells	after	the	indicated	time	points	of	
DOX-treatment.	 (B)	DNA	content	analysis	by	 flow	cytometry	after	addition	of	DOX	for	 the	 indicated	
periods	of	time.	Results	represent	the	mean	+/-	SD	(n=3).	
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Next,	 we	 performed	 miRNA-,	 RNA-	 and	 ChIP-Seq	 as	 well	 as	 pSILAC	 analyses	
(Table	1).	Co-authors	contributed	as	described	on	page	42.	For	the	miR-Seq	as	well	
as	for	the	ChIP-Seq	analyses,	a	short	period	of	16	hours	of	p53	activation	was	chosen	
in	 order	 to	 preferentially	 identify	 directly	 regulated	 miRNAs.	 For	 RNA-Seq	 and	
pSILAC,	late	time	points	of	48	and	40	hours,	respectively,	were	selected	in	order	to	
allow	 the	 identification	 of	 mRNAs	 and	 proteins	 down-regulated	 by	 p53-induced	
miRNAs.	The	NGS	analyses	resulted	in	13	to	42	million	reads	per	library.	The	pSILAC	
analysis	 identified	 67,090	 peptides	 (60,911	 unique	 sequences)	 derived	 from	 about	
5,000	proteins.	
	
	
	
5.2.2	pSILAC	analysis	of	protein	expression	after	p53	activation	
The	 pSILAC	 analysis	 (contributions	 of	 the	 co-authors	 described	 on	 page	 42)	
resulted	 in	 the	 identification	 of	 5,126	 proteins	 and	 the	 quantification	 of	 4,692	
proteins	 in	 at	 least	 two	 out	 of	 six	 replicates	 (including	 two	 replicates	with	 a	 label	
swap).	 Only	 those	 proteins	 that	 were	 identified	 by	 peptide	 hits	 in	 at	 least	 two	
replicates	(n	=	2)	with	a	p-value	≤	0.05	were	considered	for	further	analysis.	In	order	
to	 include	moderate	 effects	 by	 p53-induced	miRNAs,	which	were	 expected	due	 to	
the	 previously	 observed	 moderate	 regulation	 of	 de	 novo	 protein	 synthesis	 after	
ectopic	miRNA	expression	[217,	256],	we	applied	a	low-stringency	cutoff	of	≤	-0.3	or					
≥	0.3	log2	fold	changes	in	protein	expression.	Based	on	these	criteria,	we	determined	
542	up-	und	569	down-regulated	proteins	(Fig.	15).			
	
	
	
	
	
Method Reads	SW480/pRTR-p53-VSV
Reads
SW480/ pRTR
Addition of
DOX	(hrs)
miRNA-Seq 38,362,281 39,373,220 16
RNA-Seq 42,451,244 29,278,860 48
ChIP-Seq 13,245,968 21,820,442 16
pSILAC 67,090	peptides
(60,911	unique sequences)
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Table	 1:	 Summary	 of	 the	
sequencing	reads	obtained	by	
ChIP-,	 miRNA-	 and	 RNA-Seq	
analysis	 and	 peptide	
identifications	 by	 pSILAC	
analysis.	 The	 respective	
periods	 of	 p53	 activation	 by	
addition	of	DOX	are	indicated.		
 
Figure	 15:	 Differential	 protein	 regulation	 by	 p53.	
SW480/pRTR-p53-VSV	 were	 subjected	 to	 a	 pSILAC	
analysis	 after	 40	 hours	 DOX	 treatment.	 Volcano	 plot	
classification	 of	 quantified	 proteins.	 Log-transformed	 p-
values	 (-log2)	 are	 plotted	 against	 the	 mean	 log2	 of	 the	
corresponding	 pSILAC	 abundance	 ratios	 of	 proteins	
quantified	in	at	least	two	out	of	six	replicates.	Significantly	
regulated	 proteins	 with	 a	 log2	 fold	 change	 ≥	 0.3	 are	
indicated	 in	 green,	 with	 a	 log2	 fold	 change	 ≤	 -0.3	 are	
marked	 in	 red	 and	 with	 0.3	 ˃	 log2	 fold	 change	 ˃	 -0.3	 in	
black.	 Proteins	with	a	p-value	˃	0.05	are	 represented	by	
grey	 dots.	 Based	 on	 the	 results	 of	 the	 pSILAC	 analysis	
(isotopic	 labeling	of	 the	 cells	performed	by	myself,	mass	
spectrometric	 analysis	 performed	 by	 F.	 Drepper,	 S.	
Oeljeklaus,	B.	Warscheid),	the	figure	was	generated. 
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The	top	50	down-	and	50	up-regulated	proteins	(all	|log2	fold	changes|	>	1)	are	listed	
in	Table	2.		
	
	
Table	2:	 100	most	up-	and	down-regulated	proteins	detected	by	pSILAC	and	high-resolution	mass	
spectrometry.	List	of	the	(left)	50	most	down-	and	(right)	50	most	up-regulated	proteins	detected	by	
pSILAC	with	a	log2	fold	change	≤	-0.3	or	≥	0.3,	respectively,	and	a	p-value	≤	0.05.	The	corresponding	
mRNA	 log2	 fold	 change	 detected	 by	 RNA-Seq	 is	 indicated.	 Proteins	 that	 showed	 a	 heterogeneous	
distribution	 of	 fold	 changes	 in	 independent	 experiments	 (class	 II	 candidates,	 see	 Experimental	
procedures)	are	marked	with	an	asterisk	(*).	Proteins	marked	in	bold	harbor	an	occupied	p53	binding	
site	in	the	vicinity	of	the	respective	gene	promoter	(+/-20	kb)	according	to	our	ChIP-Seq	data.	Those	
additionally	 underlined	 represent	 already	 described,	 direct	 p53	 target	 genes.	 Based	 on	 the	 pSILAC,	
RNA-/ChIP-Seq	results	(contributions	of	the	co-authors	described	on	page	42),	the	data	were	analyzed	
and	this	table	was	generated.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Names log2 fc
protein
log2 fc
mRNA
Names log2 fc
protein
log2 fc
mRNA
NGFR 4.91 0.50 KLK6 1.40 1.08
CDKN1A 4.67 2.41 TIGAR 1.40 0.60
TP53I3 3.31 3.34 PDCD4 1.40 -0.23
ALDH1A3 2.84 -0.54 ZG16B 1.38 _
CMBL 2.60 2.29 TGM2 1.35 3.28
CST5 2.48 3.18 MT1H 1.34 _
FDXR 2.38 1.83 CDA 1.34 3.94
DDB2 2.36 1.63 ANXA4 1.32 0.80
SERPINE1 2.27 3.97 GSN 1.29 1.96
FBXO2 2.24 3.85 CST1 1.28 1.56
FUCA1 2.18 1.15 TIMP3 1.26 2.28
MVP 2.01 4.12 APOBEC3C 1.25 0.06
EPS8L2 2.00 2.00 NT5E 1.22 3.16
CCND2 1.95 0.96 PHPT1 1.21 0.49
ABAT 1.93 3.28 HMOX1 1.21 -0.91
CCND1 1.89 0.31 LIMA1 1.20 0.29
FAT1 1.88 1.35 CST7 1.13 0.56
RPS27L 1.76 2.46 DOCK9 1.13 0.00
NUCKS1 1.61 -0.86 DCP1B 1.10 0.65
PGPEP1 1.60 0.71 TUBA1A 1.09 0.24
RRM2B 1.59 2.07 OSBPL3 1.08 -0.03
SLC5A3 1.51 2.66 OTUB2 1.07 1.58
BAX 1.42 0.83 MT2A 1.06 1.65
CTSB 1.42 2.18 KIAA1609 1.06 1.43
PYCARD 1.42 2.59 FHL2 1.06 0.37
Top	50	up-regulated proteins (pval ≤	0.05)
Names log2 fc
protein
log2 fc
mRNA
Names log2 fc
protein
log2 fc
mRNA
C6orf89 -2.19 0.21 UBE2S -1.23 -0.73
KIF22 -1.84 -0.74 SMC4 -1.22 0.06
MDC1 -1.61 -0.81 BAZ1B -1.22 -0.55
NEB -1.51 -0.88 CDK1 -1.22 -0.48
TOP2A -1.50 -0.48 KIAA1524 -1.21 0.02
SPC25 -1.46 -0.57 SHCBP1 -1.21 -0.16
HIST1H4A -1.42 _ NCAPD2 -1.21 -0.40
CCNB2 -1.39 -0.66 DHRSX -1.20 _
TTK -1.37 -0.67 FANCI -1.20 -0.77
INCENP -1.33 -0.37 TMEM109* -1.18 -0.07
TK1 -1.33 0.65 FAM111B -1.17 0.23
PBK -1.30 -0.60 PTTG1 -1.16 -0.45
RIF1 -1.29 -0.53 HIST1H1B -1.16 -0.79
CISD2 -1.26 -0.06 CDC20 -1.15 -0.69
UTP20 -1.26 -0.71 NCAPG -1.15 -0.29
UBE2T -1.26 -0.64 RFT1* -1.15 -0.33
SPC24 -1.26 -0.88 SPAG5 -1.14 -0.27
BIRC5 -1.25 0.06 PTDSS1* -1.13 0.14
BUB1B -1.25 -0.44 DLGAP5 -1.13 -0.49
DHFR -1.24 -0.54 RRM2 -1.13 0.46
KIF2C -1.23 -0.67 CCNB1 -1.12 -0.57
HIST2H2AA3 -1.23 _ SMPD4* -1.12 -0.50
KIF11 -1.23 -0.75 LMO7 -1.12 -1.51
GINS3 -1.23 -0.37 UHRF1 -1.11 -0.29
RACGAP1 -1.23 -0.52 HIST2H3PS2 -1.11 _
Top	50	down-regulated proteins (pval ≤	0.05)
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A	 KEGG	 pathway	 analysis	 revealed	 that	 the	 set	 of	 proteins	 involved	 in	 DNA	
replication	(p	=	1.14E-28)	and	cell	cycle	regulation	(p	=	9.59E-14)	was	highly	enriched	
among	 the	 down-regulated	 proteins	 (Fig.	 16A).	 Almost	 all	 members	 of	 the	 mini-
chromosome	 maintenance	 (MCM)	 family,	 catalytic	 subunits	 of	 different	 DNA	
polymerases	 (POLA,	 POLE,	 POLD)	 and	 members	 of	 the	 replication	 factor	 C	 (RFC)	
family,	 which	 are	 involved	 in	 the	 initiation	 of	 eukaryotic	 DNA	 replication,	 were	
significantly	down-regulated.	 In	addition,	known	protumorigenic	 factors	 involved	 in	
cell	 cycle	 regulation,	 such	as	TTK	 [257],	BIRC5	 [258],	CDK1	 [259]	and	CDK6,	CDC20	
[260],	CCNB1	[261]	and	BUB1B,	were	also	significantly	down-regulated.	Among	the	
up-regulated	proteins,	 factors	 involved	 in	 the	p53	signaling	pathway	(p	=	6.86E-03)	
were	significantly	enriched,	including	several	proteins	encoded	by	known	p53	target	
genes,	 such	 as	 BAX,	 CDKN1A,	 DDB2,	 SERPINE1,	 TIGAR	 or	 TP53I3	 [58]	 (Fig.	 16B).	
Surprisingly,	we	detected	an	 increase	 in	proteins	 involved	 in	glycolysis	and	the	TCA	
cycle,	which	was	however	 less	significant	than	the	afore	mentioned	enriched	KEGG	
groups	DNA	replication,	cell	cycle	or	p53	signaling	pathway.	Since	the	KEGG	pathway	
analysis	 does	 not	 take	 into	 account	 the	 extent	 of	 expression	 changes	 in	 de	 novo	
protein	 synthesis,	 it	 is	 possible	 that	 significantly	 enriched	 KEGG	 groups	 include	
proteins	that	are	above	the	chosen	cutoff	for	differential	expression	(-0.3	≥	log2	fold	
change	≥	0.3)	but	only	show	relatively	weak	expression	changes.	Therefore	it	 is	not	
clear,	 whether	 the	 observed	 up-	 or	 down-regulation	 of	 enzymes	 associated	 with	
specific,	 overrepresented	KEGG	categories	 actually	 leads	 to	 the	activation	of	 these	
pathways.	 Indeed,	 a	 gene	 set	 enrichment	 analysis	 (GSEA)	 for	 the	 differentially	
regulated	proteins	detected	by	pSILAC	revealed	that	those	proteins	assigned	to	the	
KEGG	pathway	categories	glycolysis	and	TCA	cycle	display	a	relatively	weak	induction	
when	 compared	 to	 the	 log2	 fold	 changes	 of	 those	 proteins	 in	 the	 category	 p53	
signaling	pathway	(data	not	shown).	
	
	
Figure	 16:	 KEGG	 pathway	 analysis	 of	 differentially	 regulated	 proteins	 detected	 by	 pSILAC.	
Translationally	(A)	down-	and	(B)	up-regulated	proteins	detected	by	pSILAC	with	a	log2	fold	change	≤	-
0.3	 or	 ≥	 0.3,	 respectively,	 and	 a	 p-value	 ≤	 0.05	 were	 analyzed	 for	 enriched	 biological	 processes	
applying	 a	 KEGG	 pathway	 analysis.	 The	 different	 KEGG	 terms	 and	 their	 enrichment	 scores	 –log(p-
value)	are	indicated.	Based	on	the	pSILAC	results	(contributions	of	the	co-authors	described	on	page	
42),	a	KEGG	pathway	analysis	was	performed	and	this	figure	was	generated.	
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5.2.3	RNA-Seq	analysis	of	differential	RNA	expression	after	p53	activation	
In	total,	20,397	protein-coding	mRNAs	were	identified	by	RNA-Seq	(contributions	
of	the	co-authors	described	on	page	42)	(Fig.	17).	11,801	showed	robust	expression	
levels	(rpkm	≥	0.5	in	at	least	one	condition)	and	were	considered	for	further	analysis.	
	
	
	
	
	
	
	
	
	
The	 top	 50	 down-	 (all	 log2	 fold	 change	 ≤	 -3.30)	 and	 50	 up-regulated	 (all	 log2	 fold	
change	≥	5.36)	mRNAs	are	shown	in	in	Table	3.	
	
	
Table	3:	100	most	up-	and	down-regulated	mRNAs	detected	by	RNA-Seq.	List	of	the	(left)	50	most	
down-	and	 (right)	50	most	up-regulated	mRNAs	detected	by	RNA-Seq	 (log2	 fold	change	≤	 -1	or	≥	1,	
respectively;	 rpkm	≥	0.5	 in	 at	 least	one	 condition).	mRNAs	marked	 in	bold	harbor	 an	occupied	p53	
binding	site	in	the	vicinity	of	the	respective	gene	promoter	(+/-20	kb)	according	to	our	ChIP-Seq	data.	
Those	 additionally	 underlined	 represent	 already	 described,	 direct	 p53	 target	 genes.	 Based	 on	 the	
RNA-	 and	 ChIP-Seq	 results	 (contributions	 of	 the	 co-authors	 described	 on	 page	 42),	 the	 data	 were	
analyzed	and	this	table	was	generated.	
Genes log2 fc
KRTAP3-1 12.66
LCE1B 11.62
CD70 11.00
LCE1C 10.82
NTF4 9.93
IL1RL2 9.87
SPANXN3 9.69
VAV1 9.67
GNGT2 9.50
INSL3 9.18
LCE1D 9.11
DUSP13 9.09
HIST1H2AE 9.03
CAPN8 8.68
MARCH4 7.97
ICAM2 7.59
PSG5 7.51
SLC43A3 7.42
EDA2R 7.34
KRTAP2-1 7.25
RHOD 7.03
ROBO4 6.92
LCE1F 6.90
KRT23 6.76
ANTXR1 6.74
Top	50	down-regulated mRNAs
Genes log2 fc
DEFA5 -12.10
DEFA6 -10.77
AC087071.2 -10.49
AL031003.1 -10.39
DBH -10.21
AC093859.1 -9.17
DKK4 -9.03
AC005544.1 -9.02
CIB2 -9.00
TMEM47 -6.24
PCBP3 -5.69
SPNS3 -5.53
PCSK9 -5.38
CHSY3 -5.34
FSTL4 -5.23
AHRR -5.17
RFX8 -4.92
KCNJ5 -4.91
GPX2 -4.89
GRM8 -4.87
BNC2 -4.85
GNAI1 -4.71
KIF21B -4.58
CDK15 -4.39
LRRC10B -4.35
Genes log2 fc
CPNE8 -4.29
HTRA3 -4.29
AMBP -4.26
TMEM204 -4.26
C2CD4C -4.25
KCNE3 -4.20
FAM129A -4.12
ADAMTS19 -4.04
IL16 -4.02
ADAMTSL2 -3.90
CHN2 -3.90
AFF3 -3.89
CACNG4 -3.81
HOXC5 -3.79
FGF19 -3.73
CALHM3 -3.72
PRUNE2 -3.71
PROX1 -3.69
SARDH -3.62
GLT25D2 -3.58
CXCL14 -3.55
UPK3B -3.52
CYS1 -3.45
CAMK4 -3.33
ZNF501 -3.30
Top	50	up-regulated mRNAs
Genes log2 fc
PADI3 6.64
KIAA1755 6.58
C17orf72 6.46
TMC8 6.23
G0S2 6.13
HMGCS2 6.12
WFDC2 6.07
ESM1 6.06
KRT13 6.04
CSF2 5.81
RNF128 5.76
RAC2 5.74
C1orf233 5.68
INPP5D 5.67
ALCAM 5.62
ZC4H2 5.53
TP53INP1 5.53
PAPL 5.48
CHST3 5.43
KRT17 5.43
SERP2 5.40
PSG2 5.40
ZNF556 5.39
RASAL1 5.37
NHLRC1 5.36
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Figure	 17:	 Differential	 regulation	 of	 protein-
coding	 mRNAs	 by	 p53.	 SW480/pRTR-p53-VSV	
were	 subjected	 to	 a	 RNA-Seq	 analysis	 after	 48	
hours	DOX	treatment.	RPKM	scatter	plot	depicting	
expression	 changes	 of	 protein-coding	 mRNAs	
detected	by	 RNA-Seq.	Transcripts	below	 0.5	 rpkm	
in	 both	 conditions	 are	 shown	 in	 grey.	 Transcripts	
with	 a	 log2	 fold	 change	 ≥	 1	 are	 shown	 in	 green,	
with	a	log2	fold	change	≤	-1	in	red	and	with	1	˃	log2	
fold	change	˃	-1	in	black.	After	raw	data	analysis	by	
T.	Bonfert,	the	data	were	further	analyzed	and	the	
figure	was	generated	with	support	of	Dr.	M.	Kaller.	
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	A	 KEGG	 pathway	 analysis	 of	 the	 down-regulated	 mRNAs	 revealed	 down-
regulation	 of	 the	 Wnt	 signaling	 pathway	 (p	 =	 9.26E-03)	 (Fig.	 18).	 As	 expected,	
components	 of	 the	 p53	 signaling	 pathway	were	 enriched	 among	 the	 up-regulated	
mRNAs	(p	=	7.81E-04),	 including	known	p53	target	genes,	such	as	CDKN1A,	MDM2,	
TP53I3,	SERPINEB5,	ZMAT3	or	SERPINE1	[58].		
	
	
		
	
	
Next,	my	colleague	Markus	Kaller	analyzed	the	expression	of	 lncRNAs	(including	
long	 intergenic	 noncoding	 (linc)	 RNAs,	 antisense	 RNAs	 and	 transcribed	
pseudogenes),	which	were	also	detected	by	RNA-Seq	(Fig.	19).	Of	the	4,608	detected	
lncRNAs,	 1,719	 showed	 robust	 expression	 levels	 (rpkm	 ≥	 0.5	 in	 at	 least	 one	
condition)	 and	 were	 considered	 for	 further	 analysis.	 Out	 of	 these,	 270	 showed	
induced	(log2	fold	change	≥	1)	and	123	repressed	expression	(log2	fold	change	≤	-1).	
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Figure	 19:	 Differential	 regulation	 of	 lncRNAs	 by	
p53.	 SW480/pRTR-p53-VSV	 were	 subjected	 to	 a	
RNA-Seq	 analysis	 after	 48	 hours	 DOX	 treatment.	
RPKM	scatter	plot	depicting	expression	changes	of	
lncRNAs	 detected	 by	 RNA-Seq.	 Transcripts	 below	
0.5	 rpkm	 in	 both	 conditions	 are	 shown	 in	 grey.	
Transcripts	with	a	 log2	 fold	 change	≥	1	are	 shown	
in	 green,	 with	 a	 log2	 fold	 change	 ≤	 -1	 in	 red	 and	
with	 1	 ˃	 log2	 fold	 change	 ˃	 -1	 in	 black.	 After	 raw	
data	analysis	by	T.	Bonfert,	Dr.	M.	Kaller	analyzed	
the	lncRNA	data	and	generated	the	figure.		
Figure	 18:	 KEGG	 pathway	 analysis	 of	
differentially	 regulated	 mRNAs	
detected	 by	 RNA-Seq.	 (A)	 Down-	 and	
(B)	 up-regulated	 mRNAs	 detected	 by	
RNA-Seq	with	a	log2	fold	change	≤	-1	or	
≥	1,	 respectively,	 and	rpkm	≥	0.5	 in	at	
least	one	condition	were	 analyzed	 for	
enriched	biological	 processes	 applying	
a	KEGG	pathway	analysis.	The	different	
KEGG	 terms	 and	 their	 enrichment	
scores	 –log(p-value)	 are	 indicated.	
Based	 on	 the	 RNA-Seq	 data	
(contributions	 of	 the	 co-authors	
described	 on	 page	 42),	 a	 KEGG	
pathway	 analysis	 was	 performed	 and	
this	figure	was	generated. 
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The	 top	 50	 down-	 (all	 log2	 fold	 change	 ≤	 -1.57)	 and	 50	 up-regulated	 (all	 log2	 fold	
change	≥	2.95)	lncRNAs	are	shown	in	Table	4.	
	
	
Table	4:	100	most	up-	and	down-regulated	lncRNAs	detected	by	RNA-Seq.	List	of	the	(left)	50	most	
down-	and	(right)	50	most	up-regulated	 lncRNAs	detected	by	RNA-Seq	(log2	fold	change	≤	-1	or	≥	1,	
respectively;	rpkm	≥	0.5	in	at	least	one	condition).	Based	on	the	RNA-Seq	results	(contributions	of	the	
co-authors	described	on	page	42),	the	data	were	analyzed	and	this	table	was	generated.	
	
Next,	we	determined	 the	overlap	between	 the	RNA-seq	and	pSILAC	results	and	
found	 that	nearly	 all	 (93%)	of	 the	quantified	proteins	were	 also	detected	on	RNA-
level	 (Fig.	 20A).	 Moreover,	 we	 determined	 that	 a	 subset	 of	 130	 genes	 was	
differentially	 regulated	 on	 both,	 the	 mRNA-	 and	 de	 novo	 protein	 synthesis-level.	
When	 we	 applied	 a	 low-stringency	 cutoff	 (-0.3	 ≥	 log2	 fold	 change	 ≥	 0.3)	 for	
differential	mRNA	regulation	the	number	of	differentially	regulated	mRNAs	that	also	
display	 differential	de	novo	 protein	 synthesis	 increased	 from	130	 to	 636	 (data	 not	
shown).	
My	 colleague	 Markus	 Kaller	 performed	 a	 cumulative	 distribution	 analysis	 of	
differentially	 up-	 and	 down-regulated	 proteins	 that	 showed	 their	 significantly	
increased	 and	 decreased	 expression	 on	 mRNA-level	 (p	 <	 0.0001	 in	 both	 cases),	
respectively,	 substantiating	 a	 positive	 correlation	between	p53-induced	 changes	 in	
mRNA	expression	and	de	novo	protein	synthesis	(Fig.	20B).	
	
	
	
	
Top	50	up-regulated lncRNAs
lncRNA log2 fc lncRNA log2 fc
RP11-166N17.1 -10.10 RP11-544L8__B.2 -2.17
RP11-148K1.10 -9,45 RP11-498B4.5 -2.16
RP11-346A9.1 -9.34 AC013403.9 -2.06
AC011247.3 -9.24 AC015712.2 -1.99
RP11-197M22.2 -9.13 AC104186.1 -1.91
RP1-122O8.7 -9.07 Z97989.1 -1.88
NCRNA00118 -7.98 AC007362.3 -1.85
AC004671.1 -6.97 RP1-118J21.5 -1.80
AC021068.1 -4.96 CTC-338M12.6 -1.80
RP11-155L15.1 -4,73 AC018730.1 -1.79
AC005304.2 -3.57 AC015691.13 -1.79
AC093388.3 -3.28 AP001992.1 -1.79
RP11-478J18.2 -3.18 AC007405.4 -1.79
RP1-85F18.5 -3.17 AC091167.5 -1.79
AP002478.1 -2.98 AL157687.1 -1.78
AC004540.4 -2.96 AC138904.1 -1.78
RP11-478J18.1 -2.95 CTC-564N23.2 -1.75
RP11-714G18.1 -2.72 AC091805.1 -1.74
RP3-486B10.1 -2.70 AC010883.5 -1.69
AC007277.3 -2.65 RP11-46A10.4 -1.65
AC021224.1 -2.47 RP11-359P5.1 -1.64
RP4-583P15.10 -2.38 AC073321.5 -1.63
RP4-639F20.3 -2.28 BOKAS -1.58
AC147651.1 -2.21 AC007276.7 -1.57
RP11-875H7.4 -2.17 CLTCL1 -1.57
lncRNA log2 fc lncRNA log2 fc
RP3-326I13.1 12.05 RP11-521D12.1 4.11
RP3-510D11.2 11.41 RP1-14N1.2 4.05
RP11-78C3.1 10.58 RP13-463N16.6 3.91
RP11-462G8.3 10.43 C11orf76 3.90
AC019349.5 10.12 RP11-25G10.2 3.83
AC128709.2 10.11 AP005210.2 3.83
AC112721.2 10.04 AC159540.1 3.77
AP001468.58 9.89 AL583842.6 3.75
RP11-137H2.4 9.26 RP1-63G5.5 3.73
SNORA71B 9.22 RP3-467K16.7 3.69
AC022596.6 9.02 AC012065.6 3.68
RP3-510D11.1 9.02 CTC-529P8.1 3.67
RP11-267A15.1 9.01 RP11-217C7.1 3.54
LINC01021 6.44 RP3-434O14.8 3.52
RP11-399K21.6 6.24 RP3-389A20.4 3.52
RP11-11N9.4 5.89 AL356390.1 3.48
AC006948.1 5.06 RP11-240D10.2 3.43
AC104135.3 4.96 RP11-181K12.2 3.39
MYH16 4.76 CECR7 3.34
BX571672.2 4.65 RP11-554I8.2 3.22
AC004834.1 4.65 RP11-219G10.3 3.19
AC003958.2 4.55 RP11-134G8.8 3.11
CTD-2021J15.2 4.35 RP11-382A18.1 3.09
AL133493.2 4.33 BX004987.5 2.96
RP3-395M20.8 4.30 AC002558.2 2.95
Top	50	down-regulated lncRNAs
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Figure	20:	Correlation	of	mRNA-	and	protein-expression	 fold	changes.	 (A)	Venn	diagram	displaying	
the	overlap	between	quantified	mRNAs	(with	an	rpkm	≥	0.5	in	at	least	one	condition)	(shown	in	grey)	
and	proteins	(with	a	p-value	<	0.05)	(shown	in	blue)	and	differentially	regulated	mRNAs	(-1	≥	log2	fold	
change	≥	1)	 (shown	 in	orange)	and	proteins	 (-0.3	≥	 log2	 fold	change	≥	0.3)	 (shown	 in	green).	Genes	
differentially	expressed	on	the	mRNA	level	and	the	level	of	de	novo	protein	synthesis	are	indicated	in	
yellow.	 (B)	 Cumulative	 distribution	 plot	 displaying	 changes	 in	 mRNA	 expression	 of	 up-	 and	 down-
regulated	 proteins	 compared	 to	 the	 normal	 distribution	 of	 all	 mRNAs	 detected	 by	 RNA-Seq	 after	
activation	of	p53.	Dr.	Markus	Kaller	analyzed	the	data	for	Fig.	20B	and	generated	the	figure.	
	
5.2.4	miR-Seq	analysis	after	p53	activation	
 Next,	we	used	miR-Seq	(contributions	of	 the	co-authors	described	on	page	42)	
to	 determine	miRNA	 expression	 after	 activation	 of	 p53	 for	 16	 hours.	 In	 total,	 411	
different	miRNAs	were	detected:	107	miRNAs	were	up-regulated	(log2	fold	change	≥	
1),	whereas	101	were	down-regulated	(log2	fold	change	≤	-1)	by	p53	(Fig.	21).			
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Figure	 21:	 Differential	 regulation	 of	 miRNAs	 by	
p53.	 SW480/pRTR-p53-VSV	 were	 subjected	 to	 a	
miRNA-Seq	analysis	after	16	hours	DOX	treatment.	
RPKM	scatter	plot	depicting	expression	changes	of	
miRNAs	detected	by	miRNA-Seq.	Transcripts	below	
0.5	 rpkm	 in	 both	 conditions	 are	 shown	 in	 grey.	
Transcripts	with	a	 log2	 fold	 change	≥	1	are	 shown	
in	 green,	 with	 a	 log2	 fold	 change	 ≤	 -1	 in	 red	 and	
with	 1	 ˃	 log2	 fold	 change	 ˃	 -1	 in	 black.	 After	 raw	
data	 analysis	 by	 F.	 Erhard,	 the	 data	 were	 further	
analyzed	 and	 the	 figure	 was	 generated	 with	
support	of	M.	Kaller.	
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The	top	50	up-	 (all	 log2	 fold	change	≥	5.64)	and	50	down-regulated	(almost	all	 log2	
fold	change	≤	-4.67)	miRNAs	are	listed	in	Table	5.		
	
	
	
Table	5:	100	most	up-	and	down-regulated	miRNAs	detected	by	miRNA-Seq.	List	of	the	(left)	50	most	
up-	and	(right)	50	most	down-regulated	miRNAs	detected	by	miRNA-Seq	with	a	log2	fold	change	≤	-1	
or	 ≥	 1,	 respectively.	 The	mature	miRNA	 is	 referred	 to	 as	miR-x,	whereas	 the	 strand	 that	 is	 usually	
degraded	 is	 indicated	as	miR-x*.	 Starting	with	mirBase	 v18,	miRNA	 strands	 from	one	precursor	 are	
referred	to	as	miR-x-5p	and	miR-x-3p	depending	on	the	arm	from	which	they	are	processed	since	it	is	
not	clear	which	sequence	serves	as	the	predominant	one	under	varying	conditions.	Marked	 in	bold:	
miRNAs	that	harbor	an	occupied	p53	binding	site	in	the	vicinity	of	the	respective	gene	promoter	(+/-
20	 kb)	 according	 to	 our	 ChIP-Seq	 data.	 Those	 additionally	 underlined	 represent	 already	 described,	
direct	p53	target	genes.	Based	on	the	miRNA-	and	ChIP-Seq	results	 (contributions	of	 the	co-authors	
described	on	page	42),	the	data	were	analyzed	and	this	table	was	generated.	
	
As	 expected,	 we	 detected	 the	 induction	 of	 several,	 tumor-suppressive	miRNAs	
known	to	be	encoded	by	direct	p53	 target	genes,	 such	as	miR-34a	 [89,	90,	92-94],	
miR-205	 [262],	 members	 of	 the	 miR-200	 family	 (miR-141/-141*	 and	 miR-
200c/200c*)	[98],	as	well	as	the	miR-192	family	(miR-192,	-194	and	-215)	[101,	102]	
and	miR-145	 [106].	 Interestingly,	 several,	 putatively	 tumor-supressive	miRNAs	 not	
previously	 linked	 to	 p53	were	 induced	 after	 p53	 activation:	 e.g.	miR-486-5p	 [263],	
miR-1266	 [264]	 or	 miR-218	 [265].	 Furthermore,	 we	 identified	 oncogenic	 factors	
among	 the	 down-regulated	 miRNAs,	 such	 as	 miR-25	 and	 miR-92a	 [266]	 and	 the	
miRNA	family	miR-221/222,	which	is	known	to	promote	EMT	[267].	
	
	
Top	50	up-regulated miRNAs
miRNA log2 fc miRNA log2 fc
miR-200a* -9.78 miR-627 -6.04
miR-1908 -9.62 miR-2116* -6.04
miR-191* -9.12 miR-20a* -6.04
miR-200a -8.81 let-7g* -6.04
miR-767-5p -8.52 miR-935 -6.00
miR-23b* -8.38 miR-502-3p -6.00
miR-374b* -8.34 miR-142-3p -6.00
miR-3131 -8.11 miR-196b* -5.95
miR-200b* -7.96 miR-3194 -5.86
miR-1262 -7.57 miR-1227 -5.86
miR-184 -7.32 miR-3159 -5.78
miR-3192 -7.27 miR-1 -5.73
miR-125b -7.11 miR-365* -5.70
miR-939 -6.89 miR-1226 -5.64
miR-636 -6.77 miR-664* -5.61
miR-181a* -6.59 miR-3181 -5.55
miR-3188 -6.57 miR-3928 -5.43
miR-3200-5p -6.49 miR-508-3p -5.33
miR-3909 -6.21 miR-3613-5p -5.32
miR-551a -6.17 miR-3191 -5.28
miR-1305 -6.13 miR-381 -5.21
miR-429 -6.11 miR-3124 -5.21
miR-3939 -6.11 miR-2277-5p -5.04
miR-501-5p -6.07 miR-1254 -5.03
miR-32* -6.07 miR-200b -4.73
miRNA log2 fc miRNA log2 fc
miR-34a 10.04 miR-23a* 6.65
miR-373 9.38 miR-629* 6.65
miR-1266 8.97 miR-1293 6.63
miR-205 8.94 miR-548j 6.63
miR-576-5p 8.86 miR-195* 6.59
miR-34a* 8.61 miR-1287 6.57
miR-361-3p 8.17 miR-145 6.57
miR-199a-5p 7.82 miR-3691 6.55
miR-362-3p 7.75 miR-491-3p 6.53
miR-141* 7.69 miR-891a 6.53
miR-194 7.68 miR-193a-3p 6.51
miR-200c* 7.65 miR-1294 6.49
miR-3663-5p 7.63 miR-877* 6.46
miR-218 7.13 miR-18a* 6.45
miR-3174 7.02 miR-3617 6.42
miR-548u 6.99 miR-371-3p 6.38
miR-2355-3p 6.85 miR-3065-3p 6.30
miR-499-3p 6.85 miR-570 6.30
miR-1468 6.82 miR-1914 6.20
miR-3162 6.82 miR-449a 6.15
miR-592 6.82 miR-199a-3p 5.95
miR-34c-3p 6.80 miR-3937 5.91
miR-3661 6.78 miR-29c* 5.67
miR-130a 6.77 miR-3938 5.67
miR-1229 6.73 miR-22* 5.64
Top	50	down-regulated miRNAs
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5.2.5	Genome-wide	mapping	of	p53	DNA-binding	
Next,	DNA	was	isolated	16	hours	after	addition	of	DOX	by	VSV-antibody	mediated	
ChIP	from	SW480/pRTR-p53-VSV	and,	as	a	control,	SW480/pRTR	cells	and	subjected	
to	 NGS	 (contributions	 of	 the	 co-authors	 described	 on	 page	 42).	 In	 total,	
bioinformatics	analysis	of	the	NGS	data	by	Thomas	Bonfert	 led	to	the	identification	
of	 1,827	 ChIP-signals	 in	 the	 p53-inducible	 SW480	 cell	 line	 of	 which	 97%	 (1,771	
signals)	colocalized	with	a	predicted	p53	binding	sequence	(data	not	shown).	22%	of	
the	 ChIP-signals	 with	 p53	 binding	 sites	 were	 located	 in	 a	 region	 <	 10	 kbp	 from	 a	
transcription	start	site	(TSS)	and	27%	were	located	>	10	kbp	upstream	of	a	TSS	(Fig.	
22A).	39%	of	the	ChIP-signals	with	p53	binding	site	were	found	in	intragenic	regions	
and	 12%	 were	 located	 downstream	 of	 genes.	 The	 ChIP	 signals	 that	 localized	 in	 a	
region	within	100	 kbp	up-	 and	downstream	 from	a	 TSS	were	 centered	around	 the	
TSS	(Fig.	22B).		
	
	
Figure	 22:	Genome-wide	 analysis	 of	 p53	 occupancy.	 ChIP-Seq	 analysis	was	performed	with	 a	VSV-
specific	antibody	16	hours	after	addition	of	DOX	to	SW480/pRTR-p53-VSV	and	SW480/pRTR	cells.	(A)	
Localization	of	called	ChIP-peaks	obtained	after	p53-ChIP	in	SW480/pRTR-p53-VSV.	(B)	Distribution	of	
p53-derived	ChIP-Seq	peaks	100	kbp	up-	and	downstream	of	 the	TSS.	Thomas	Bonfert	analyzed	the	
ChIP-Seq	raw	data	and	generated	the	figures.	
	
When	 p53-derived	 ChIP	 signals	 20	 kbp	 up-	 and	 downstream	 of	 transcriptional	
start	sites	were	analyzed	by	Thomas	Bonfert	for	enriched	binding	motifs	using	MEME	
[234],	 the	 identified	motif	was	 identical	 to	 the	previously	described	p53	consensus	
site	 [56,	 57]	 and	 only	minor	 differences	 between	 the	motifs	 associated	with	 p53-
induced	and	-repressed	genes	were	observed	(Fig.	23A),	which	is	in	accordance	with	
previous	 findings	 [65,	 268].	 The	 motif	 associated	 with	 repressed	 genes	 showed	 a	
preference	 for	 A	 (instead	 of	 G)	 at	 position	 1,	 11	 and	 12,	 and	 a	 preference	 for	 C	
(instead	of	T)	at	position	18.	However,	 the	changes	were	 restricted	 to	 the	 flanking	
sequences.	A	search	for	neighboring	binding	motifs	of	other	transcription	factors	in	
the	vicinity	of	the	detected	p53	ChIP-signals	(+/-	250	bp)	revealed	an	enrichment	for	
the	consensus	motif	WGATAR	(W	=	A/T,	R	=	A/G)	of	the	GATA1	transcription	factor	
which	was	 present	 in	 29%	of	 the	 up-regulated	 genes	 harboring	 a	 p53	 binding	 site	
(Fig.	 23B).	 Therefore,	 it	 is	 possible	 that	 GATA	 factors	 and	 p53	 cooperate	 in	 gene	
regulation.	
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By	using	the	presence	of	a	ChIP-Seq	signal	located	in	a	region	+/-	20	kbp	from	the	
corresponding	gene	promoter	as	a	criterion,	we	determined	that	changes	in	de	novo	
protein	 synthesis	 of	 proteins	 showing	 promoter-proximal	 p53	 binding	 near	 the	
respective	gene	promoter	positively	correlated	with	the	respective	changes	in	mRNA	
abundance	 (p	 <	 0.0001)	 (Fig.	 24A).	 Compared	 to	 the	 correlation	 of	 changes	 in	 de	
novo	protein	synthesis	of	all	differentially	regulated	proteins	to	the	respective	mRNA	
fold	changes	(r	=	0.50),	the	Pearson	correlation	coefficient	was	higher	for	direct	p53	
targets	 (r	 =	 0.54),	 including	 several	 known	 p53-regulated	 target	 genes,	 such	 as	
CDKN1A,	TIGAR	or	BAX.	Among	the	differentially	regulated	candidates,	we	identified	
43	putative	direct	 targets	via	analysis	of	de	novo	protein	synthesis	 (32	 induced,	11	
repressed)	 and	 61	 via	 differential	 mRNA	 expression	 (52	 induced,	 9	 repressed)							
(Fig.	 24B).	 Among	 the	 putative	 direct	 targets,	 14	 genes	 were	 co-regulated	 on	 the	
level	of	mRNA	expression	and	de	novo	protein	synthesis.	These	results	indicate	that	
only	2.4%	(1.9%)	of	the	down-regulated	mRNAs	(proteins)	showed	a	p53	ChIP-signal	
in	 a	 region	 of	 +/-	 20	 kbp	 from	 the	 corresponding	 gene	 promoter,	 whereas	 4.3%	
(5.8%)	 of	 the	 up-regulated	 mRNAs	 (proteins)	 displayed	 p53	 binding	 near	 their	
corresponding	gene	TSS.	A	cumulative	distribution	analysis	of	those	proteins/mRNAs	
showing	 a	 p53	 peak	 in	 a	 region	 of	 +/-	 20	 kbp	 from	 their	 corresponding	 gene	
promoter	 plotted	 against	 all	 detected	 proteins/mRNAs	 which	 was	 performed	 by	
Markus	Kaller	confirmed	that	genes	bound	by	p53	are	preferentially	up-regulated	(p	
<	 0.0001)	 (Fig.	 24C).	 These	 results	 indicate	 that	 a	 large	 number	 of	 the	 genes	
repressed	by	p53	are	not	regulated	by	direct	p53	binding,	but	rather	indirectly,	e.g.	
by	miRNA-mediated	repression	or	due	to	secondary	consequences	of	p53	activation.	
In	addition,	we	found	18	differentially	expressed	lncRNAs	showing	p53	binding	near	
their	 corresponding	 gene	 TSS	 (Fig.	 24B).	 17	 induced	 lncRNAs	 (6.3%	 of	 all	 induced	
lncRNAs)	displayed	p53	chromatin	occupancy	in	a	+/-	20	kbp	region	surrounding	the	
corresponding	 gene	 TSS,	 whereas	 only	 one	 repressed	 lncRNA	 (0.8%	 of	 all	 down-
regulated	lncRNAs)	showed	p53	binding	near	the	respective	gene	promoter.	
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Figure	 23:	 DNA-binding	 motifs	 of	 p53	 and	
neighboring	 transcription	 factors.	 (A)	 MEME	
analyses	 of	 p53-derived	 ChIP-peaks	 in	
SW480/pRTR-p53-VSV	 (+/-	 20	 kbp	 of	 the	
corresponding	 TSS)	 associated	 with	 all	 genes,	
induced	 (log2	 fc	 ≥	 1)	 and	 repressed	 (log2	 fc	 ≤	 -1)	
genes	according	to	RNA-Seq.	 (B)	Enrichment	of	the	
GATA1	 DNA	 binding	 motif	 in	 the	 vicinity	 of	 p53	
ChIP-signals	 of	 induced	 genes	 detected	 by	 SpaMo.	
Thomas	 Bonfert	 analyzed	 the	 ChIP-Seq	 raw	 data	
and	generated	the	figures.	
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Figure	24:	ChIP-Seq	results	combined	with	the	results	obtained	from	pSILAC,	RNA-	and	miRNA-Seq.	
(A)	Scatter	plot	correlating	changes	in	de	novo	protein	synthesis	of	all	differentially	regulated	proteins	
with	 the	 corresponding	 mRNA	 fold	 changes	 after	 induction	 of	 p53	 (marked	 in	 grey).	 Molecules	
showing	p53	occupancy	near	 the	 respective	gene	promoter	are	 indicated	 in	orange.	The	 respective	
Pearson	correlation	coefficient	and	statistical	 significance	are	 indicated.	 (B)	Proteins,	protein-coding	
mRNAs,	lncRNAs	and	miRNAs	that	have	an	occupied	p53	binding	site	within	+/-	20	kbp	of	the	TSS	of	
their	host	gene	are	shown	in	colors	or	black	as	described	under	Fig.	10.	Molecules	without	promoter-
proximal	 p53	 binding	 are	 shown	 in	 grey.	 M.	 Kaller	 analyzed	 the	 lncRNA	 data	 and	 generated	 the	
respective	figure.	(C)	Cumulative	distribution	plot	displaying	expression	changes	of	(upper	panel)	p53-
occupied,	 protein-coding	 genes	 compared	 to	 the	 normal	 distribution	 of	 all	 detected	 proteins	 as	
detected	 by	 pSILAC,	 (lower	 panel)	 p53-occupied,	 mRNA-coding	 genes	 compared	 to	 the	 normal	
distribution	of	 all	 detected	mRNAs	as	detected	by	RNA-Seq.	 (C)	was	analyzed	and	generated	by	M.	
Kaller,	 based	 on	 the	 RNA-,	 miRNA-,	 ChIP-Seq	 and	 pSILAC-data	 (contributions	 of	 the	 co-authors	
described	on	page	42).	
	
The	 previously	 described	 p53-induced	 lncRNA	TP53TG1	 [269,	 270],	 but	 none	 of	
the	other	described	lncRNAs	regulated	by	p53,	was	among	the	p53-induced	lncRNAs.	
Notably,	we	detected	 the	 lncRNA	RP3-510D11.2	 that	 is	 transcribed	 in	 the	opposite	
direction	 from	 the	 previously	 described	 promoter	 of	 the	 p53	 target	 gene	miR-34a	
[94]	to	be	induced	and	bound	by	p53	at	the	respective	gene	promoter	(Fig.	25).	
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Figure	 25:	 ChIP-	 and	 RNA-Seq	
results	 of	 the	 RP3-510D11.2	
locus.	 ChIP-	 and	 RNA-Seq	 results	
of	 SW480/pRTR-p53-VSV	 and	
SW480/pRTR	 for	 the	 genes	
encoding	 miR-34a	 and	 lncRNA	
RP3-510D11.2	are	displayed	using	
the	 UCSC	 genome	 browser	 and	
the	 CLC	 Genomics	 Workbench	
8.0,	 respectively.	 Based	 on	 the	
RNA-	 and	 ChIP-Seq	 results	
(contributions	 of	 the	 co-authors	
described	 on	 page	 42),	 the	 data	
were	analyzed	and	this	figure	was	
generated.	
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Next,	we	determined	whether	p53	binds	in	the	vicinity	of	TSSs	of	genes	encoding	
miRNAs	 (according	 to	miRStart	 [271])	 (Fig.	 24B).	 Among	 the	 up-regulated	miRNAs,	
miR-34a,	 miR-205,	 miR-34-3p,	 miR-1293,	 miR-145,	 miR-486-5p,	 miR-143	 and								
miR-641	 showed	p53	binding	near	 their	 corresponding	 gene	promoter	 (7.2%	of	 all	
differentially	up-regulated	miRNAs).	In	addition,	genes	encoding	the	down-regulated	
miRNAs	 miR-3191,	 miR-3928	 and	 miR-1908	 displayed	 p53	 binding	 (3.2%	 of	 all	
differentially	 down-regulated	 miRNAs).	 Therefore,	 only	 a	 minor	 fraction	 of	 the	
detected	differential	miRNA	regulations	may	be	directly	mediated	by	p53.		
5.2.6	Identification	and	confirmation	of	novel	putative	p53	target	genes	
Next,	we	compared	the	differentially	regulated	mRNAs	and	proteins	with	a	p53	
binding	 site	 in	 a	 region	 +/-	 20	 kbp	 from	 the	 TSS	 of	 the	 corresponding	 gene	 with	
recent	 genome-wide	 studies	 of	 p53-mediated	 gene	 regulation	 [65,	 268,	 272,	 273].	
Thereby,	 we	 confirmed	 that	 52	 putative	 direct	 p53	 targets,	 with	 31	 targets	 being	
identified	by	RNA-Seq	and	21	by	pSILAC,	have	not	been	characterized	as	p53	targets	
previously	 (Table	6).	 Interestingly,	 three	of	 these	novel	p53	 targets	were	 identified	
by	 both	 approaches:	 ETV3,	 ST14	 and	 TGFBI.	 In	 addition,	 we	 identified	 17	
differentially	 regulated	 lncRNAs	 and	 6	 differentially	 regulated	 miRNAs	 with	 p53	
binding	 near	 their	 TSS	 that	were	 not	 previously	 described	 as	 directly	 regulated	 by	
p53	(Table	6).	Subsequently,	we	used	independent	methods	to	confirm	novel	direct	
p53	 targets.	 We	 demonstrated	 the	 up-regulation	 of	 MDFI,	 ST14	 and	 LINC01021	
(RP11-46C20.1)	 after	 ectopic	 p53-expression	 in	 the	 DOX-inducible	 cell	 line	
SW480/pRTR-p53-VSV	(Fig.	26A). Moreover,	p53	occupancy	was	confirmed	by	qChIP	
analysis	for	MDFI,	ST14	and	LINC01021,	which	was	in	line	with	the	ChIP-Seq	results	
(Fig.	26B,	C).		
Figure	26:	Exemplary	validation	of	the	newly	identified	p53	target	genes	MDFI,	ST14	and	LINC01021.	
(A)	 qPCR	 analyses	 of	 MDFI,	 ST14	 and	 LINC01021	 expression	 in	 SW480/pRTR-p53-VSV	 cells	 after	
addition	of	DOX	 for	 the	 indicated	periods.	 (B)	qChIP	validation	of	p53	occupancy	at	 the	MDFI,	ST14	
and	LINC01021	promoters	in	SW480/pRTR-p53-VSV	after	16	hours	of	DOX	treatment	and	subsequent	
VSV-ChIP.	 (C)	 p53-VSV-derived	 ChIP-Seq	 results	 are	 displayed	 using	 the	 UCSC	 genome	 browser.	
Results	 in	 (A)	and	 (B)	 represent	 the	mean	+/-	SD	 (n	=	3).	Raw	data	analysis	of	ChIP-Seq	 results	was	
performed	by	T.	Bonfert.		
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Table	6:	Novel	p53	target	genes	identified	by	RNA-Seq,	pSILAC	and	ChIP-Seq.	The	table	indicates	21	
new	direct	p53	targets	identified	by	pSILAC,	31	targets	identified	by	RNA-Seq,	17	new	p53-regulated	
lncRNAs	identified	by	RNA-Seq	(if	available,	the	ENSEMBL	gene	name	for	the	corresponding	ENSEMBL	
gene	ID	is	indicated)	and	6	new	p53-regulated	miRNAs	identified	by	miRNA-Seq	in	combination	with	
ChIP-Seq.	The	log2	fold	change	of	the	respective	target,	the	sequence	of	the	p53	binding	motif	and	its	
distance	 from	 the	 TSS	 (bp)	 are	 indicated.	 Based	 on	 the	 pSILAC,	 RNA-/miRNA-/ChIP-Seq	 results	
(contributions	of	 the	 co-authors	described	on	page	42),	 the	data	were	 analyzed	 and	 this	 table	was	
generated.	
	
proteins
protein
name
log2
fc
p53_motif TSS	(bp) protein
name
log2
fc
p53_motif TSS	(bp)
OSBPL3 1.08 AGGCAAGCCCGGGCACAGCT 9861 TKT 0.41 AGACATGACCCTGCTTGTCC 13810
ACTN1 0.96 AGACATGTACCAACATGCCC 8606 FAM162A 0.31 AGACATGCCCCAACATGCAC 9965
TGFBI 0.9 ATGCATGTGCGAACATGTCT 4770 PNN -0.4 AAACTTGTAAAAACTTGTTT 12847
S100A4 0.89 GAACGTGCCCACACATGCCC 17237 URB1 -0.4 CTGCAAGCCAGGACGTGCCC 6312
PRDX5 0.7 TTGCCTGTCCTAGCATGCCC 6609 GRPEL2 -0.5 AGGCATGTCTGGACAAGAAA 19941
ALDH7A1 0.63 TGGCATGCTTTTACTAGTCC 4321 ST14 -0.6 TTTCATGACCAGACAAGTCC 19290
STAT6 0.55 CTGCAGGTGCAGGCATGTTG 14903 MTA2 -0.6 ATACCTGCAGGGACATGCCC 1475
FAH 0.55 GGGCATGTGTGGACATGCGC 15684 ZWILCH -0.9 AGACATGTTTTCACATGTCT 18854
ETV3 0.55 AGACTAGTCTCAAACATGCCC 19095 CDK1 -1.2 TGATATGCTTGGGCATGTAC 17178
NPEPPS 0.44 CAACAAGCAGTGACATGTTT 2351 BAZ1B -1.2 AGGCATGCACCAACATGCCC 11343
USP48 0.43 AAGCATGCCAGGGCAAATAT 4412
protein-coding mRNAs
gene
symbol
log2
fc
p53_motif TSS	(bp) gene
symbol
log2							
fc
p53_motif TSS	(bp)
CD70 11 GGGCTTGTCTGGGCTTGCCC 13243 TGFBI 1.58 ATGCATGTGCGAACATGTCT 4770
LCE1D 9.11 GGGCAAGTCCTCTCATGCCC 10422 LOXL4 1.53 AGGCATGCGCCAACATGCCC 2506
LCE1F 6.9 GGGCAAGTCCTCTCATGCCC 9458 SLC25A42 1.44 GCTCATGCTAAGACATGTCC 12896
RASAL1 5.37 AGACAAGTGTGGACAGGTAT 19376 PPP4R1L 1.39 AGGCATGTGCCAGCATGCCC 10077
APOD 5.32 GGACGTGTTGCAACATGTTT 156 GAS7 1.13 GGACTTGCCCAGACATGCCC 6959
ST14 4.39 TTTCATGACCAGACAAGTCC 19290 IFNGR2 1.11 TGACATGCCCAGACATGTTC 17245
MDFI 4.02 GGGCAGGTGAGAGCATGCCT 7276 LRIG3 1.09 GTACATGCCCAGGCATCTTC 13121
DHRS2 2.89 AGGCAAGTTCAGACAAGCAG 1662 NELL2 -1.2 AGGCATGTAACAACATGCCC 1188
ELFN2 2.71 TGACAGGTCAGGGCATGCAA 4585 FTH1 -1.3 AGGCATGTAACAACATGCCC 1188
CDC42BPG 2.66 GGACAAGTAGAGACAAGCAG 1178 FAM183A -1.3 AGACATGCCTGGGCTTGAAC 8442
PRDM1 2.6 GTGCAAGTCTGGACATGTTT 11869 NRP2 -1.6 ATGCTTGTCC13bpGGAAGAGCAT 2684
DENND2D 2.58 GGGCATGTCTTAGGCAAGCCC 9820 OTOP1 -1.7 AGACATGTTATGACAAGTTA 7271
RNF182 2.05 CCACAAGTCAGGACAAGCCT 10981 HSPG2 -1.7 AGACTTGCCCAAGCTTGCCC 18529
ETV3 1.98 AGACTAGTCTCAAACATGCCC 19095 FGF9 -3 GGAGACGTTCAGACACGTCC 16485
SCAMP5 1.83 GAACATGTTTTCACATGATT 4790 PCBP3 -5.7 AGACATGTCCTGGCATGCCC 10611
PARD6B 1.78 TTACAGGCCCTGACATGCAC 1582
lncRNAs
lncRNA														
gene	name
log2
fc
p53_motif TSS	(bp) lncRNA
gene name
log2						
fc
p53_motif TSS	(bp)
RP3-326I13.1 12.1 GCCCTTGTCTGGACATGCCC 54 RP11-34A14.3 1.47 AGGCATGCGCCAACATGCCC 13222
RP3-510D11.2 11.4 GAACAAGCCCAGGCAAGCCC 184 AP000944.1	
(NEAT1)
1.36 GAGCAAGCCTGGGCTTGCCA 1183
RP11-462G8.3	
(TCERG1L-AS1)
10.4 AGACTTGCCTGGGCTTGTTC 165 BX470102.3 1.29 GCACATGTTTAGGCAAGCCC 7120
LINC01021
(RP11-46C20.1)
6.44 GGGCTTGTCTGGGCATGCCC 51 RPL39P5 1.21 GGGCTTGCCTGTGACTTGCTT 14805
BX571672.2 4.65 TGTCTTGCCTGGACATGCCC 8650 AP000525.8	
(DUXAP8)
1.21 AGACATGCCTGTGCAAGCCT 11881
AC012065.6	
(HS1BP3-IT1)
3.68 GGACATGCACACCACATGTCT 7567 AC078883.4 1.2 GAGCATGTGTGAGCTTGTTT 14043
RP11-432J9.5 2.12 TGGCTTGACGACTCTTGTGA 288 AC008759.1	
(ZNF256-AS1)
1.19 ATACATGTTCAAAATGCTTGTTC 314
RP11-553A21.3 1.94 TAGCATGCCCCTGCAAGCCT 8009 AC008937.2 -1.1 AGGCAAGTCTCAACATGCAG 76
RP11-611D20.2	
(MIR4674HG)
1.61 GGGCAAGTCC 4220
miRNAs
miRNA
gene name
log2
fc
p53_motif TSS	(bp) miRNA
gene name
log2
fc
p53_motif TSS	(bp)
miR-1293 6.5 AGACAAGTCTGCAGGCATGTTA 23563 miR-3191 -5.9 GGACATGCCTGGGCAGACCC 158
miR-486-5p 2.7 TAACTTGCCCAGACATGCCG 20047 miR-3928 -6.1 AGACAGGCTCAGGCATGCCA 17299
miR-641 1.3 AGGCATGAACCAACATGCCT 10361 miR-1908 -9.3 GGTCATGCCTAGTCATGTCT 3811
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Furthermore,	MDFI,	ST14	and	LINC01021	 showed	an	up-regulation	after	Nutlin-
treatment	in	HCT116	p53+/+	but	not	in	HCT116	p53-/-	cells (Fig.	27).		
	
	
Figure	 27:	 p53-dependent	 regulation	 of	 the	 newly	 identified	 p53	 target	 genes	MDFI,	 ST14	 and	
LINC01021	 after	 Nutlin	 treatment.	 qPCR	 analyses	 of	MDFI,	 ST14	 and	 LINC01021	 expression	 after	
addition	 of	 Nutlin	 or	 DMSO	 for	 48	 hours	 in	 HCT116	 p53+/+	 and	 HCT116	 p53-/-.	 Results	 were	
normalized	to	β-actin	expression	and	represent	the	mean	+/-	SD	(n	=	3).		
	
In	 addition,	we	 confirmed	 induced	 levels	 of	 primary	 and	mature	miR-486	 after	
ectopic	 p53-expression	 in	 the	 DOX-inducible	 cell	 line	 SW480/pRTR-p53-VSV											
(Fig.	 28A).	Moreover,	we	 confirmed	p53	occupancy	by	qChIP	 analysis	 for	miR-486,	
which	is	line	with	the	ChIP-Seq	results	(Fig.	28B,	C).	A	reporter	assay	showed	that	the	
isolated	 p53	 binding	 site	 upstream	 of	 the	 miR-486	 host	 gene	 ANK1	 is	 indeed	
responsive	to	p53,	providing	further	evidence	for	the	direct	regulation	of	miR-486-5p	
by	p53	(Fig.	28D).		
	
	
	
Figure	28:	 Validation	 of	 the	 new	p53	 target	miRNA	miR-486-5p.	 (A)	qPCR	analyses	of	primary	
and	 mature	 miR-486-5p	 expression	 in	 SW480/pRTR-p53-VSV	 cells	 after	 addition	 of	 DOX	 for	 the	
indicated	periods.	(B)	p53-VSV-derived	ChIP-Seq	result	displayed	using	the	UCSC	genome	browser.	(C)	
qChIP	validation	of	p53	occupancy	at	the	miR-486	promoter	in	SW480/pRTR-p53-VSV	after	16	hours	
of	DOX	treatment	and	subsequent	VSV-ChIP.	Raw	data	analysis	of	ChIP-Seq	results	was	performed	by	
T.	Bonfert.	(D)	Luciferase-reporter	assay	after	transfection	of	a	pcDNA-p53-VSV	or	pcDNA-VSV	vector	
together	 with	 a	 pBV-Luc	 vector	 harboring	 the	 p53	 binding	 site	 of	 the	 gene	 encoding	 miR-486-5p.	
Results	in	(A),	(C)	and	(D)	represent	the	mean	+/-	SD	(n	=	3).		
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							Moreover,	the	induction	of	primary	and	mature	miR-34a	and	miR-205	by	p53	was	
confirmed	 by	 qPCR	 (Fig.	 29A).	 In	 contrast	 to	 a	 previously	 identified	 p53	 RE	 1	 kbp	
upstream	 of	 the	 gene	 encoding	 miR-205	 [262],	 we	 validated	 a	 p53	 binding	 site	
approximately	17	kbp	upstream	of	the	miR-205	TSS	(Fig.	29B).		
	
	
	
Fig.	 …:	 Validation	 of	 the	
p53-regulated	 miR-34a	
and	 miR-205.	 (A)	 qPCR	
analyses	 of	 left:	 primary	
and	right:	mature	miRNA-
levels	 of	 miR-34a	 and	
miR-205	 in	 SW480/pRTR-
p53-VSV	 cells	 after	
addition	 of	 DOX	 for	 the	
indicated	 periods.	 (B)	
p53-VSV-derived	ChIP-Seq	
results	are	displayed	using	
the	UCSC	genome		
	
	
Because	 of	 its	 exceptionally	 pronounced	 induction	 after	 p53-activation,	 we	
further	 analyzed	 LINC01021.	 According	 to	 the	 ENSEMBL	 genome	 browser,	 the	
LINC01021	 locus	 encodes	 six	 alternatively	 spliced	 transcripts	 (Fig.	 30A).	 We	
introduced	the	longest	transcript,	LINC01021_A,	into	the	DOX-inducible	pRTR-vector	
and	 subsequently	 confirmed	 its	 prominent	 induction	 after	 treatment	 with	 DOX	 in	
SW480/pRTR-LINC01021_A	cells	(Fig.	30B).	
	
	
Figure	 30:	 Ectopic	 expression	 of	 LINC01021.	 (A)	 Scheme	 showing	 the	 different	 splice	 variants	 of	
LINC01021.	 The	 longest	 LINC01021	 transcripts,	 LINC01021_A,	 has	 945	nt	 and	was	 inserted	 into	 the	
pRTR	vector.	 (B)	qPCR	analysis	of	LINC01021	 expression	 in	SW480/pRTR-LINC01021_A	cells	after	48	
hours	 of	 DOX	 treatment.	 Results	 were	 normalized	 to	 β-actin	 expression	 and	 represent	 the	 mean							
+/-	SD	(n	=	3).	
	
Notably,	 ectopic	 LINC01021_A	 expression	 after	 addition	 of	 DOX	 resulted	 in	
decreased	proliferation	as	determined	by	realtime	impedance	measurement	and	cell	
counting	 (Fig.	 31A),	 whereas	 addition	 of	 DOX	 had	 no	 effect	 on	 SW480/pRTR	 cells	
(Fig.	31B).	
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Figure	29:	Validation	of	 the	
p53-regulated	 miR-34a	 and	
miR-205.		
(A)	 qPCR	 analyses	 of	 (left)	
primary	 and	 (right)	 mature	
miRNA-levels	 of	 miR-34a	
and	 miR-205	 in	
SW480/pRTR-p53-VSV	 cells	
after	addition	of	DOX	for	the	
indicated	 periods.	 Results	
re-present	 the	mean	 +/-	 SD	
(n	=	3).		(B)	p53-VSV-derived	
ChIP-Seq	 results	 are	
displayed	 using	 the	 UCSC	
genome	 browser.	 Raw	 data	
analysis	 of	 ChIP-Seq	 results	
was	 performed	 by	 T.	
Bonfert.		
		
primary
miR-34a
0
5
10
primary
miR-205
0
10
20
30
mature
miR-34a
0
2
4
6
8
mature
miR-205
0
10
20
30
fo
ld
	in
du
ct
io
n
fo
ld
	in
du
ct
io
n
0		24	48	72		hrs DOX 0			24			hrs DOX
0		24	48	72		hrs DOX 0			24			hrs DOX
fo
ld
	in
du
ct
io
n
fo
ld
	in
du
ct
io
n***
***
*** ***
***
***
***
*
►
MIR-205
►
1
28
1
28
SW480/
pRTR-p53-VSV
SW480/
pRTRGGGCTTGCCTGGGCTTGTTC
10	kbp
1
36
1
36
AAACATGTTATGTCATGCCC
SW480/
pRTR-p53-VSV
SW480/
pRTR
10	kbp
p53	binding	site:	miR-34a
p53	binding	site:	miR-205
re
ad
s
re
ad
s
re
ad
s
re
ad
s
MIR-34a
   RESULTS  
59 
 
	
Figure	 31:	 Effect	 of	 LINC01021	 expression	 on	 proliferation.	 (A)	 SW480/pRTR-LINC01021_A	and	 (B)	
SW480/pRTR	 cell	 pools	were	 subjected	 to	 (left)	 impedance	measurements	 and	 (right)	 cell	 counting	
using	trypan	blue	exclusion.	24	hours	after	seeding,	DOX	was	added	as	indicated	by	the	dotted	line	in	
the	left	panel.	Results	represent	the	mean	+/-	SD	(n=3).	
	
5.2.7	Comparison	of	p53	and	miR-34a	effects	on	de	novo	protein	synthesis	
Recently,	 my	 colleague	 Markus	 Kaller	 performed	 a	 proteome-wide	 analysis	 of	
miR-34a	 targets	 in	 the	 colorectal	 cancer	 cell	 line	 SW480	 using	 the	 pSILAC	method	
[217].	When	we	compared	the	sets	of	down-regulated	proteins	from	both	analyses,	
a	 significant	 overlap	 was	 detected	 (Fig.	 32):	 Almost	 35%	 of	 the	 proteins	 down-
regulated	 in	 the	 miR-34a	 pSILAC	 analysis	 were	 also	 down-regulated	 after	 ectopic	
expression	of	p53.	
	
	
Figure	32:	Overlap	between	changes	in	de	novo	protein	synthesis	after	p53-	or	miR-34a-induction.	
(Left)	Cumulative	distribution	plot	displaying	p53-induced	changes	in	de	novo	protein	synthesis	of	113	
proteins	down-regulated	after	induction	of	miR-34a	[217]	compared	to	the	normal	distribution	of	all	
detected	 proteins.	 (Right)	 Venn	 diagram	 displaying	 the	 overlap	 between	 proteins	 down-regulated	
(log2	fold	change	<	-0.3)	after	ectopic	p53	and	miR-34a	expression.	Based	on	the	p53	pSILAC	results	
(contributions	 of	 the	 co-authors	 described	 on	 page	 42),	 the	 data	 were	 analyzed	 and	 the	 figures	
generated	with	support	of	M.	Kaller.	
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Moreover,	 the	 log2	 fold	 changes	 of	 those	 co-regulated	 proteins	 showed	 a	
significant,	positive	correlation	(Fig.	33).		
	
	
Interestingly,	 almost	 all	 members	 of	 the	 MCM	 protein	 family,	 which	 mediate	
initiation	of	DNA	 replication,	were	 among	 the	 co-regulated	proteins.	 Among	 these	
were	 only	 four	 direct	 miR-34a	 targets:	 MTA2,	 SURF4,	 TMEM109	 and	 UCK2.	
Therefore,	 Markus	 Kaller	 determined	 whether	 the	 proteins	 down-regulated	 after	
p53	and	miR-34a	expression	harbor	common	transcription	factor	binding	motifs	in	a	
region	 +/-2	 kbp	 from	 the	 corresponding	 gene	 promoter	 using	 the	 Molecular	
signatures	database	 (MSigDB)	 [274,	275]	 (Fig.	 34).	 Interestingly,	we	 found	 that	 the	
binding	 motif	 for	 the	 transcription	 factor	 E2F1	 was	 significantly	 enriched	 among	
down-regulated	proteins	 in	both	pSILAC-datasets	(Fig.	34A),	but	not	among	the	up-
regulated	proteins	 (data	not	 shown).	A	 cumulative	distribution	analysis	of	proteins	
with	 an	 E2F1	 binding	 motif	 near	 their	 corresponding	 TSS	 (+/-2	 kbp)	 revealed	
significantly	 decreased	 protein	 expression	 (p	 <	 0.0001)	 when	 compared	 to	 the	
normal	 distribution	 of	 all	 proteins	 detected	 in	 the	 p53	 pSILAC	 analysis	 (Fig.	 34B).	
Using	a	dataset	of	experimentally	validated	E2F1	regulated	genes	further	supported	
this	finding	(Fig.	34B).	It	is	known	that	E2F	transcription	factors	are	targeted	by	miR-
34a	[95,	218,	276,	277].	Indeed,	a	cumulative	distribution	analysis	of	proteins	with	an	
E2F1	 binding	 motif	 near	 their	 corresponding	 gene	 TSS	 (+/-2	 kbp)	 revealed	
significantly	decreased	de	novo	protein	synthesis	(p	<	0.0001)	when	compared	to	the	
normal	 distribution	 of	 all	 proteins	 detected	 in	 the	 miR-34a	 pSILAC	 approach	 (Fig.	
34C).	 Interestingly,	almost	all	members	of	the	MCM	protein	family,	that	are	known	
E2F	target	genes	[120,	278-280],	were	among	the	proteins	co-regulated	by	miR-34a	
and	 p53	 (data	 not	 shown).	 Therefore,	 it	 is	 possible	 that	 miR-34a	 indirectly	
contributes	to	a	p53-induced	cell	cycle	arrest	by	targeting	E2F	and	thereby	E2F	target	
genes.	
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Figure	33:	Changes	in	de	novo	protein	synthesis	after	
p53-induction	 positively	 correlate	 with	 miR-34a-
induced	changes	in	de	novo	protein	synthesis.	Scatter	
plot	 displaying	 the	 correlation	of	 changes	 in	de	 novo	
protein	 synthesis	 between	 proteins	 down-regulated	
by	 p53	 and	 miR-34a.	 The	 Pearson	 correlation	
coefficient	 and	 statistical	 significance	 are	 indicated.	
Based	on	the	p53	pSILAC	results	 (contributions	of	the	
co-authors	 described	 on	 page	 42),	 the	 data	 were	
analyzed	 and	 this	 figure	was	 generated	with	 support	
of	M.	Kaller.	
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Figure	34:	Common	transcription	factor	binding	motifs	among	proteins	down-regulated	after	miR-
34a	or	p53.	 (A)	Enrichment	of	E2F1,	E2F1DP1	and	E2FDP2	binding	motifs	 in	the	promoters	of	genes	
encoding	 proteins	 down-regulated	 by	 p53	 and	 miR-34a.	 pSILAC	 datasets	 were	 analyzed	 with	 the	
Molecular	Signature	database	 (MSigDB)	at	http://www.broadinstitute.org/gsea/msigdb/index.jsp.	TF	
=	transcription	factor.	(B)	Cumulative	distribution	plot	displaying	in	black	the	p53-induced	changes	in	
de	 novo	 protein	 synthesis	 of	 proteins	 with	 E2F1	 binding	motifs	 in	 their	 gene	 promoters	 (in	 black)	
compared	 with	 the	 normal	 distribution	 of	 all	 detected	 proteins.	 p53-induced	 changes	 in	 de	 novo	
protein	synthesis	of	proteins	(in	light	grey)	positively	regulated	by	E2F1	are	displayed	in	dark	grey.	(C)	
Cumulative	 distribution	 plot	 displaying	 miR-34a-induced	 changes	 in	 de	 novo	 protein	 synthesis	 of	
proteins	with	E2F1	binding	motifs	in	their	gene	promoters	compared	to	the	normal	distribution	of	all	
detected	 proteins.The	 E2F1	 datasets	 V$E2F_Q6	 [281]	 and	 E2F1_UP.V1_UP	 [282]	 for	 (B)	 and	
V$E2F1_Q3_01	 for	 (C)	were	obtained	at	MSigDB.	Based	on	 the	p53	pSILAC	 results	 (contributions	of	
the	 co-authors	 described	 on	 page	 42),	 the	 data	 were	 analyzed	 and	 figures	 were	 generated	 by	M.	
Kaller.	
	
5.2.8	miRNA-mediated	repression	by	p53	
To	 assess	 the	 effect	 of	miRNA-mediated	 repression	 after	 activation	 of	 p53,	we	
performed	 a	 scan	 for	 targets	 of	 the	 p53-induced	 miRNAs	 (log2	 fold	 change	 ≥	 1)	
among	the	differentially	down-regulated	proteins	and	mRNAs	identified	in	this	study	
by	 using	 a	 combination	 of	 the	 TargetScan	 and	 Pictar	 [239,	 240]	 target	 prediction	
algorithms.	 Thereby,	 284	 predicted	 targets	 of	 the	 p53-induced	 microRNAs	 were	
identified	among	the	down-regulated	proteins	(log2	fold	change	≤	-0.3;	pval	≤	0.05)	
(data	 not	 shown).	 37%	 (105)	 of	 these	 targets	 were	 also	 down-regulated	 on	 the	
mRNA	 level.	 In	 addition,	we	detected	203	putative	 targets	 that	were	 regulated	on	
mRNA	level	only.	A	KEGG	pathway	analysis	of	the	284	predicted	targets	using	DAVID	
[241,	 242]	 revealed	 a	 significant	 over-representation	 of	miRNA	 targets	 involved	 in	
DNA	 replication	 (p	=	9.40E-07)	and	cell	 cycle	progression	 (p	=	6.80E-04),	 indicating	
that	 induction	 of	 miRNAs	may	 contribute	 to	 inhibition	 of	 these	 processes	 by	 p53	
(data	not	shown).	Subsequently,	we	focused	on	the	targets	of	the	miRNAs	miR-34a,	-
34c-3p,	-145,	-205	and	-486-5p,	which	are	directly	induced	by	p53.	Out	of	77	putative	
miRNA	targets	with	reduced	de	novo	protein	synthesis,	33	were	repressed	on	both,	
the	protein-	and	mRNA-level	and	44	only	on	the	 level	of	de	novo	protein	synthesis	
(Fig.	35A	and	B,	respectively).	
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Figure	35:	Putative	targets	of	miRNAs	directly	induced	by	p53	with	down-regulated	mRNA-	and	de	
novo	protein	synthesis	or	reduced	de	novo	protein	synthesis	only.	Predicted	miRNA	targets	with	(A)	
down-regulated	mRNA-	and	de	novo	protein	synthesis,	(B)	reduced	de	novo	protein	synthesis	only	are	
displayed.	 Proteins	 that	 showed	 a	 heterogeneous	 distribution	 of	 fold	 changes	 in	 independent	
experiments	 (class	 II	 candidates,	 see	 Experimental	 procedures)	 are	 marked	 with	 an	 asterisk	 (*).	
Known	miRNA	targets	are	underlined	and	 targets	experimentally	validated	 in	 this	 study	are	marked	
with	 a	 black	 arrow.	 The	mature	miRNA	 is	 referred	 to	 as	miR-x,	 whereas	 the	 strand	 that	 is	 usually	
degraded	 is	 indicated	as	miR-x*.	 Starting	with	mirBase	 v18,	miRNA	 strands	 from	one	precursor	 are	
referred	to	as	miR-x-5p	and	miR-x-3p	depending	on	the	arm	from	which	they	are	processed	since	it	is	
not	 clear	 which	 sequence	 serves	 as	 the	 predominant	 one	 under	 varying	 conditions.	 Based	 on	 the	
pSILAC,	RNA-	and	miRNA-Seq	results	(contributions	of	the	co-authors	described	on	page	42),	the	data	
were	analyzed	and	this	figure	was	generated.	
		
In	addition,	we	identified	51	repressed	putative	miRNA	target	mRNAs	for	which	
the	 corresponding	 protein	 was	 not	 detected	 by	 pSILAC	 (Fig.	 36).	 Among	 the	
identified	targets,	several	were	already	shown	to	be	regulated	by	one	or	several	of	
the	 studied	 miRNAs,	 such	 as	 the	 miR-34a	 targets	 CDK6,	 MTA2	 and	 YY1	 [217]	
(underlined	 in	 Fig.	 35,	 36).	 None	 of	 the	 predicted	 conserved	 targets	 showed	 p53	
enrichment	in	the	ChIP-Seq	analysis	in	the	vicinity	(+/-	20	kbp)	of	the	respective	gene	
promoter	 except	 for	MTA2.	 Since	MTA2	 is	 a	 known	 target	 of	 miR-34a	 [217],	 this	
indicates	 that	additional	direct	 transcriptional	 repression	by	p53	may	augment	 the	
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miRNA-mediated	 down-regulation	 of	 this	 gene	 by	 a	 coherent	 feed	 forward	
regulation	[283].		
These	results	indicate	that	p53	indirectly	down-regulates	many	genes	on	mRNA-	
and/or	 protein-level	 by	 inducing	 miRNAs	 on	 a	 genome-wide	 scale.	 Part	 of	 the	
miRNA-mediated	 repression	 is	 presumably	 mediated	 by	 enhanced	 mRNA	
degradation.	 However,	 approximately	 60%	 of	 the	 conserved	 miRNA	 targets	 are	
presumably	 not	 repressed	 on	 the	 mRNA	 level,	 but	 only	 on	 the	 level	 of	 de	 novo	
protein	 synthesis,	 indicating	 that	 miRNA-mediated	 translational	 repression	 may	
represent	an	important	regulatory	mechanism	employed	by	p53.		
	
	
	
Figure	 36:	 Putative	 targets	 of	 miRNAs	 directly	 induced	 by	 p53	 with	 down-regulation	 of	 mRNA	
expression.	Predicted	miRNA	targets	down-regulated	only	on	the	mRNA	level.	Known	miRNA	targets	
are	 underlined	 and	 targets	 experimentally	 validated	 in	 this	 study	 are	 marked	 with	 a	 black	 arrow.	
Based	on	the	RNA-	and	miRNA-Seq	results	(contributions	of	the	co-authors	described	on	page	42),	the	
data	were	analyzed	and	this	figure	was	generated.	
	
5.2.9	p53-induced	miRNAs	regulate	putative	prognostic	markers	
Next,	we	focussed	on	three	factors	that	displayed	down-regulation	by	p53,	were	
putative	targets	of	p53-induced	miRNAs	and	had	previously	reported	cancer-relevant	
functions.	 HMGB1,	 which	 was	 down-regulated	 on	 the	 mRNA	 level	 and	 showed	
reduced	 de	 novo	 protein	 synthesis	 after	 p53	 induction	 (Fig.	 35A),	 has	 a	 predicted	
conserved	seed-match	(SM)	for	miR-205	in	its	3´-UTR	(Fig.	37A)	and	a	published	SM	
for	miR-34c-3p	and	miR-34a	[284].	KLF12	also	showed	a	prominent	down-regulation	
on	mRNA-level	(Fig.	36)	and	has	predicted	conserved	seed-matches	for	miR-34a	and	
miR-205	 (Fig.	 37B).	 The	 citron	 rho-interacting	 serine/threonine	 kinase	 (CIT),	 which	
was	also	down-regulated	on	 the	mRNA	 level	and	showed	reduced	de	novo	protein	
-5 0
ZBTB46
TNFAIP8
RALGPS2
MPZL2
TRIM9
PLEKHC1
RASAL2
FOXO1
TLE4
ZC3H6
HOXA5
FZD7
PPP1R9A
CEP350
CHN1
RBM20
AMOT
RUNX2
SP5
ZNF704
CPLX2
ST5
NKD1
C16orf5
IVNS1ABP
TTC9
-5 0
SYPL2
LRP4
CADM1
KLF12
EPHA4
INHBB
HOXC11
PMP22
SLC7A8
CAMK2D
KITLG
FAM189A1
EDAR
WWC3
GSDMA
C1orf21
SLC7A11
PLXNA2
CDKN1C
NAV2
SNTB1
FGF9
TNFRSF11B
AFF3
BNC2
RNA-Seq
miR-34a
miR-205
miR-145
miR-34a,	-145,	-205,	-486-5p
miR-205
miR-205
miR-486-5p
miR-34a
miR-145
miR-34a
miR-34a
miR-145
miR-34a
miR-145
miR-34a
miR-145
miR-34c-3p
miR-34a,	-486-5p
miR-145
miR-145
miR-145
miR-145
miR-34a,	-145
miR-34a,	-205
miR-205
miR-486-5p
miR-34a,	-145
miR-145
miR-145,	-486-5p
miR-145
miR-486-5p
miR-486-5p
miR-34a
miR-205
miR-145
miR-145
miR-205
miR-205
miR-34a
miR-145
miR-34a
miR-34a
miR-34c-3p,	-145,	-205
miR-205
miR-205
miR-145
miR-34c-3p
miR-145
miR-145
miR-205
miR-145
-1 -1
log2 fold change log2 fold change
   RESULTS  
64 
 
synthesis	 (Fig.	 35A),	 is	 a	 predicted	 target	 of	 the	 newly	 identified	 p53-regulated	
miRNA	miR-486-5p	(Fig.	37C).	
	
Figure	37:	Detection	of	 conserved	 seed-matching	 sites	of	p53-regulated	miRNAs	 in	 the	3´-UTRs	of	
HMGB1,	 KLF12	 and	 CIT.	 The	 indicated	 3´-UTRs	 were	 analyzed	 with	 TargetScan	
(http://www.targetscan.org)	and	Pictar	(http://pictar.mdc-berlin.de).	
	 	
Down-regulation	of	HMGB1,	KLF12	and	CIT	expression	by	p53	was	confirmed	on	
the	 mRNA	 level	 in	 SW480/pRTR-p53-VSV	 cells	 (Fig.	 38A).	 Furthermore,	 all	 three	
genes	 were	 down-regulated	 after	 treatment	 with	 Nutlin	 or	 Etoposide	 in	 HCT116	
p53+/+	but	not	in	HCT116	p53-/-	cells	(Fig.	38B).	Therefore,	their	repression	by	DNA-
damage	is	p53-dependent.	
	
	
Figure	 38:	 Validation	 of	 p53-mediated	 down-regulation	 on	 mRNA	 level.	 qPCR	 analyses	 of	 the	
indicated	mRNAs	after	(A)	addition	of	DOX	to	SW480/pRTR-p53-VSV	cells	for	the	indicated	periods,	(B)	
treatment	of	HCT116	p53+/+	and	p53-/-	cells	with	Nutlin	or	Etoposide	for	48	hours.	Results	in	(A)	and	
(B)	represent	the	mean	+/-	SD	(n	=	3).	
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To	 confirm	direct	miRNA-mediated	down-regulation	of	KLF12,	HMGB1	 and	CIT,	
dual	reporter	assays	were	performed	(Fig.	39A).	3’-UTR-reporters	of	KLF12,	HMGB1	
and	 CIT	 displayed	 a	 significant	 repression	 after	 cotransfection	 with	 the	 matching	
miRNA.	 Mutation	 of	 the	 seed-matching	 sequences	 in	 the	 3´-UTRs	 abolished	 the	
miRNA-mediated	repression	in	all	cases	(Fig.	39A,	39B).	Therefore,	the	three	selected	
miRNA	targets	represent	direct	targets	of	p53-induced	miRNAs.	
	
	
	
Figure	 39:	 Validation	 of	 p53-	 and	 miRNA-mediated	 down-regulation.	 (A)	 Dual	 reporter	 assays	 of	
H1299	 cells	 co-transfected	 with	 the	 indicated	miRNA	mimics	 or	 controls	 and	 the	 indicated	 3´-UTR	
constructs.	 Results	 represent	 the	 mean	 +/-	 SD	 (n	 =	 3).	 (B)	 Details	 of	 the	 mutant	 3´-UTR	 reporter	
constructs.	SM	=	seed-match.	
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We	then	asked	whether	up-regulation	of	any	of	the	three	miRNA	targets	occurs	
during	tumor	progression	using	expression	data	 from	collections	of	patient-derived	
tumor	samples	in	the	databases	Oncomine	[237],	TCGA	(The	Cancer	Genome	Atlas)	
[244]	 and	 PROGgene	 [238].	 Analysis	 of	 the	 Oncomine	 database	 [237]	 showed	 a	
significant	 up-regulation	 of	HMGB1	 in	 tumor	 versus	 normal	 tissue	 in	 15	 out	 of	 20	
different	 tumor	 entities,	 such	 as	 colon,	 pancreatic,	 prostate	 and	 invasive	 breast	
carcinoma	(Fig.	40).		
	
	
	
Figure	40:	Analysis	of	the	HMGB1	mRNA	level	in	different	tumor	entities.	Analysis	of	HMGB1	mRNA	
expression	 in	 the	 human	 Oncomine	 dataset	 (p-value	 <	 0.05;	 fold	 change	 ˃	 1.5).	 (A)	 Summary	 of	
HMGB1	 expression	 in	 different	 types	 of	 human	 cancer;	 red:	 up-regulated,	 blue:	 down-regulated.	
Comparison	 of	 HMGB1	 mRNA	 expression	 in	 corresponding	 normal	 tissue	 and	 (B)	 colon	
adenocarcinoma	 in	 the	 Alon	 colon	 dataset	 [285],	 (C)	 pancreatic	 ductal	 adenocarcinoma	 in	 the	
Buchholz	 pancreas	 dataset	 [286],	 (D)	 prostate	 carcinoma	 in	 the	 Tomlins	 prostate	 dataset	 [287],	 (E)	
invasive	breast	carcinoma	in	the	Finak	breast	dataset	[288].	
	
Similarly,	 KLF12	 was	 up-regulated	 in	 different	 tumor	 types,	 such	 as	 pancreatic	
ductal	 adenocarcinoma,	 invasive	 breast	 carcinoma,	 gastrointestinal	 stromal	 tumor,	
melanoma,	 T-cell	 acute	 lymphoblastic	 leukemia	 and	 teratoma	 (Fig.	 41A-D).	 When	
expression	 data	 of	 424	 colorectal	 tumors	 from	 TCGA	 were	 analyzed,	 a	 significant	
increase	 in	 KLF12	 mRNA	 expression	 in	 those	 cases	 showing	 metastasis	 to	 distant	
organs	(M1)	compared	to	those	without	distant	metastasis	(M0)	was	detected	(Fig.	
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41E).	KLF12	mRNA	expression	was	 also	 significantly	 elevated	 in	 tumors	with	 nodal	
status	N2	compared	to	N0	and	in	advanced	tumor	stage	IV	versus	tumor	stage	I.		
	
	
Figure	41:	Analysis	of	the	KLF12	mRNA	level	in	different	tumor	entities	and	advanced	tumor	stages.	
Analysis	of	KLF12	mRNA	expression	in	(A-D)	the	human	Oncomine	dataset	(p-value	<	0.05;	fold	change	
˃	1.5)	and	(E)	the	public	database	TCGA.	Comparison	of	KLF12	mRNA	expression	in	the	corresponding	
normal	 tissue	 and	 (A)	 pancreatic	 ductal	 adenocarcinoma	 in	 the	 Badea	 pancreas	 dataset	 [289],	 (B)	
invasive	breast	carcinoma	in	the	Finak	breast	dataset	[288],	(C)	gastrointestinal	stromal	tumor	in	the	
Cho	gastric	dataset	[290],	(D)	melanoma	in	the	Haqq	melanoma	dataset.	(E)	KLF12	mRNA	expression	
data	derived	from	primary	CRC	samples	(n	=	424)	from	the	public	database	TCGA.		
	
Furthermore,	CIT	mRNA	expression	was	elevated	 in	 several	 tumor	entities,	 such	
as	colon,	lung,	breast,	pancreas	and	gastric	cancer	(Fig.	42).		
	
Figure	42:	Analysis	of	the	CIT	mRNA	
level	 in	 different	 tumor	 entities.	
Analysis	 of	 CIT	mRNA	 expression	 in	
the	 human	 Oncomine	 dataset	 (p-
value	 <	 0.05;	 fold	 change	 ˃	 1.5).	
Comparison	of	CIT	mRNA	expression	
in	 corresponding	 normal	 tissue	 and	
(A)	colorectal	carcinoma	in	the	Hong	
colon	 dataset	 [291],	 (B)	 ductal	
breast	 carcinoma	 in	 the	 Richardson	
breast	 2	 dataset	 [292],	 (C)	
pancreatic	 adenocarcinoma	 in	 the	
Iacobuzio-Donahue	 pancreas	 2	
dataset	 [293],	 (D)	 gastrointestinal	
stromal	 tumor	 in	 the	 Cho	 gastric	
dataset	[290].	
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Interestingly,	 patients	 showing	decreased	expression	of	HMGB1,	KLF12	 and	CIT	
had	 an	 increased	 overall	 and	 metastasis-free	 survival	 in	 two	 different	 colorectal	
cancer	 patient	 cohorts	 (Fig.	 43).	 In	 summary,	 these	 results	 suggest	 that	 HMGB1,	
KLF12	 and	CIT	may	 represent	 clinically	 relevant	prognostic	markers.	Moreover,	 the	
serine/threonine	 kinase	 CIT	 represents	 an	 interesting	 candidate	 for	 tumor	
therapeutic	approaches,	since	its	activity	may	be	inhibited	by	small	molecules.	
	
	
	
Figure	 43:	 Correlation	 of	 HMGB1,	 KLF12	 and	 CIT	 mRNA	 expression	 with	 increased	 overall	 and	
metastasis	 free	 survival.	 Association	 analysis	 of	 (A)	 overall	 and	 (B)	 metastasis	 free	 survival	 of	
colorectal	 cancer	 patients	 and	 HMGB1,	 KLF12	 and	 CIT	 expression	 in	 the	 primary	 tumor	 using	 the	
datasets	 GSE15736	 and	 GSE11121,	 respectively,	 from	 the	 PROGgene	 database	
(www.compbio.iupui.edu/proggene).	
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5.3	p53	directly	activates	CST5	to	mediate	mesenchymal-epithelial	transition	
	
The	following	results	are	published	in:		
	
Hünten,	 S.	 and	 H.	 Hermeking,	 p53	 directly	 activates	 cystatin	 D/CST5	 to	 mediate	
mesenchymal-epithelial	 transition:	 a	 possible	 link	 to	 tumor	 suppression	by	 vitamin	
D3.	Oncotarget,	2015.	6(18):	p.	15842-56.	[3]	
	
					All	 figures	 shown	 in	 this	 section	are	exclusively	based	on	my	experimental	work	
under	supervision	of	Prof.	Hermeking.	
	
5.3.1	p53	induces	CST5	expression	
In	the	screen	for	p53-regulated	factors	described	in	the	previous	chapter	(5.2)	we	
had	 detected an	 ~6-fold	 increase	 of	 CST5	 protein	 by	 pulsed	 SILAC	 and	 a	 ~9-fold	
induction	 of	 CST5	 mRNA	 expression	 by	 RNA-Seq	 analysis	 after	 addition	 of	
doxycycline	(DOX)	to	activate	expression	of	ectopic	p53	in	the	colorectal	cancer	cell	
line	SW480	harboring	a	pRTR-p53-VSV	vector	for	48	and	40	hours,	respectively.	Here,	
we	confirmed	the	up-regulation	of	the	CST5	protein	by	p53	by	Western	blot	analysis	
(Fig.	44A).	As	expected,	p53	expression	also	resulted	in	the	induction	of	the	known	
p53	target	p21.	The	kinetics	of	induction	by	p53	were	similar	for	p21	and	CST5:	at	24	
hours	an	induction	was	detectable	and	by	72	hours	both	proteins	were	still	elevated.	
After	p53	activation,	CST5	mRNA	expression	displayed	a	similar	induction	as	p21	(Fig.	
44B).		
	
Figure	44:	CST5	is	up-regulated	after	ectopic	p53	expression	in	SW480/pRTR-p53-VSV.	SW480/pRTR-
p53-VSV	or	SW480/pRTR	cells	were	treated	with	DOX	for	the	indicated	timepoints.	(A)	Western	blot	
analysis	of	the	indicated	proteins.	β-actin	served	as	a	loading	control.	(B)	The	indicated	mRNAs	were	
measured	by	qPCR-analysis.	β-actin	served	as	a	normalization	control.	Fold	changes	represent	mean	
values	of	triplicate	analyses	of	DOX-treated	versus	untreated	cells	and	error	bars	represent	standard	
deviations.	
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An	 immunofluorescence	 analysis	 confirmed	 increased	 CST5	 protein	 levels	 after	
ectopic	 p53	 expression	 and	 showed	 its	 predominant	 cytoplasmic	 localization	 after	
DOX	treatment	in	SW480/pRTR-p53-VSV	cells	(Fig.	45).	
	
	
Recently,	CST5	was	shown	to	be	 induced	by	vitamin	D3	via	direct	binding	of	the	
vitamin	D	receptor	(VDR)	to	 its	promoter	 in	human	colon	cancer	cell	 lines	[200].	 In	
addition,	 the	 VDR	 gene	 is	 a	 known	 p53	 target	 [294].	 To	 determine	 whether	 p53	
induces	 CST5	 in	 a	 VDR-independent	 manner,	 VDR-deficient	 HEK293T	 cells	 were	
transfected	with	 a	 DOX-inducible	 pRTR-p53-VSV	 vector	 (Fig.	 46).	 Activation	 of	 p53	
expression	by	treatment	with	DOX	resulted	in	a	significant	induction	of	CST5	and,	as	
a	control,	p21	mRNA.	These	results	show	that	p53	induces	CST5	expression	in	a	VDR-
independent	manner.	
	
	
To	further	interrogate	the	p53-dependency	of	the	CST5	expression,	the	colorectal	
cancer	 cell	 lines	 HCT116	 and	 RKO	 and	 their	 isogenic	 p53-deficient	 variants,	 which	
were	 generated	 by	 homologous	 recombination	 [246],	 were	 treated	 with	 either	
Nutlin-3a,	 a	 small-molecule	 inhibitor	 of	MDM2	 [247],	 or	 the	 DNA-damaging	 agent	
Etoposide	 (Fig.	47).	Both	treatments	 resulted	 in	a	 time-dependent	up-regulation	of	
CST5	 in	 HCT116	p53+/+	 cells	 (Fig.	 47A).	 Since	CST5	 expression	was	 not	 induced	 in	
HCT116	p53-/-	cells,	the	activation	of	CST5	transcription	was	mediated	by	p53.	Also	
Figure	45:	 Localization	 of	 the	
CST5	 protein	 after	 ectopic	
p53-expression	 in	 SW480/	
pRTR-p53-VSV.	 Analysis	 of	
CST5	 expression	 and	
localization	 in	 SW480/pRTR-
p53-VSV	 cells	 by	 confocal	
immunofluorescence	 micros-
copy	 after	 48	 hours	with	 and	
without	 DOX	 treatment.	
Nuclear	 DNA	 was	 visualized	
by	 DAPI	 staining.	 200x	
magnification.	
Figure	 46:	 CST5	 up-regulation	 after	 p53	 is	 independent	 of	 VDR.	
qPCR-analysis	of	CST5-	and	p21-mRNA	levels	in	HEK293T/pRTR-p53-
VSV	 cells	 after	 24	 hour	 DOX-treatment.	 β-actin	 served	 as	 a	
normalization	 control.	 Fold	 changes	 represent	 mean	 values	 of	
triplicate	 analyses	of	DOX-treated	versus	untreated	 cells	 and	 error	
bars	represent	standard	deviations.	
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RKO	cells	showed	p53-dependent	induction	of	CST5	after	induction	of	DNA	damage	
by	 Etoposide	 (Fig.	 47B).	 The	 p53-dependent	 induction	 of	 p21	 mRNA	 was	 more	
pronounced	 than	 the	 induction	 of	 CST5	 expression	 in	 RKO	 and	 HCT116	 cells											
(Fig.	47C,	D).	Taken	together,	these	results	show	that	p53	mediates	the	induction	of	
CST5	by	DNA	damage.		
	
	
Figure	47:	p53-dependent	regulation	of	CST5	 in	HCT116	and	RKO	cells.	(A,	B)	CST5-	and	(C,	D)	p21-
mRNA	 levels	were	measured	by	qPCR	analysis	after	 the	 indicated	 time	points.	 (A,	C)	HCT116	p53-/-	
and	 p53	 +/+	 and	 (B,	 D)	 RKO	 p53+/+	 and	 p53-/-	 were	 treated	with	 Nutlin-3a	 or	 Etoposide	 and	 the	
vehicle	 DMSO.	 Fold	 changes	 represent	 mean	 values	 of	 triplicate	 analyses	 of	 Nutlin-3a/Etoposide	
versus	DMSO	treated	cells	normalized	to	𝛽-actin	expression.	Error	bars	represent	standard	deviations.	
	
5.3.2	CST5	is	a	direct	p53	target	
In	a	genome-wide	p53/ChIP-Seq	analysis	we	had	previously	detected	ChIP-signals	
in	the	vicinity	of	the	CST5	promoter	indicating	direct	p53	binding	(Fig.	48A;	see	5.2).		
A	 sequence	 that	 fits	 well	 to	 the	 p53	 binding	 consensus	 sequence	 [56,	 57]	 was	
identified	 1106	 base-pairs	 upstream	 of	 the	 transcriptional	 start	 site	 (TSS)	 of	 CST5	
underneath	 a	 ChIP-signal	with	 ~10	 reads	 (Fig.	 48A).	 This	 p53	 binding	 element	was	
conserved	between	human	and	rat	(Fig.	48B).	
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p53	binding	at	this	site	was	confirmed	by	qChIP	analysis	in	SW480/pRTR-p53-VSV	
cells	 treated	with	 DOX	 for	 16	 hours,	 whereas	 no	 enrichment	was	 detected	 in	 the	
control	 cell	 line	SW480/pRTR	 (Fig.	49A).	After	DNA	damage	 induced	by	addition	of	
Etoposide,	 HCT116	 p53+/+,	 but	 not	 HCT116	 p53-/-	 cells,	 displayed	 increased	 p53	
occupancy	 at	 this	 site	 (Fig.	 49B).	 Therefore,	 also	 endogenous	 p53	 occupied	 these	
binding	 sites.	 Together	 with	 the	 results	 presented	 above,	 these	 findings	 establish	
CST5	as	a	direct	transcriptional	target	of	p53.	
	
	
				
	
	
	
	
	
	
	
	
	
	
	
Figure	49:	Experimental	validation	of	p53	binding	upstream	of	the	CST5	promoter.	(A)	qChIP	analysis	
of	 SW480/pRTR-p53-VSV	 cells	 16	 hours	 after	 activation	 of	 p53-VSV	 expression	 versus	 SW480/pRTR	
cells	using	anti-VSV	and	anti-rabbit	IgG	for	ChIP.	Experiments	were	performed	in	triplicates.	Error	bars	
represent	+/-	 SD	 (n	=	3).	 (B)	qChIP	analysis	of	HCT116	p53+/+	versus	HCT116	p53-/-	after	16	hours	
Etoposide	treatment	using	anti-p53	and	anti-mouse	IgG	for	ChIP;	this	ChIP	analysis	was	performed	in	
unicates	and	measured	in	triplicates.		
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Figure	 48:	 Direct	 binding	 of	 p53	
upstream	 of	 the	 CST5	 promoter.	
(A)	 ChIP-Seq	 analysis	 was	
performed	 with	 a	 VSV-specific	
antibody	16	hours	after	addition	of	
DOX	to	SW480/pRTR-p53-VSV	and	
SW480/pRTR	 cells.	 The	 ChIP-Seq	
results	 are	 represented	 in	 the	
UCSC	 browser	 showing	 p53	
binding	 to	 the	 indicated	 p53	
binding	 site	 in	 a	 region	 1106	 bp	
upstream	 of	 the	 CST5	 promoter.	
(B)	 p53	 binding	 site	 upstream	 of	
the	 CST5	 locus	 of	 Rattus	
norvegicus.	 BS	 =	 binding	 site,													
CBS	=	consensus	binding	site.	
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5.3.3	Role	of	CST5	in	p53-mediated	MET	
In	order	to	determine	the	requirement	of	CST5	for	p53-mediated	mesenchymal-
epithelial	 transition	 (MET)	 and	 related	 processes,	 such	 as	 cellular	 migration,	 we	
silenced	 CST5	 expression	 in	 the	 colorectal	 cancer	 cell	 line	 SW480/pRTR-p53-VSV	
using	siRNAs	(Fig.	50).	After	treatment	with	a	CST5-directed	siRNA	CST5	protein	was	
undetectable	after	induction	of	ectopic	p53	expression	(Fig.	50A).	In	the	presence	of	
CST5	 silencing	 the	p53-mediated	 repression	of	 SNAIL	 protein	was	 less	 pronounced	
than	in	cells	transfected	with	control	siRNAs.	The	same	effect	was	observed	on	the	
level	of	mRNA	expression	(Fig.	50B).		
	
	
Figure	50:	Knock-down	of	CST5	leads	to	reduced	repression	of	SNAIL	after	ectopic	p53	expression	in	
SW480/pRTR-p53-VSV	cells.	SW480/pRTR-p53-VSV	cells	were	transfected	with	a	CST5-specific	siRNA	
or	a	control	oligonucleotide	for	72	hours	and	treated	with	DOX	for	the	last	48	hours.	(A)	Western	blot	
analysis	of	the	indicated	proteins.	ß-actin	served	as	a	loading	control.	(B)	The	indicated	mRNAs	were	
measured	by	qPCR-analysis.	ß-actin	served	as	a	normalization	control.	Fold	changes	represent	mean	
values	of	triplicate	analyses	and	error	bars	represent	standard	deviations.	The	relative	p53-mediated	
repression	of	SNAIL	is	indicated.	Error	bars	represent	+/-	SD	(n	=	3).	
	
	
Subsequently,	we	determined	whether	down-regulation	of	CST5	 influences	p53-
mediated	inhibition	of	cellular	migration	in	a	scratch/	wound-closure	assay	and	in	a	
Boyden-chamber	assay		(Fig.	51).	When	CST5	was	silenced	by	siRNAs,	wound	closure	
of	SW480/pRTR-p53-VSV	cells	was	generally	 less	suppressed	by	p53	than	in	control	
cells	 (Fig.	 51A,	B).	Also	 in	 a	Boyden-chamber	assay	a	 reduction	 in	 the	 inhibition	of	
migration	 by	 p53	 after	 treatment	 with	 siCST5	 was	 observed	 (Fig.	 51C).	 Taken	
together,	 these	 results	 show	 that	 the	 induction	of	 CST5	by	 p53	 contributes	 to	 the	
inhibition	of	migration	by	p53.		
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5.3.4	Combined	treatment	with	calcitriol	and	DOX	enhances	CST5	induction		
Recently,	the	active	metabolite	of	vitamin	D3,	calcitriol	(1,25(OH)2D3),	was	shown	
to	 induce	 CST5	 expression	 in	 colorectal	 cancer	 cells	 [200].	 To	 examine	 whether	 a	
combination	 of	 p53	 activation	 and	 treatment	with	 calcitriol	 leads	 to	 an	 enhanced	
CST5	induction,	we	treated	the	colorectal	cancer	cell	line	SW480/pRTR-p53-VSV	with	
DOX,	calcitriol	or	both	agents	(Fig.	52).		
	
	
	
Figure	 52:	 p53	 activation	 in	 combination	 with	 calcitriol	 treatment	 enhances	 CST5	 induction	 on	
mRNA	 level.	 SW480/pRTR-p53-VSV	 cells	 were	 treated	 with	 DOX,	 calcitriol	 or	 both	 agents	 for	 the	
indicated	timepoints.	(A)	The	indicated	mRNAs	were	measured	by	qPCR-analysis.	β-actin	served	as	a	
normalization	control.	Fold	changes	represent	mean	values	of	triplicate	analyses	of	DOX	/	calcitriol	/	
DOX	 +	 calcitriol	 treatment	 versus	 vehicle	 treated	 cells	 normalized	 to	 β-actin	 expression.	 Error	 bars	
represent	standard	deviations	(n	=	3).	
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Figure	 51:	 CST5	 knock-down	 results	 in	
reduced	 repression	 of	 migration	 after	
ectopic	 expression	 of	 p53	 in	
SW480/pRTR-p53-VSV	 cells.	 Wound-
healing	 assay	 using	 Ibidi-Inlets.														
(A)	 Representative	 pictures	 of	 the	
wound	 area	 obtained	 48	 hours	 after	
scratching.	100	x	magnification.	(B)	Left:	
Average	 [%]	 of	 the	 closed	 wound	 area	
determined	 by	 the	 final	 width	 of	 the	
scratch	 in	 three	 independent	 wells.	
Right:	 The	 relative	 p53-mediated	
inhibition	of	wound-closure.	 (C)	Boyden	
chamber-assay	 of	 cellular	 migration.	
Left:	The	relative	migration	through	the	
filter	 with	 the	 untreated	 control	 set	 as	
one.	 Right:	 The	 relative	 p53-mediated	
inhibition	of	migration.	(B,	C):	Error	bars	
represent	+/-	SD	(n	=	3).	
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As	shown	before,	induction	of	ectopic	p53	expression	led	to	a	robust	increase	in	
CST5	 expression	 on	 mRNA	 level	 (Fig.	 52).	 Calcitriol	 treatment	 alone	 resulted	 in	 a	
comparatively	minor	induction	in	CST5	expression,	whereas	the	combination	of	DOX	
and	calcitriol	 led	to	significantly	higher	CST5	mRNA	levels	when	compared	to	single	
DOX	 or	 calcitriol	 treatments.	 Furthermore,	 CST5	 protein	 induction	 was	 more	
pronounced	 after	 combined	 activation	 of	 p53	 and	 the	 VDR	 when	 compared	 to	
addition	of	DOX	or	calcitriol	alone	(Fig.	53).	In	addition,	the	EMT	transcription	factor	
SNAIL	displayed	a	stronger	decrease	on	the	mRNA	and	protein	level	after	a	combined	
treatment	with	DOX	and	calcitriol	when	compared	 to	each	 stimulus	alone	 (Fig.	52,	
53).	
		
	
	
	
	
	
	
	
	
	
	
5.3.5	Opposing	regulation	of	CST5	by	SNAIL	and	VDR	activation	
Since	we	had	observed	that	VDR	activation	via	calcitriol	results	in	the	repression	
of	 SNAIL,	 we	 asked	 whether	 conversely	 SNAIL	 may	 directly	 or	 indirectly	 lead	 to	
repression	 of	 CST5	 as	 part	 of	 a	 SNAIL-induced	 EMT	 program.	 Indeed,	CST5	 mRNA	
levels	 decreased	 by	 up	 to	 80%	 after	 induction	 of	 SNAIL	 by	 DOX	 treatment	 in	
SW480/pRTR-SNAIL-VSV	 cells	 (Fig.	 54).	 Expectedly,	 SNAIL	 mRNA	 levels	 were	 up-
regulated.	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	54:	CST5	 expression	 after	 SNAIL	 induction.	CST5	and	SNAIL	mRNA	 levels	were	measured	by	
qPCR	analysis	after	treatment	with	DOX	at	the	indicated	time	points	in	SW480/pRTR-SNAIL-VSV	cells.	
Fold	changes	represent	mean	values	of	triplicate	analyses	after	DOX	treatment	versus	vehicle	treated	
cells	normalized	to	β-actin	expression.	Error	bars	represent	standard	deviations	(n	=	3).	SW480/pRTR-
SNAIL-VSV	cells	were	generated	by	Dr.	Helge	Siemens.	
		
	
- CST5
0     24    48    72      0    24   48    72     0     24    48   72     hrs  
DOX Calcitriol DOX + Calcitriol
SW480/pRTR-p53-VSV
- p53-VSV
- β-actin
- SNAIL
Figure	 53:	 p53	 activation	 in	
combination	 with	 calcitriol	
treatment	 enhances	 CST5	
induction	 on	 protein	 level.	
SW480/pRTR-p53-VSV	were	treated	
with	 	DOX,	calcitriol	or	both	agents	
for	 the	 indicated	 timepoints.	
Western	 blot	 analysis	 of	 the	
indicated	 proteins.	 β-actin	 served	
as	a	loading	control.	
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To	determine	whether	this	repression	is	mediated	directly	by	SNAIL	occupancy	at	
the	CST5	promoter,	we	inspected	this	region	for	E-boxes,	which	may	mediate	SNAIL	
binding.	 We	 identified	 several	 E-boxes	 upstream	 of	 the	 CST5	 promoter	 and	
confirmed	the	direct	binding	of	SNAIL	to	an	E-box,	which	is	located	50	bp	upstream	
of	the	CST5	promoter,	using	qChIP	analysis	(Fig.	55A,	B).	The	SNAIL	binding	site	in	the																			
E-cadherin/CDH1	promoter	served	as	a	positive	control	(Fig.	55B).			
	
	
Figure	55:	SNAIL	directly	targets	CST5.	(A)	Schematic	SNAIL	binding	site	50	bp	upstream	of	the	CST5	
transcriptional	start	site.	(B)	qChIP	analysis	of	DLD1/pRTR-SNAIL-VSV	cells	24	hours	after	activation	of	
SNAIL-VSV	 expression	 by	 addition	 of	 DOX	 using	 anti-VSV	 and	 anti-rabbit	 IgG	 for	 ChIP;	 this	 ChIP	
analysis	was	performed	in	unicates	and	measured	in	triplicates.	
	
Next,	 we	 assessed	 the	 combined	 effect	 of	 SNAIL	 activation	 with	 calcitriol	
treatment	in	SW480/pRTR-SNAIL-VSV	cells	(Fig.	56).	When	ectopic	SNAIL	expression	
was	combined	with	calcitriol	treatment,	CST5	was	no	longer	repressed	by	SNAIL	but	
showed	 a	 five-fold	 induction.	 Treatment	 with	 calcitriol	 alone	 led	 to	 a	 robust	
induction	 of	 CST5,	 whereas	 SNAIL	 mRNA	 levels	 were	 not	 affected.	 Therefore,	
induction	 of	CST5	expression	 by	VDR	 activation	 is	 dominant	 over	 its	 repression	 by	
SNAIL.	This	may	at	least	partially	explain	the	effect	of	vitamin	D3	in	the	treatment	of	
cancer.			
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Figure	 56:	 Calcitriol	 treatment	 prevents	 SNAIL-
mediated	 repression	 of	 CST5.	 CST5	 and	 SNAIL	
mRNA	 levels	 were	 measured	 by	 qPCR	 analysis	
after	treatment	with	DOX,	calcitriol	or	both	agents	
at	 the	 indicated	 time	 points	 in	 SW480/pRTR-
SNAIL-VSV	 cells.	 Fold	 changes	 represent	 mean	
values	 of	 triplicate	 analyses	 of	 DOX	 /	 calcitriol	 /	
DOX+calcitriol	 treatment	 versus	 vehicle	 treated	
cells	 normalized	 to	 β-actin	 expression.	 Error	 bars	
represent	 standard	 deviations	 (n	 =	 3).	 SW480/	
pRTR-SNAIL-VSV	cells	were	generated	by	Dr.	Helge	
Siemens.	
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6.	DISCUSSION	
	
6.1	p53-induced	miR-34	targets	SNAIL	to	repress	EMT	and	stemness	
The	miR-34	family,	 including	miR-34a/b/c,	were	the	first	miRNA	encoding	genes	
that	were	shown	to	be	directly	 induced	by	p53	[89,	90,	92-94].	Since	then,	a	 lot	of	
different	targets	of	miR-34a	have	been	identified	and	validated	[86,	96,	217].	As	part	
of	this	thesis,	we	investigated	the	importance	of	miR-34	as	a	downstream	effector	of	
p53´s	tumor	suppressive	functions	and	showed	that	the	induction	of	MET	by	p53	is	
mediated	by	miR-34a.	Additionally,	we	demonstrated	that	SNAIL	is	a	direct	miR-34a	
target	 and	 identified	 a	double-negative	 feedback	 loop	between	miR-34	and	 SNAIL.	
The	down-regulation	of	SNAIL	shifted	the	cells	towards	an	epithelial	state	and	led	to	
reduced	expression	of	stemness	factors.	Furthermore,	 invasion	and	migration	were	
down-regulated	 in	 a	 miR-34	 dependent	 manner	 and	 the	 expression	 of	 stemness	
markers	such	as	BMI1,	CD44,	c-Myc,	OLFM4	or	CD133	was	decreased	after	ectopic	
miR-34	expression.	Our	findings	are	illustrated	in	Figure	57.	
	
	
Figure	57:	Two	double-negative	feedback	loops	that	control	cellular	plasticity. Model	of	the	findings	
published	 in	 [1]	 combined	 with	 previous	 results	 concerning	 the	 p53/miR-200/ZEB1/2	 axis	 [97,	 98,	
245].	The	p53-induced	miRNAs	miR-34a/b/c	and	miR-200	and	the	TGF-β	induced	transcription	factors	
SNAIL	and	ZEB1/2	form	a	double-negative	feedback	loop	to	control	EMT/MET	and	stemness.		
	
The	 EMT-transcription	 factor	 SNAIL	 has	 been	 shown	 to	 be	 overexpressed	 in	
colorectal	cancer	and	to	be	responsible	for	the	enhanced	invasive	potential	and	self-
renewal	 capacity	 of	 tumor	 initiating	 cells	 [295,	 296].	 It	 has	 been	 demonstrated	 in	
several	studies	that	increased	expression	of	SNAIL	correlates	with	stemness	features	
in	different	 types	of	cancer	 [71,	180,	297-301].	Mani	and	colleagues	demonstrated	
that	high	SNAIL-expression	generates	cells	with	stem	cell-like	properties	by	showing	
that	 the	 number	 of	 mammospheres	 increases	 along	 with	 SNAIL	 expression	 in	
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immortalized	mammary	epithelial	cells	[180].	Furthermore,	colonospheres	that	were	
derived	 from	a	 colorectal	 tumor,	 showed	high	expression	of	 the	EMT-transcription	
factor	 SNAIL	 and	 increased	 formation	 of	 colonospheres	 was	 seen	 in	 human	
colorectal	carcinoma	cell	lines	when	SNAIL	was	ectopically	expressed	indicating	that	
SNAIL	regulates	stem	cell-like	activites	of	cancer	cells	[302].	In	addition,	high	nuclear	
SNAIL	expression	was	observed	in	the	stem	cell	niche	of	the	murine	small	 intestine	
[303].	By	 showing	 that	miR-34	directly	 regulates	SNAIL	 expression	we	unravelled	a	
new	mechanism	 that	 explains	 how	miR-34	 expression	 leads	 to	 reduced	 stemness	
properties	in	colorectal	cancer	cells.		
Apart	 from	 SNAIL,	 multiple	 miR-34	 targets	 were	 shown	 to	 be	 involved	 in	
stemness	regulation.	It	has	been	demonstrated	that	miR-34a	directly	targets	Notch1	
in	 colorectal	 cancer	 stem	 cells	 [304].	 The	 authors	 report	 that	 a	 bimodal	 switch	
between	 miR-34a	 and	 Notch1	 decides	 between	 a	 symmetric	 or	 asymmetric	 cell	
division	 and	 therefore	 leads	 the	 cells	 towards	 self-renewal	 or	 differentiation.	
Differentiated	 cells	 are	 characterized	 by	 increased	 miR-34a-	 and	 low	 Notch1-
expression	 levels	whereas	 colorectal	 cancer	 stem	 cells	 show	 the	 opposite	 pattern,	
i.e.	 low	miR-34a-	 and	 high	 Notch1-levels.	 Furthermore,	 it	 has	 been	 reported	 that	
miR-34a	 represses	 the	 receptor	 tyrosine	 kinase	 c-Kit	 which	 leads	 to	 reduced	
stemness	 and	migration	 in	 colorectal	 cancer	 cells	 [305].	 Additionally,	miR-34a	was	
shown	 to	 repress	ZNF281,	which	was	 demonstrated	 to	 promote	 EMT	 in	 colorectal	
cancer	 cells	 [5].	 Moreover,	 the	 stemness	 marker	 CD44	 was	 shown	 to	 be	 directly	
targeted	by	miR-34a	[250].		
Apart	 from	 the	 direct	 repression,	 there	 are	 several	 indirect	 ways	 as	 to	 how					
miR-34	 might	 negatively	 affect	 SNAIL	 expression.	 miR-200c	 was	 shown	 to	 be	
repressed	 by	 SNAIL	 and	 to	 directly	 target	 the	 polycomb	 repressor	 BMI1	 [181].	
Consequently,	miR-34a-mediated	down-regulation	of	SNAIL	might	lead	to	increased	
miR-200c	 levels	and	reduced	expression	of	BMI1.	Moreover,	SNAIL	 functions	might	
be	 affected	 by	 HDAC1	 that	 was	 recently	 described	 as	 a	 miR-34a	 target	 and	 as	 a	
cofactor	of	SNAIL	in	E-cadherin	repression	[217,	306,	307].		
Besides	 down-regulating	 stemness	 factors	 and	 inhibiting	 EMT,	miR-34	 controls	
numerous	other	cancer-relevant	pathways	and	processes.	It	has	been	demonstrated	
that	 miR-34	 negatively	 affects	 cell	 cycle	 progression,	 enhances	 apoptosis	 and	
regulates	 the	 metabolic	 switch	 to	 aerobic	 glycolysis	 also	 known	 as	 the	 Warburg	
effect	 (reviewed	 in	 [96]).	 SNAIL-mediated	 repression	of	miR-34,	may	 therefore	not	
only	lead	to	enhanced	invasion,	migration	and	stemness	features	but	also	to	a	loss	of	
cell	cycle	control,	enhanced	aerobic	glycolysis	and	decreased	apoptosis.		
Apart	 from	 miR-34,	 p53	 controls	 EMT	 and	 stemness	 via	 multiple																		
miRNA-mediated	 regulations	 including	 miR-145,	 the	 miR-200	 family	 and	 miR-15a/	
16-1	 [97,	 110,	 308].	 Furthermore,	 mutant	 p53	 was	 shown	 to	 gain	 oncogenic	
functions	by	inducing	miR-130b,	a	repressor	of	ZEB1,	to	promote	mesenchymal	traits	
[309].		
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Besides	miRNA-mediated	 regulations,	p53	has	been	shown	to	 regulate	 invasion	
via	 the	MDM2-mediated	 degradation	 of	 SLUG	 in	 non-small	 cell	 lung	 cancer	 [248].	
The	authors	showed	that	mutant	p53	represses	MDM2	expression	which	results	 in	
increased	SLUG	levels.	Similar	to	this	finding,	p53	decreases	SNAIL	protein	levels	via	
MDM2-mediated	 proteasomal	 degradation	 [310].	 Moreover,	 CXCR4,	 a	 chemokine	
receptor	 that	 is	 involved	 in	 metastasis	 of	 breast	 cancer	 cells,	 was	 shown	 to	 be	
repressed	by	p53	[311].		
Similar	 to	 our	 results,	 a	 double-negative	 feedback	 loop	 between	 the	 p53-
controlled	 miR-200	 family	 and	 the	 EMT	 transcription	 factors	 ZEB1	 and	 ZEB2	 was	
already	 described	 [97,	 98,	 245].	 Based	 on	 a	 bioinformatically	 derived	 hypothetical	
model,	 Lu	 and	 colleagues	 suggested	 that	 the	 determination	 of	 a	 mesenchymal,	
epithelial	or	a	mixed	phenotype	mainly	depends	on	these	two	highly	interconnected	
circuits,	the	miR-34/SNAIL	and	the	miR-200/ZEB1/2	double-negative	feedback	loops	
[312].	 They	 proposed	 that	 the	 miR-200/ZEB1/2	 circuit	 acts	 as	 a	 ternary	 switch	
between	 the	 three	 phenotypes	 and	 that	 the	 miR-34/SNAIL	 loop	 functions	 as	 a	
module	 integrating	 internal	 and	 external	 signals.	 In	 addition,	 another	 double-
negative	feedback	loop	between	SNAIL	and	the	tumor	suppressive	miR-203,	which	is	
post-transcriptionally	 induced	 by	 p53	 through	 p53´s	 interaction	 with	 the	 Drosha	
complex	[126],	was	shown	to	regulate	EMT	[313].	Moreover,	the	p53-target	miRNAs	
miR-15a/16-1	 have	 recently	 been	 demonstrated	 to	 directly	 suppress	 the	 c-MYC	
induced	 EMT-transcription	 factor	 AP4,	 that	 was	 shown	 to	 directly	 induce	 the	
expression	 of	 SNAIL	 and	 to	 repress	miR-15a/16-1	 expression	 [109,	 110,	 220].	 The	
present	results	add	another	p53-controlled	and	miRNA-mediated	negative	feedback	
loop	to	the	complex	network	of	p53´s	transcriptional	control	and	suggest	that	a	loop-
like	 regulation	 of	 gene	 expression	 is	 a	 mechanism	 widely	 applied	 by	miRNAs	 and	
their	respective	targets.		
The	 described	 double-negative	 feedback	 loops	 demonstrate	 the	 importance	 of	
epithelial-mesenchymal	plasticity.	First,	tumor	cells	need	to	undergo	EMT	in	order	to	
disseminate	 from	 the	 tumor,	 intravasate	 into	 the	 lymph	 or	 bloodstream	 and	
extravasate	at	a	distant	site.	However,	once	settled	down	in	a	distant	organ,	cancer	
cells	 regain	 epithelial	 traits	 during	 mesenchymal-epithelial	 transition,	 a	 process	
necessary	to	proliferate	and	build	micro-	and	macrometastases	[174,	182,	295,	314].	
It	 has	 been	 reported	 that	 the	 same	 epithelial-like	 pattern	 was	 found	 in	 primary	
colorectal	carcinomas	and	the	corresponding	metastases	which	further	confirms	that	
MET	 is	 implicated	 in	 metastasis	 formation	 [315].	 Additionally,	 cells	 that	 have	
undergone	EMT	and	express	high	levels	of	the	EMT	transcription	factor	SNAIL,	show	
decreased	proliferative	potential	with	a	partial	G1/S	cell	cycle	arrest	[316,	317].		
Among	the	important	EMT	transciption	factors	ZEB1/2,	TWIST,	SLUG	and	SNAIL,	
the	 latter	 is	 so	 far	 the	 only	 EMT	 regulator	 that	 is	 directly	 targeted	 by	 miR-34.	
However,	miR-34	may	 indirectly	 influence	the	expression	of	 the	described	miR-200	
targets	 ZEB1/2	 and	 SLUG	 via	 the	 repression	 of	 SNAIL:	miR-34	 targets	 SNAIL	 which	
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results	 in	a	derepression	of	miR-200.	Subsequently,	 increased	miR-200	 levels	might	
lead	to	the	repression	of	ZEB1/2	and	SLUG.	
Due	to	its	diverse	tumor	suppressive	functions	it	is	not	surprising	that	the	miR-34	
family	 is	 permanently	 inactivated	 by	 epigenetic	 silencing	 in	 different	 tumor	 types	
[318-320].	 In	 colorectal	 cancer,	CpG	methylation	 leads	 to	 silencing	of	miR-34b/c	 in	
99%	 and	 of	miR-34a	 in	 74%	 of	 the	 studied	 114	 cases	 [320].	 The	 authors	 report	 a	
significant	 correlation	 between	 miR-34a	 methylation	 and	 the	 absence	 of	 p53	
mutations	 in	 colorectal	 cancer.	 Recently,	 epigenetic	 inactivation	 of	 miR-34a	 in	
combination	with	elevated	SNAIL,	c-Met	and	β-catenin	expression	has	been	shown	
to	be	strongly	associated	with	 liver	metastasis	 in	colon	cancer	 [321].	 In	addition	to	
epigenetic	 silencing,	miR-34a	 resides	 on	 a	 chromosomal	 locus	 that	 is	 frequently	
deleted	 in	 neuroblastoma	 and	 other	 tumor	 types	 [322].	 This	 frequent	 loss	 or	
constriction	 of	 miR-34´s	 function	 as	 a	 tumor	 suppressor	 further	 substantiates	 the	
need	 and	 importance	 for	 establishing	 a	 miRNA	 replacement	 as	 a	 potential	
therapeutic	 approach	 in	 the	 clinic.	 Indeed,	 treatment	 with	 miR-34a	 mimics	 was	
successful	 in	 several	 preclinical	 studies	 [323-325].	 Recently,	 treatment	 with	 a	
liposome	 based	 miR-34	 mimic,	 MRX34	 (developed	 by	Mirna	 Therapeutics),	 led	 to	
decreased	tumor	burden	 in	two	orthotopic	mouse	models	of	 liver	cancer	after	tail-
vein	 injection	 and	 subsequently	 entered	 clinical	 phase	 I	 studies	 in	 patients	 with	
advanced	hepatocellular	carcinoma	[326,	327].			
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6.2	Genome-wide	analysis	of	the	p53-induced	transcriptome	and	proteome		
The	genome-wide	screen	performed	here	led	to	the	identification	of	a	number	of	
p53-regulated	targets	including	miRNAs,	lncRNAs,	mRNAs	and	proteins	(summarized	
in	Figure	58).		
	
Figure	 58:	Schematic	model	 of	 effector	 pathways	 that	mediate	 tumor	 suppression	 by	 p53.	 Upon	
activation,	regulates	the	transcription	of	mRNAs	that	encode	proteins	and/or	non-coding	RNAs,	such	
as	miRNAs	 and	 lncRNAs.	 p53	mainly	 acts	 as	 a	 transcriptional	 activator	 and	 to	 a	minor	 extent	 as	 a	
transcriptional	repressor.	In	addition,	p53	indirectly	regulates	numerous	effectors,	for	example	E2F	or	
MCM	complex	components	via	 its	direct	target	genes,	such	as	p21	and	miR-34a.	Moreover,	there	 is	
extensive	crosstalk	between	direct	and	indirect	p53	targets.	The	differential	expression	of	direct	and	
indirect	 p53	 targets	 leads	 to	 the	 induction	 of	 specific	 cellular	 processes,	 such	 as	 cell-cycle	 arrest,	
apoptosis	or	mesenchymal-epithelial	transition,	which	supress	tumor	progression.	Figure	from	[2].				
	
We	 found	 that	 the	 majority	 of	 the	 down-regulated	 genes	 show	 no	 promoter-
proximal	p53	binding,	which	 indicates	 that	 they	must	be	 regulated	via	 indirect,	 for	
example	 miRNA-mediated	 mechanisms.	 This	 result	 is	 similar	 to	 the	 findings	 of	 a	
previous	 study,	 which	 reported	 that	 only	 ~15%	 of	 the	 known	 and	 validated	 p53	
binding	 sites	 are	 linked	 to	 transcriptional	 repression	 [60].	 Several	 genome-wide	
screens	have	been	conducted	in	the	past	to	identify	p53-regulated	gene	expression	
[65,	 268,	 272,	 273,	 328,	 329].	 Similar	 to	our	 results,	more	 induced	 than	 repressed	
genes	displayed	promoter-proximal	p53	binding	 [65,	 204,	 268,	 273].	 Similar	 to	our	
results,	 Nikulenkov	 and	 colleagues	 showed	 that	 the	 p53	 binding	 motif	 associated	
with	 up-	 and	 down-regulated	 target	 genes	 only	 showed	minor	 differences	 [65].	 A	
recent	 computational	 meta-analysis	 based	 on	 the	 results	 of	 several	 genome-wide	
studies	 even	 reported	 that	 p53	 binding	 to	 its	 consensus	 elements	 only	 results	 in	
transcriptional	activation	and	that	transcriptional	repression	by	p53	solely	occurs	via	
indirect	mechanisms	[204].	The	authors	re-analyzed	different	p53	targets	that	were	
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reported	to	be	repressed	via	direct	p53-binding	but	could	not	confirm	these	results.	
Furthermore,	they	showed	that	 indirect	p53-mediated	repression	mainly	occurs	via	
p21-DREAM	and	E2F/RB	complex	formation	at	promoters.	
Our	 results	 demonstrate	 that	 the	 consensus	 binding	 motif	 of	 the	 GATA1	
transcription	factor	is	present	in	a	significant	number	of	p53-bound	and	up-regulated	
genes.	Transcription	factors	of	the	GATA	family	activate	and	repress	transcription	of	
their	 targets	 and	 are	 known	 to	 have	 both,	 oncogenic	 and	 tumor-suppressive	
functions	 (reviewed	 in	 [330]).	 GATA1,	 for	 example,	 is	 known	 to	 control	 erythroid-
specific	 genes	 but	 has	 also	 been	 observed	 to	 control	 cellular	 proliferation	 by	
silencing	the	proto-oncogenes	Kit,	Myc	and	Myb	during	erythroid	maturation	 [331-
333].	However,	GATA1	may	interact	with	the	transactivation	domain	of	p53	to	inhibit	
p53´s	function	[334]	and	activate	the	expression	of	the	anti-apoptotic	gene	Bcl-xL	in	
erythroid	 cells	 [335].	 Furthermore,	 the	 GATA1	 motif	 is	 enriched	 near	 p53	 REs	 in	
response	to	genotoxic	stress	 [272].	 In	addition,	GATA3	has	opposing	 functions	 that	
seem	to	be	highly	context-dependent.	It	partly	reverses	EMT	in	a	breast	cancer	cell	
line	by	 inducing	 E-cadherin	 and	 inhibiting	N-cadherin	 and	 vimentin	 [336],	 but	may	
indirectly	increase	the	expression	of	Myc	[337].	How	GATA1	binding	in	the	vicinity	of	
p53	binding	 sites	of	 induced	genes	 influences	 their	expression	needs	 to	be	 further	
investigated.	Another	study	showed	that	distal	enhancer-activity	might	be	important	
for	p53-mediated	repression	in	mouse	embryonic	stem	cells	[338].	This	shows	that	in	
addition	 to	 direct	 binding	 of	 p53	 to	 p53	 response	 elements,	 many	 other	 indirect	
mechanisms	are	relevant	for	p53-mediated	gene	repression	(reviewed	in	[60]).	
The	 results	 presented	 here	 indicate	 that	 besides	 p53-mediated	 repression	 via	
direct	binding	to	p53	response	elements,	many	other	indirect	e.g.	miRNA-mediated	
mechanisms	 are	 relevant	 for	 p53-mediated	 gene	 repression	 (reviewed	 in	 [60]).	 In	
fact,	 different	 examples	 of	 miRNA-mediated	 gene	 repression	 by	 p53	 are	 known	
[339].	 By	 directly	 inducing	 miR-34a,	 p53	 down-regulates	 genes	 with	 oncogenic	
functions	 like	 SNAIL	 [1,	 98]	 or	 ZNF281	 [5],	 thereby	 inducing	 MET	 (mesenchymal-
epithelial	 transition).	 Moreover,	 our	 data	 indicate	 that	 the	 p53-mediated	
transcriptional	 repression	 may	 involve	 a	 combination	 of	 different	 mechanisms	 as	
shown	 in	 this	 study	 for	 the	 known	 miR-34a	 target	MTA2	 [217].	 Apart	 from	 the	
miRNA-mediated	 repression	 by	 miR-34a,	MTA2	 also	 shows	 p53	 occupancy	 in	 the	
vicinity	of	 its	 transcriptional	 start	 site	 that	may	additionally	mediate	 its	 repression.	
This	 indicates	 that	 the	 different	mechanisms	 for	 p53-mediated	 repression	 are	 not	
mutually	 exclusive.	 This	 is	 also	 in	 accordance	 with	 previous	 studies	 showing	 that							
c-Myc	 is	repressed	by	direct	transcriptional	repression	by	p53	as	well	as	by	miRNA-
mediated	mechanisms	of	the	p53-induced	miRNA	miR-145	[68,	106].		
In	our	study	we	confirmed	several	p53	target	genes	that	were	already	described	
to	 be	 directly	 regulated	 by	 p53,	 such	 as	 CDKN1A,	 BAX,	DDB2,	 RPS27L,	 RRM2B	 or	
SERPINE1.	However,	some	known	p53	target	genes	were	not	detected	in	our	study.	
Since	 p53	 target	 genes	 have	 different	 expression	 kinetics	 [340,	 341],	 some	 direct	
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targets	 might	 not	 have	 been	 detected	 at	 the	 specific	 time	 point	 selected	 in	 this	
study.	 Moreover,	 pSILAC	 might	 not	 detect	 all	 cellular	 proteins	 since	 insufficient	
labelling	with	Arg	and	Lys	misses	certain	proteins.		
Moreover,	we	detected	several	new	p53-regulated	miRNA-,	 lncRNA	and	protein-
encoding	 genes.	 We	 identified	miR-486	 as	 a	 direct	 p53-induced	 target	 gene.	 This	
potentially	tumor-suppressive	miRNA	has	been	shown	to	target	the	stem	cell	marker	
OLFM4	 in	 gastric	 cancer	 [342]	 and	 ARHGAP5,	 a	 protumorigenic	 member	 of	 the	
RhoGAP	 family,	 in	 lung	 cancer	 [263],	 thereby	 negatively	 regulating	 tumor	
progression.	 In	addition,	miR-486-5p	was	shown	to	target	PIM-1	 in	breast	and	 lung	
cancer	cells	suppressing	cell	proliferation	[343,	344].	Moreover,	miR-486-5p	is	down-
regulated	 in	hepatocellular	carcinoma	where	 it	suppresses	tumor	growth	by	down-
regulating	p85α	 [345].	 In	 addition,	we	detected	miR-205	 to	be	directly	 induced	by	
p53.	Recently,	miR-205	was	described	as	a	p53-induced	miRNA	in	a	breast	cancer	cell	
line	and	a	p53	RE	1	kbp	upstream	of	the	pre-miR	genomic	sequence	was	suggested	
[262].	 Additionally,	 miR-205	 was	 shown	 to	 inhibit	 EMT	 by	 targeting	 ZEB1	 and	
ZEB2/SIP1	 [97].	Here	we	 identifed	a	p53	binding	sequence	17	kbp	upstream	of	 the	
miR-205	 host	 gene	 in	 the	 colorectal	 cancer	 cell	 line	 SW480	 and	 validated	 p53	
occupancy	at	this	motif.	
Furthermore,	 we	 identified	 several	 putatively	 p53-regulated	 lncRNAs	 and	
determined	an	anti-proliferative	effect	of	the	newly	identified	p53	target	LINC01021.	
In	 addition,	 the	 lncRNA	 lnc-H6PD-1	 (RP3-510D11.2),	 which	 is	 transcribed	 from	 the	
miR-34a	 promoter	 but	 in	 the	 opposite	 direction	 than	MIR-34a,	 was	 induced	 and	
directly	bound	by	p53	at	its	promoter	after	p53	activation.	This	type	of	regulation	is	
similar	to	the	recently	identified	 lincRNA-p21,	which	is	located	upstream	of	the	p53	
target	gene	p21/CDKN1A	[153].		
A	recent	genome-wide	analysis	unveiled	a	p53-specific	lncRNA	tumor	suppressor	
signature	 in	 a	 colorectal	 cancer	 cell	 line	 [346].	 The	 authors	 show	 that	 18	different	
lncRNAs	 are	 transcriptionally	 controlled	 by	 p53	 and	 demonstrate	 that	 two	 out	 of	
those	 lncRNAs	 contribute	 to	 p53´s	 ability	 to	 bind	 to	 some	 of	 its	 target	 genes.	
However,	 there	 is	 no	 overlap	 with	 our	 results,	 presumably	 due	 to	 different	
approaches	and	cell	lines	that	were	used.	Several	studies	revealed	that	lncRNAs	have	
important	 functions	 during	 tumorigenesis	 [347].	 Moreover,	 lncRNAs	 offer	 an	
important	 advantage	 over	 protein-coding	 genes:	 they	 show	 a	 highly	 tissue-	 and	
tumor	type-specific	expression	pattern	suggesting	that	they	may	represent	superior	
biomarkers.	For	example,	the	lncRNAs	PCA3	and	HULC	are	used	for	the	detection	of	
prostate	 and	 hepatocellular	 carcinoma,	 respectively	 [348-350].	 lncRNA-based	
therapies	 are	 only	 in	 the	 early	 steps	 of	 development	 and	 far	 from	 a	 clinical	 use.	
RNAi-based	therapies	targeting	protein-coding	mRNAs	are	currently	tested	in	clinical	
trials	 and	 could	 potentially	 be	 applied	 for	 non-coding	 RNAs	 as	 well	 [351,	 352].	
Additionally,	antisense	oligonucleotides	or	 (deoxy-)	 ribozymes	might	be	applied	 for	
targeting	 lncRNAs	 in	 case	 a	 siRNA-targeted	 approach	 is	 not	 applicable	 due	 to	 an	
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intensive	secondary	structure	or	an	unfavourable	nucleotide	sequence	of	the	lncRNA	
[353].	
In	addition	to	non-protein	coding	genes,	we	identified	numerous	protein-coding	
direct	 p53	 target	 genes.	 Several	 of	 the	 detected	 genes	 have	 known	 tumor	
suppressive	 functions:	 RASAL1	 for	 example,	 a	 transcriptional	 target	 of	 the	 tumor	
suppressor	 PITX1,	 suppresses	 RAS	 activity	 in	 colon	 cancer	 cells	 [354].	 In	 addition,	
decreased	RASAL1	protein	 levels	 are	 associated	with	 colorectal	 cancer	progression	
[355].	Moreover,	RASAL1	 is	 hypermethylated	 in	 gastric	 and	 thyroid	 cancer	 and	 its	
overexpression	inhibits	the	proliferation	and	transformation	ability	of	gastric	cancer	
cells	[356-360].	Recently	it	was	shown	that	RASAL1	inhibits	gastric	carcinogenesis	in	
nude	 mice	 by	 blocking	 RAS/ERK	 signaling	 [361].	 Moreover,	 we	 identified	 and	
confirmed	ST14	as	new	p53	target	gene.	ST14	was	shown	to	exert	tumor-suppressive	
functions	 in	 inflammation-associated	 colon	 carcinogenesis	 [362].	 In	 addition,	 ST14	
exerts	an	inhibitory	effect	on	cell	growth	in	human	breast	cancer	cells	[363].	MDFI,	
which	was	also	experimentally	confirmed	as	a	new	p53-regulated	target	gene	in	this	
study,	 is	a	candidate	tumor	suppressor	gene	that	 is	highly	methylated	 in	colorectal	
cancer	 and	 pancreatic	 adenocarcinoma	 [364,	 365].	 Furthermore,	 we	 identified	
DHRS2,	which	 encodes	 a	mitochondrial	 protein	 that	 –	 similar	 to	 p14ARF	 –	 inhibits	
MDM2	 which	 leads	 to	 the	 stabilization	 of	 p53	 [366].	 Another	 new	 p53	 target,	
DENND2D,	inhibits	proliferation	and	tumorigenicity	of	non-small	cell	lung	cancer	and	
is	 hypermethylated	 in	 hepatocellular	 and	 squamous	 cell	 carcinoma	 [367-369].	 The	
identified	p53-regulated	gene	TGFBI	seems	 to	have	opposing	 functions	 in	different	
tumor	 types.	 In	 mesothelioma	 and	 breast	 cancer	 it	 is	 associated	 with	 tumor	
suppression	[370,	371].	In	addition,	it	decreases	the	metastatic	potential	of	lung	and	
breast	 cancer	 cells	 [372]	 and	 its	 expression	 positively	 correlates	 with	 a	 better	
response	to	chemotherapy	in	non-small	cell	lung	cancer	[373].	Moreover,	TGFBI	was	
shown	to	function	as	a	tumor	suppressor	in	mice	[374].	However,	TGFBI	expression	
promotes	 metastasis	 and	 is	 associated	 with	 poor	 prognosis	 in	 colorectal	 cancer	
patients	[375,	376]	and	induces	invasion	in	melanoma	cells	[377].	LOXL4,	which	was	
up-regulated	 and	 directly	 bound	 by	 p53,	 is	 hypermethylated	 in	 human	 bladder	
cancer	[378]	but	has	tumor-promoting	functions	in	gastric,	breast	and	head	and	neck	
cancer	[379-382].	Furthermore,	LRIG3	inhibits	growth	and	invasion	in	bladder	cancer	
cells	but	promotes	cell	cycle	arrest	and	apoptosis	in	glioma	cells	[383-385].		
We	 also	 detected	 a	 small	 number	 of	 directly	 regulated	 p53	 target	 genes	 that	
showed	 decreased	 expression	 on	 the	 level	 of	de	 novo	 protein	 synthesis	 after	 p53	
activation.	One	of	these	genes	was	NELL2.	Interestingly,	NELL2	has	cancer-promoting	
functions	 in	 human	 breast	 cancer	 cells	 and	 is	 transcriptionally	 regulated	 by	 E2F1	
[386].	Moreover,	NELL2	 is	 a	 target	 of	miR-22,	which	 is	 induced	by	 vitamin	D3	 and	
inhibits	 proliferation	 and	 migration	 [387].	 Another	 down-regulated	 direct	 target	
identified	 in	 this	 study,	 Neuropilin-2	 (NRP2),	 is	 up-regulated	 in	 lung	 cancer	 cells	
[388],	 promotes	 EMT	 in	 colorectal	 cancer	 cells	 [389]	 and	 was	 also	 shown	 to	
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contribute	 to	 tumorigenicity	 in	 vivo	 [390].	 FGF9,	 which	 was	 down-regulated	 and	
showed	 promoter-proximal	 p53-binding	 in	 our	 study,	 is	 overexpressed	 in	 colon	
cancer	cells	and	is	associated	with	EMT	in	prostate	cancer	cells	[391,	392].	Moreover,	
FGF9	 expression	 positively	 correlates	 with	 poor	 prognosis	 in	 non-small	 cell	 lung	
cancer	patients	[393].	
In	 addition	 to	 direct	 targets,	we	 identified	many	 indirect	 target	 genes	 that	 are	
predicted	to	be	regulated	by	one	or	several	of	the	miRNAs	directly	induced	by	p53.	
We	confirmed	that	HMGB1	is	down-regulated	by	the	p53-inducible	miR-205.	HMGB1	
promotes	 invasion,	 metastasis	 and	 angiogenesis	 in	 different	 cancer	 types,	 inhibits	
antitumor	 immunity	and	represents	a	possible	cancer	therapeutic	target	[394-396].	
Furthermore,	p53	interacts	with	the	transcription	factor	CTF2	and	thereby	indirectly	
down-regulates	 HMGB1	 expression	 [397].	 Furthermore,	 it	 has	 been	 shown	 that	
direct	 molecular	 interactions	 between	 HMGB1	 and	 p53	 regulates	 the	 balance	
between	 apoptosis	 and	 autophagy	 in	 colorectal	 cancer	 cells	 [398].	 In	 p53-/-	 cells,	
HMGB1	 is	 required	 for	 autophagy	 and	 knockdown	 of	HMGB1	 results	 in	 increased	
apoptosis	and	decreased	autophagy.	Because	autophagy	is	important	for	resistance	
to	chemo-	and	radiation	therapy,	HMGB1	might	represent	an	attractive	therapeutic	
target	 in	 p53-deficient	 cells	 [399].	 In	 addition,	 HMGB1	 is	 targeted	 by	 the	 p53-
inducible	 miR-200c	 and	 miR-34a	 in	 breast	 cancer	 [400]	 and	 retinoblastoma	 cells	
[284],	 respectively.	 Here	 we	 provide	 an	 additional	 mechanism	 as	 to	 how	HMGB1	
expression	may	be	down-regulated	by	p53	via	miRNA-mediated	mechanisms.		
In	 addition,	 the	 miRNA-34a/205	 target	 KLF12	 emerged	 as	 an	 interesting	
candidate	for	a	use	as	a	prognostic	marker.	Interestingly,	ectopic	expression	of	KLF12	
promotes	 invasion,	 whereas	 its	 knockdown	 results	 in	 a	 growth	 arrest	 in	 human	
gastric	cancer	cells.	Therefore,	KLF12	may	have	oncogenic	functions	in	gastric	cancer	
progression	[401].		
Furthermore,	we	confirmed	that	CIT	is	down-regulated	by	the	p53-inducible	miR-
486-5p.	 It	 was	 shown	 before	 that	 knock-down	 of	 CIT	 in	 hepatocellular	 carcinoma	
cells	 significantly	 inhibits	proliferation	 [402].	 In	addition,	CIT	 induces	cell	 growth	 in	
prostate	cancer	cells	 [403]	and	 is	highly	expressed	 in	ovarian	carcinoma	[404].	 In	a	
recent	study,	CIT	was	shown	to	phosphorylate	the	GLI2	transcription	factor,	thereby	
activating	 a	 non-canonical	 hedgehog/GLI2	 transcriptional	 program	 to	 promote	
breast	cancer	metastasis	 [405].	Therefore,	 loss	of	p53-mediated	suppression	of	CIT	
may	 promote	 tumor	 formation.	 Moreover,	 the	 serine/threonine	 kinase	 CIT	 is	 an	
attractive	 candidate	 for	 therapeutic	 inhibition	 by	 small	 molecules	 as	 previously		
shown	for	other	serine/threonine	kinases	[406].	
Because	 p53	 is	 inactivated	 late	 during	 colorectal	 cancer	 progression	 [407],	
increased	expression	of	HMGB1,	KLF12	and	CIT	 in	advanced	tumor	stages	and/or	in	
different	 tumor	 types	 in	 the	 TCGA	 and	Oncomine	 databases	 is	 in	 accordance	with	
our	 findings.	 It	 also	 suggests	 that	miRNA	 replacement	may	be	used	as	 therapeutic	
approach	to	treat	advanced	cancer	in	the	future	(as	discussed	for	miR-34	in	6.1).		
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This	 thesis	 shows	 that	 p53	 controls	 diverse	 tumor	 suppressive	 targets	 in	
colorectal	cancer	cells.	Therefore,	 the	pharmacological	 reactivation	of	p53	 function	
in	 tumor	cells,	where	p53	 is	mostly	mutated	or	 inactivated,	might	be	an	attractive	
strategy	for	cancer	therapy	[11-14,	17].	There	are	several	approaches	trying	to	find	
specific	and	efficient	ways	to	reactivate	either	wild-type	or	mutant	p53.	Activators	of	
wild-type	p53,	such	as	the	small	molecules	Nutlin	or	RITA	(Reactivation	of	p53	and	
Induction	of	Tumor	cell	Apoptosis),	antagonize	the	function	of	MDM2	to	prevent	p53	
ubiquitination	 and	 degradation	 [247,	 408,	 409].	 Moreover,	 APR-246	 and	 PRIMA-1	
restore	 the	 wild-type	 conformation	 of	 mutant	 p53	 and	 APR-246	 has	 been	 tested	
recently	 in	 a	 phase	 I/II	 clinical	 trial	 in	 patients	 with	 refractory	 hematologic	
malignancies	and	prostate	cancer	[410,	411].	
Several	 quantitative	 mass	 spectrometry-based	 proteomic	 studies	 after	 p53-
mediated	 regulations	 have	 been	 conducted	 previously	 [412-414].	 An	 amino	 acid-
coded	 mass	 tagging	 (AACT)-assisted	 mass	 spectrometry	 approach	 identified	 417	
different	proteins	and	revealed	several	pathways	involved	in	p53-induced	apoptosis	
in	DLD-1	cells	transfected	with	an	inducible	p53	construct	[412].	In	addition,	an	ICAT	
(isotope-coded	 affinity	 tag)	 quantitative	 mass	 spectrometry	 analysis	 identified	 46	
proteins	 that	 show	 differential	 expression	 after	 infrared	 radiation	 [413].	 A	 recent	
iTRAQ	 (isobaric	 tag	 for	 relative	 and	 absolute	 quantitation)	 proteomics	 screen	
identified	 78	 unique	 proteins	 that	 showed	 expression	 changes	 upon	 Nutlin	
treatment	in	MCF7	cells	[414].	However,	pSILAC	with	its	advantages	to	study	de	novo	
protein	 synthesis	 and	 to	 detect	 modest	 changes	 in	 protein	 expression	 typical	 for	
miRNA-mediated	 effects	 was	 never	 applied	 before	 to	 study	 differential	 protein	
expression	after	p53	activation.	The	current	p53	pSILAC	study	allowed	us	to	identify	
more	than	1,000	significantly	and	differentially	regulated	proteins	after	ectopic	p53	
expression.	We	have	recently	applied	pSILAC	after	ectopic	expression	of	miR-34a	in	
colorectal	 cancer	 cells	 to	 comprehensively	 identify	 miR-34a-targets	 [217].	 As	
observed	 after	 miR-34a	 activation,	 changes	 in	 mRNA	 expression	 correlated	 with	
those	 in	 protein	 expression	 after	 p53	 activation.	 Surprisingly,	 only	 four	 out	 of	 36	
putative	miR-34a	 targets	 that	 were	 down-regulated	 in	 the	miR-34a	 pSILAC	 screen	
were	also	 identified	as	down-regulated	proteins	after	p53	activation.	This	 indicates	
that	activation	of	p53	has	numerous	other	effects	on	protein	expression	in	addition	
to	the	activation	of	miR-34a.	Known	miR-34a	targets	might	be	targeted	by	other	p53-
regulated	 genes	 which	 results	 in	 a	 gene	 expression	 pattern	 different	 to	 the	 one	
observed	after	miR-34a	activation	alone.	Furthermore,	p53	might	induce	competitive	
endogenous	 RNAs	 (ceRNAs)	 functioning	 as	 miRNA	 sponges,	 which	 may	 attenuate	
target	repression	by	miR-34a	[415].		
However,	we	 found	 that	a	 large	number	of	 the	proteins	down-regulated	 in	 the	
miR-34a	pSILAC	analysis	were	also	down-regulated	after	ectopic	expression	of	p53,	
including	 almost	 all	members	of	 the	MCM	protein	 family,	which	 are	 important	 for	
the	initiation	of	DNA	replication.	Interestingly,	the	E2F1	transcription	factor	binding	
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motif	was	overrepresented	in	the	promoters	of	genes	encoding	the	proteins	down-
regulated	 by	 both,	 miR-34a	 and	 p53.	 MCM	 proteins	 are	 induced	 by	 the	 E2F	
transcription	factors,	which	are	known	targets	of	miR-34a	[95,	218,	276,	277,	279].	
Taken	together,	 this	 suggests	 that,	 in	addition	 to	p21-mediated	suppression	of	E2F	
[416],	miR-34a-mediated	inhibition	of	the	E2F	pathway	contributes	to	the	cell	cycle	
arrest	induced	by	p53	via	down-regulation	of	MCM	proteins.		
E2F	transcription	factors	are	downstream	targets	of	the	retinoblastoma	protein.	
Since	mutations	 in	 the	 RB	 pathway	 occur	 in	 nearly	 all	 human	 cancers,	 E2Fs	might	
play	a	significant	role	in	oncogenesis	[417].	However,	E2Fs	are	known	to	act	as	both,	
tumor	 suppressors	 and	 oncogenes	 in	 a	 probably	 context-specific	 manner	 [418].	
Nikulenkov	and	colleagues	 found	 that	 the	E2F	 response	element	 is	enriched	 in	 the	
vicinity	 of	 p53-binding	 sites	 of	 repressed	 genes	 [65].	 They	 stated	 that	 the	
transcription	factors	E2F	and	IRF	cooperate	with	p53	to	mediate	gene	repression	and	
that	 p53	 interferes	 with	 STAT3-mediated	 activation	 of	 genes	 by	 occupying	
overlapping	 binding	 sites	 at	 several	 promoters.	 Another	 study	 also	 confirmed	 that	
genes	repressed	by	p53	are	enriched	for	E2F	binding	sites	[204].	
In	 conclusion,	 our	 results	 indicate	 that	 p53	 indirectly	 down-regulates	 a	 large	
number	of	genes	via	the	activation	of	miRNAs.	The	results	add	new	insights	into	the	
p53-regulated	 network	 of	 gene	 expression.	 Furthermore,	 our	 results	 will	 promote	
further	studies	by	providing	numerous	p53-regulated	molecules	and	pathways	that	
represent	attractive	candidates	for	biomarkers	and/or	therapeutic	targets.	
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6.3	The	p53	target	gene	CST5	mediates	in	part	p53´s	tumor	suppressive	functions	
The	third	part	of	this	thesis	describes	the	characterization	of	cystatin	D	(CST5),	an	
inhibitor	of	cysteine	cathepsins,	as	a	new	p53	target	gene	that	was	identified	in	the	
genome-wide	screen	described	 in	5.2.	Our	 findings	combined	with	previous	 results	
are	summarized	in	Figure	59.					
	
	
	
Figure	 59:	 The	 p53	 -	 vitamin	 D3	 -	 CST5	 regulatory	 network.	 Schematic	model	 of	 CST5	 regulation	
integrating	the	results	of	this	study	(marked	with	orange	arrows)	with	previous	findings	(marked	with	
black	 arrows	 Vitamin	 D3,	 that	 is	 converted	 to	 its	 active	metabolite	 calcitriol,	 induces	 CST5	 via	 the	
vitamin	D	 receptor	 (VDR)	 [200].	 In	 addition,	 p53	 positively	 influences	CST5	 expression	 via	 different	
pathways.	p53	directly	binds	to	a	p53	binding	site	upstream	of	the	CST5	promoter.	Furthermore,	p53	
directly	 induces	 VDR	 which	 might	 lead	 to	 the	 induction	 of	 CST5	 [294].	 And	 third,	 p53	 indirectly	
represses	 SNAIL	 expression	 which	 results	 in	 the	 induction	 of	 CST5	 [1,	 178,	 310].	 Moreover,	 CST5	
expression	 indirectly	 leads	 to	 the	 repression	 of	 SNAIL	 by	 inhibiting	 the	 transcriptional	 activity	 of									
β-catenin/TCF	complexes	[200].	Upon	induction,	CST5	promotes	mesenchymal-epithelial	transition	to	
suppress	tumor	progression	and	metastasis.	Figure	from	[3].	
	
Individual	 cysteine	 cathepsins	 were	 shown	 to	 have	 diverse	 cancer	 promoting	
roles	during	tumorigenesis	[419,	420].	Especially	cathepsin	B	plays	an	oncogenic	role	
and	 is	 overexpressed	 in	 a	 variety	 of	 human	 tumors	 [421].	 Cathepsins	 are	 up-
regulated	 in	 various	 tumors	 due	 to	 different	 mechanisms	 including	 gene	
amplification,	 posttranscriptional-	 and	 epigenetic-regulation,	 as	 well	 as	 transcript	
variants	 that	arise	 from	alternative	promoters	and	alternative	splicing	 (reviewed	 in	
[422]).	 Several	 studies	 show	 a	 positive	 correlation	 between	 increased	 cathepsin	
expression	 and	 poor	 outcome	 for	 cancer	 patients	 [423,	 424].	 Cathepsins	 often	
change	their	subcellular	 localization	during	cancer	progression.	 In	normal	cells	they	
are	 located	 in	 lysosomes.	 During	 tumorigenesis	 they	 are	 relocated	 to	 the	 cellular	
surface	 and	 secreted	 into	 the	 extracellular	 milileu	 [422].	 A	 multistep	 process	
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chronologically	 integrating	different	members	of	 the	cysteine	cathepsin	 family	was	
characterized	in	a	cancer	mouse	model	of	pancreatic	islet	cell	tumors	[419,	425]:	In	
the	beginning,	cathepsins	B	and	S	contribute	to	the	release	of	pro-angiogenic	factors	
and	 the	 degradation	 of	 the	 basement	 membrane,	 followed	 by	 the	 expression	 of	
cathepsins	C	and	Z	that	are	in	part	responsible	for	the	exponential	tumor	growth.	In	
later	 tumor	stages,	 cathepsins	H	and	L	contribute	 to	 invasive	 tumor	growth	by	 the	
degradation	 of	 the	 basement	 membrane,	 extracellular	 matrix	 and	 the	 directed	
proteolysis	of	specific	 targets	on	the	cell-surface,	such	as	E-cadherin.	Recently,	 this	
proposed	model	was	tested	using	cathepsin	B,	S,	L	and	C	knockout	mice	[426].	This	
study	revealed	that	cathepsin	B/S	knockout	mice	show	reduced	tumor	formation	and	
angiogenesis,	while	cathepsin	B/L	knockout	mice	display	decreased	cell	proliferation	
and	tumor	growth.	However,	knockout	of	cathepsin	C	did	not	affect	tumor	formation	
and	progression.		
Different	 members	 of	 the	 cystatin	 family	 of	 protease	 inhibitors	 are	 known	 to	
inhibit	 the	 protumorigenic	 actions	 of	 cathepsins.	 Cystatin	 M	 exerts	 tumor-
suppressive	effects	by	 inhibiting	 cell	proliferation,	migration	and	 invasion	 in	breast	
cancer	 cells	 and	 is	 epigenetically	 silenced	 in	 breast	 cancer	 [427-429].	 In	 addition,	
silencing	 of	 cystatin	M	 leads	 to	 increased	 cell	 proliferation	 and	 invasion	 in	 an	oral	
cancer	cell	line	[430].	Overexpression	of	cystatin	C	results	in	decreased	invasion	and	
metastasis	and	leads	to	increased	apoptosis	in	melanoma	and	squamous	carcinoma	
cells	[431-434].	Cystatin	D	(CST5),	an	endogenous	inhibitor	of	cathepsins	S,	H	and	L,	
was	 recently	 demonstrated	 to	 exert	 tumor-suppressive	 functions	 in	 colon	 cancer	
cells	 and	 to	 be	 directly	 induced	 by	 calcitriol	 [183,	 187,	 200].	 The	 underlying	
mechanisms	as	to	how	cystatin	D	exerts	its	functions	are	unclear.	The	use	of	cystatin	
D	 proteins	 with	 a	 mutated	 proteolytic	 site	 revealed	 that	 the	 inhibition	 of	
proliferation	 and	 down-regulation	 of	 c-MYC	 were	 independent	 of	 cathepsin-
suppression	and	rather	mediated	by	the	repression	of	the	Wnt/β-catenin	pathway	by	
cystatin	 D.	 However,	 the	 induction	 and	 repression	 of	 mesenchymal	 and	 epithelial	
markers,	respectively,	and	the	decrease	in	migration	were	supposed	to	be	cathepsin-
dependent.	This	is	in	accordance	with	the	finding	that	cathepsin	L,	one	of	the	targets	
of	cystatin	D,	cleaves	E-cadherin	[426].	Furthermore,	it	was	demonstrated	that	CST5	
expression	 negatively	 correlated	 with	 human	 colon	 cancer	 progression	 in	 tumor	
tissue	 [200].	 By	 showing	 that	 p53	 directly	 induces	 the	 expression	 of	 CST5	 we	
uncovered	a	new	mechanism	as	 to	how	p53	 indirectly	 inhibits	 tumor	development	
and	growth.		
During	 the	 last	 years	 there	 has	 been	 increasing	 evidence	 that	 vitamin	 D3	
deficiency	is	protumorigenic,	especially	since	it	enhances	colorectal	cancer	incidence	
and	mortality.	 In	addition	to	convincing	effects	of	vitamin	D3	 in	 in	vivo	and	 in	vitro	
studies,	data	from	several	preclinical	and	clinical	trials	provide	evidence	for	the	anti-
tumoral	effects	of	vitamin	D3	supplementation	(reviewed	in	[187]).		
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Vitamin	 D3	 deficiency	 is	 a	 worldwide	 problem	 [435].	 It	 is	 caused	 by	 reduced	
sunlight	 exposure	 due	 to	 the	 fear	 of	 developing	 skin	 cancer,	 increased	 skin	
pigmentation,	 the	 use	 of	 sunscreen	 or	 the	 living	 in	 northern	 latitudes	 [436-438].	
Moreover,	vitamin	D3	deficiency	increases	along	with	aging	and	obesity	[439,	440].	
Given	that	there	is	strong	evidence	that	vitamin	D3	decreases	the	risk	for	colorectal	
cancer,	 it	 would	 be	 an	 easy	 and	 economical	 way	 to	 reduce	 colorectal	 cancer	
incidence	and	risk	by	supplementation	of	vitamin	D3	[435].		
Our	results	suggest	that	p53	activation	might	even	enhance	the	oncosuppressive	
effect	 of	 vitamin	 D3.	 A	 combination	 of	 small	 molecules	 reactivating	 p53	 such	 as	
PRIMA	 or	 RITA	 [441]	 together	 with	 calcitriol	 -	 or	 an	 analog	 like	 EB1089	 to	 avoid	
hypercalcemia	 -	 might	 potentially	 lead	 to	 an	 enhanced	 inhibition	 of	 cancer	
progression	 in	 the	 clinic.	 The	 VDR	 is	 highly	 expressed	 in	 early	 stages	 but	 shows	
decreased	expression	in	advanced	stages	of	colorectal	tumorigenesis	[192,	195,	442-
444].	 Also	 the	 occurrence	 of	 p53	 mutations	 is	 a	 late	 event	 in	 colorectal	 cancer	
development	 which	 is	 mostly	 observed	 during	 the	 transition	 from	 adenoma	 to	
carcinoma	[407].	Therefore,	a	combination	of	p53	activation	and	calcitriol	treatment	
might	be	more	 important	 to	prevent	 tumor	 initiation	or	early	progression.	At	 later	
stages,	 reactivation	 of	 the	 wild-type	 p53	 conformation	 may	 inhibit	 tumor	
progression	via	preventing	the	interaction	of	mutant	p53	with	VDR	[445].	
Similar	approaches	combining	calcitriol	with	different	known	anti-cancer	agents	
to	 achieve	an	enhanced	anti-tumorigenic	effect	have	been	 conducted	 in	 several	 in	
vitro	 and	 in	 vivo	 analyses,	 and	 provide	 an	 opportunity	 for	 successful	 anticancer	
treatment	 when	 chemotherapy	 alone	 is	 not	 effective	 [186].	 Combined	 treatment	
with	 calcitriol	 and	 the	 chemotherapeutic	 docetaxel	 significantly	 enhanced	 overall	
survival	 and	 time	 to	 progression	 in	 prostate	 cancer	 [446].	 In	 addition,	 the	
combination	of	calcitriol	and	docetaxel	reestablished	the	sensitivity	to	chemotherapy	
in	prostate	cancer	patients	that	showed	no	inhibition	of	tumor	growth	after	first	line	
chemotherapy	[447].		
Cystatin	D	is	not	the	only	cystatin	that	is	 induced	by	calcitriol:	cystatin	E/M	was	
identifed	as	a	target	of	the	VDR	in	squamous	carcinoma	cells	and	shows	decreased	
expression	in	breast	cancer	[428,	429,	448,	449].	Furthermore,	cystatin	A	is	induced	
by	calcitriol	addition	in	normal	keratinocytes	[450].	Besides	cystatins,	VDR	regulates	
a	 large	 set	 of	 target	 genes	 upon	 calcitriol	 binding	 [451,	 452].	 The	 intracellular	
modulator	 of	 EGFR,	 SPROUTY-2,	 is	 negatively	 regulated	 by	 calcitriol-bound	 VDR	
[451].	 In	 xenografted	 colorectal	 cancer	 tumors,	 SPROUTY-2	 is	 overexpressed	 and	
shows	an	inverse	expression	to	CDH1	[453].	In	addition,	several	proteins	implicated	
in	 the	epigenetic	control	of	gene	expression	are	regulated	by	calcitriol-bound	VDR.	
The	 histone	 demethylase	 JMJD3,	 that	 exerts	 anti-proliferative,	 pro-differentiative	
and	MET-like	effects	in	colon	cancer	cells,	is	induced	by	VDR	after	calcitriol	treatment	
[454-456].	In	addition,	miRNAs	have	been	shown	to	be	under	the	control	of	the	VDR	
in	calcitriol-treated	colon	cancer	cells	[387].	Especially	miR-22	was	demonstrated	to	
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be	important	for	mediating	calcitriol´s	anti-proliferative	and	anti-migratory	effects	in	
those	cells.	This	shows	that	VDR	acts	via	various	targets	to	effectively	function	as	a	
tumor-suppressive	transcription	factor.		
Our	 study	 showed	 that	 SNAIL	 directly	 suppresses	 CST5	 expression	 and	 that	
calcitriol	 treatment	 counteracts	 this	 effect.	 It	 has	 been	 shown	 that	 SNAIL	 directly	
represses	 VDR	 which	 might	 contribute	 to	 the	 inhibition	 of	 CST5	 [457],	 but	 direct	
binding	of	SNAIL	to	the	CST5	promoter,	as	shown	here,	has	not	been	demonstrated	
before.	The	abrogation	of	SNAIL-mediated	repression	of	CST5	by	calcitriol	treatment	
may	 explain	 how	 calcitriol	 inhibits	 tumor	 progression	 even	 in	 cells	 that	 show	high	
SNAIL-expression	and	 therefore	have	a	high	metastatic	potential.	 It	was	previously	
demonstrated	that	p53	inhibits	the	EMT-TF	SNAIL	via	the	induction	of	MDM2,	which	
mediates	 ubiquitylation	 and	 proteasomal	 degradation	 of	 SNAIL	 [310].	 Moreover,	
others	 and	 we	 have	 shown	 that	 p53	 mediates	 the	 inhibition	 of	 SNAIL	 via	 the	
induction	of	miR-34a	[1,	178].	Based	on	our	findings,	p53	therefore	not	only	directly	
induces	 CST5	 expression	 but	 also	 enhances	 CST5	 expression	 by	 the	 indirect	
repression	of	SNAIL.		
Taken	 together,	 we	 identified	 CST5	 as	 a	 new	 direct	 p53	 target	 gene,	 which	 is	
relevant	 for	 the	 tumor	 suppressive	 function	 of	 p53.	 Due	 to	 its	 diverse	 anti-cancer	
functions	 and	 decreased	 expression	 during	 colorectal	 cancer	 tumorigenesis	 [200],	
which	 is	 reversible	 by	 p53	 and/or	 VDR	 activation,	 CST5	 might	 be	 an	 important	
therapeutic	target	in	the	treatment	of	colorectal	cancer.		
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7.	SUMMARY	
p53	is	one	of	the	most	 important	tumor	suppressors	and	was	found	to	be	mutated	
or	 inactivated	 in	 more	 than	 half	 of	 all	 human	 tumors.	 As	 a	 transcription	 factor	 p53	
controls	 the	 expression	 of	 target	 genes	 that	 are	 involved	 in	 processes	 such	 as	 the	
regulation	 of	 cell	 cycle	 arrest,	 DNA	 repair	 or	 apoptosis	 and	 thereby	 prevents	 the	
development	 and	 the	 spreading	 of	 cancer.	 Though	 extensive	 research	 led	 to	 the	
identification	of	a	lot	of	p53-regulated	target	genes,	the	list	of	p53	targets	still	continues	
to	grow	and	seems	to	be	far	from	complete.	
Here,	 we	 showed	 that	 p53	 controls	 the	 EMT	 transcription	 factor	 SNAIL	 via	 the	
induction	of	miR-34	in	colorectal	cancer	cells.	This	regulation	shifted	the	cells	towards	an	
epithelial	 phenotype	 and	 inhibited	 migration,	 invasion	 and	 stemness	 features.	 In	
addition,	we	demonstrated	a	double-negative	feedback	loop	between	miR-34	and	SNAIL	
that	controls	the	transition	between	epithelial	and	mesenchymal	states.		
In	 a	 further	 study	 we	 determined	 p53-regulated	 mRNAs,	 lncRNAs,	 miRNAs	 and	
proteins	on	a	genome-wide	scale.	In	combination	with	a	p53	DNA	binding	analysis,	this	
led	 to	 the	 identification	 of	 genes	 that	 are	 directly	 or	 indirectly	 regulated	 by	 p53.	We	
found	that	the	majority	of	differentially	expressed	genes,	which	were	directly	bound	by	
p53	 near	 their	 TSS,	 were	 up-regulated	 and	 experimentally	 confirmed	 several	 induced	
target	 genes	 that	 showed	 promoter	 proximal	 p53	 binding.	Moreover,	 we	 determined	
that	transcriptional	repression	by	p53	mainly	occurs	via	indirect	mechanisms	and	studied	
the	impact	of	miRNA-mediated	mechanisms	on	p53-controlled	gene	repression.	Almost	
half	of	the	down-regulated	proteins	displayed	seed-matching	sequences	of	p53-induced	
miRNAs	in	the	corresponding	3’-UTRs.	Exemplarily,	the	clinically	relevant	miRNA	targets	
HMGB1,	CIT	 and	KLF12	were	 confirmed	 to	 be	 directly	 repressed	 by	 the	 p53-regulated	
miRNAs	miR-34a,	miR-486-5p	and	miR-205,	respectively.		
Subsequently,	we	characterized	cystatin	D	(CST5),	a	vitamin	D3-inducible	inhibitor	of	
cysteine	proteases,	as	a	new	direct	p53	target	gene	that	resulted	from	the	genome-wide	
analysis	mentioned	above.	CST5	 inactivation	decreased	p53-induced	MET,	as	evidenced	
by	 decreased	 inhibition	 of	 SNAIL	 and	 of	 migration	 by	 p53.	 In	 addition,	 simultaneous	
activation	of	p53	and	 treatment	with	calcitriol	enhanced	CST5	 induction.	Furthermore,	
we	 provided	 evidence	 that	 SNAIL	 directly	 represses	 CST5	 expression	 which	 could	 be	
diminished	by	calcitriol	treatment.		
Taken	 together,	 our	 results	 illustrate	 the	 complex	 network	 of	 protein-coding	 and	
non-coding	genes	 that	 is	directly	or	 indirectly	controlled	by	 the	 tumor	suppressor	p53.	
The	 data	 obtained	 in	 these	 studies	 might	 pave	 the	 way	 for	 new	 diagnostic	 and	
therapeutic	approaches	in	the	treatment	of	cancer.	
   ZUSAMMENFASSUNG 
93 
 
8.	ZUSAMMENFASSUNG	
p53	 ist	 einer	 der	 wichtigsten	 Tumorsuppressoren	 und	 ist	 in	 etwa	 der	 Hälfte	 aller	
menschlichen	 Krebsarten	mutiert	 oder	 inaktiviert.	 Als	 Transkriptionsfaktor	 kontrolliert	
p53	 die	 Expression	 von	 Zielgenen,	 die	 an	 der	 Regulierung	 des	 Zellzyklus,	 der	 DNA-
Reparatur	 oder	 Apoptose	 beteiligt	 sind,	 und	 verhindert	 dadurch	 die	 Entstehung	 und	
Ausbreitung	von	Krebs.	Trotz	umfangreicher	Forschungsarbeiten	ist	die	Gesamtheit	der	
durch	p53-regulierten	Gene	noch	nicht	vollständig	erfasst.	
In	 dieser	 Arbeit	 konnten	wir	 zeigen,	 dass	 p53	 den	 EMT	 Transkriptionsfaktor	 SNAIL	
indirekt	 über	 die	 Induktion	 von	 miR-34	 reprimiert.	 Diese	 Regulation	 überführte	 die	
untersuchten	Zellen	in	einen	epithelialen	Zustand	und	inhibierte	Migration,	Invasion	und	
Stammzelligkeit.	Des	Weiteren	wiesen	wir	eine	doppelt-negative	Rückkopplungsschleife	
zwischen	 SNAIL	 und	 miR-34	 nach,	 die	 den	 Übergang	 zwischen	 den	 epithelialen	 und	
mesenchymalen	Zuständen	kontrolliert.		
Zudem	bestimmten	wir	 in	 einer	 genomweiten	Studie	die	p53-regulierte	Expression	
von	mRNAs,	 lncRNAs,	miRNAs	 und	 Proteinen.	 In	 Kombination	mit	 einer	 genomweiten	
Analyse	der	p53	DNA-Bindung	konnten	wir	direkt	oder	 indirekt	 regulierte	p53-Zielgene	
identifizieren.	Wir	stellten	fest,	dass	die	Mehrheit	der	differentiell	regulierten	Gene,	die	
in	 der	 Nähe	 ihres	 Transkriptionsstarts	 von	 p53	 gebunden	 sind,	 induziert	 wird	 und	
bestätigten	 experimentell	 die	 Induktion	 von	 einigen	 neuen	 p53-regulierten	 Zielgenen.	
Außerdem	 konnten	 wir	 zeigen,	 dass	 die	 transkriptionelle	 Repression	 durch	 p53	 zum	
Großteil	über	indirekte	Mechanismen	erfolgen	muss	und	untersuchten,	welchen	Einfluss	
miRNA-vermittelte	 Effekte	 auf	 die	 p53-kontrollierte	Genrepression	 haben.	Wir	 stellten	
fest,	 dass	 etwa	 die	 Hälfte	 der	 reprimierten	 Proteine	 Bindestellen	 für	 p53-induzierte	
miRNAs	 in	 den	 entsprechenden	 3´-UTRs	 aufzeigen.	 Exemplarisch	 wurde	 die	 direkte	
Repression	 der	 klinisch	 relevanten	 Gene	 HMGB1,	 CIT	 und	 KLF12	 durch	 die	 p53-
regulierten	miRNAs	miR-34a,	miR-486-5p	beziehungsweise	miR-205	bestätigt.		
Nachfolgend	wurde	das	zuvor	identifizierte	p53-Zielgen	Cystatin	D	(CST5),	ein	durch	
Vitamin	D3	induzierbarer	Inhibitor	von	Cystein	Proteasen,	genauer	charakterisiert.	CST5-
Inaktivierung	führte	zu	einer	abgeschwächten	p53-induzierten	MET.	Dies	konnte	anhand	
einer	verminderten	Inhibition	von	SNAIL	und	von	Migration	nach	p53-Aktivierung	gezeigt	
werden.	 Zudem	 verstärkte	 eine	 zeitgleiche	 p53-Aktivierung	 und	 Calcitriol-Behandlung	
die	 Induktion	 von	 CST5.	 Außerdem	 wurde	 nachgewiesen,	 dass	 CST5	 direkt	 von	 SNAIL	
reprimiert	 wird	 und	 diese	 Repression	 durch	 die	 Behandlung	 mit	 Calcitriol	 vermindert	
werden	kann.		
Zusammenfassend	verdeutlichen	die	Ergebnisse	das	komplexe	Netzwerk	aus	Protein-
kodierenden	 und	 nicht-kodierenden	 Genen,	 das	 direkt	 oder	 indirekt	 durch	 den	
Tumorsuppressor	 p53	 kontrolliert	wird.	 In	 Zukunft	 könnten	 diese	Daten	 als	Grundlage	
für	 neue	 diagnostische	 und	 therapeutische	 Ansätze	 in	 der	 Behandlung	 von	
Krebserkrankungen	dienen.		
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9.	ABBREVIATIONS	
AGO	 argonaute	protein	
ANRIL	 antisense	noncoding	RNA	in	the	INK4	locus	
APS	 ammonium	peroxodisulfate	
AP4	 activating	enhancer	binding	protein	4	
ARHGAP5	 Rho	GTPase-activating	protein	5	
ATM	 ataxia	telangiectasia	mutated	
ATR	 ataxia	telangiectasia	and	Rad3-related	protein	
bp	 base	pair(s)	
BRN3A	 brain-specific	homeobox/POU-domain	protein	3A	
CDK	 cyclin-dependent	kinase	
CDKN1A	 cyclin-dependent	kinase	inhibitor	1A	
cDNA	 complementary	DNA	
ceRNA	 competitive	endogenous	RNA	
(q)ChIP		 (quantitative)	chromatin	immunoprecipitation	
CHK	 checkpoint	kinase	
CIT	 citron	rho-interacting	serine/threonine	kinase	
c-MYC	 v-MYC	avian	myelocytomatosis	viral	oncogene	homologue	
CpG	 cytidine-phosphate-guanidin	
CRC	 colorectal	cancer	
CSC	 cancer	stem	cell	
CST5	 cystatin	D	
CYP24A1	 1,25-dihydroxyvitamin	D3	24-hydroxylase	
Cy3	 cyanine	3	
DAPI	 2-(4-Amidinophenyl)-6-indolecarbamidine	dihydrochloride	
DGCR8	 diGeorge	syndrome	critical	region	gene	8	
DMEM	 Dulbecco`s	modified	Eagles	medium	
DMSO	 dimethyl-sulfoxide	
DNA	 deoxyribonucleic	acid	
DOX	 doxycycline	
DUSP4	 dual	specificity	phosphatase	4	
E.coli	 Escherichia	coli	
E-box		 enhancer	box	
eGFP	 enhanced	green	fluorescent	proteine	
ELISA	 enzyme-linked	immunosorbent	assay	
EMT	 epithelial-mesenchymal	transition	
eRNA	 enhancer	RNA	
FACS	 fluorescence-activated	cell	sorting	
FCS	 fetal	calf	serum	
HBSS	 Hank’s	balanced	salt	solution	
HDAC	 histone	deacetylase	
HMGB1	 high	mobility	group	box	1	
HOTAIR	 HOX	transcript	antisense	RNA	
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HRP	 horseradish	peroxidase	
hTERT	 human	telomerase	reverse	transcriptase	
IF	 immunofluorescence	
IgG	 immunoglobulin	
IP	 immunoprecipitation	
kbp	 kilo	base	pairs	
KLF	 Krüppel-like	factor		
KRAS	 kirsten	rat	sarcoma	
LB	 lysogeny	broth	
lincRNA	 large	intergenic	non-coding	RNA	
lncRNA	 large	non-coding	RNA	
MALAT1	 metastasis	associated	lung	adenocarcinoma	transcript	1	
MDM	 mouse	double-minute	
MEG3	 maternally	expressed	3	
MET	 mesenchymal-epithelial	transition	
miRNA	 microRNA	
mRNA	 messenger	RNA	
MTA2	 metastasis-associated	1	family,	member	2	
ncRNA	 non-coding	RNA	
NFĸB	 nuclear	factor	'kappa-light-chain-enhancer'	of	activated	B-cells	
NGS	 next	generation	sequencing	
OCT4	 octamer	binding	transcription	factor	4	
OLFM4	 olfactomedin	4	
ORF	 open	reading	frame	
PAGE	 polyacrylamide	gel	electrophoresis	
PANDA	 p21	associated	ncRNA	DNA	damage	activated	
PAPPA	 pregnancy-associated	plasma	protein	A	
P/C	 phase	constrast	
PBS	 phosphate	buffered	saline	
(q)PCR	 (quantitative)	polymerase	chain	reaction	
PI	 propidium	iodide	
PI3K	 phosphoinositid-3-kinase	
PRC	 polycomb-repressive	complex	
pri-miRNA	 primary	microRNA		
pSILAC	 pulsed	stable	isotope	labeling	by	amino	acids	in	cell	culture	
RBM38	 RNA-binding	protein	38	
RISC	 RNA	induced	silencing	complex	
RNA	 ribonucleic	acid	
RoR	 regulator	of	reprogramming	
rpkm	 reads	per	kilobase	per	million	reads	
RT	 room	temperature	
SD	 standard	deviation	
SDS	 sodium	dodecyl	sulfate	
SGK	 serum/glucocorticoid	regulated	kinase	
siRNA	 small	interfering	RNA	
SIRT1	 sirtuin-1	
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SOX2	 sex	determining	region	Y-box	2	
TCGA	 the	cancer	genome	atlas	
temed	 tetramethylethylenediamine	
TF	 transcription	factor	
TRIS	 tris(hydroxymethyl)-aminomethan	
TSS	 transcription	start	site	
UTR	 untranslated	region	
VDR	 vitamin	D	receptor	
VSV	 vesicular	stomatitis	virus	(tag)	
WB	 Western	blot	
WNT	 wingless-related	integration	site	
WRAP53	 WD	repeat	containing,	antisense	to	TP53	
ZEB	 zinc	finger	E-box-binding	homeobox	protein	
ZNF281	 zinc	finger	protein	281	
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